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Abstract 
A study of cystic fibrosis related chronic liver 
disease 
To assess the influence of chronic liver disease on survival a 
time dependent multivariate Cox regression analysis was 
It 
performed. The results confirmed that patients with evidence of 
chronic liver disease have a worse prognosis. The effect of liver 
disease upon survival was not related to hepatic 
decompensation, as only 2.2% of deaths were liver-related, 
suggesting an occult adverse effect. 
To establish a non-invasive means for the diagnosis of chronic 
liver disease an ultrasound scoring system was developed, and 
validated for reproducibility by two independent radiologists. 
This scoring system correlated well with the capacity of the liver 
to metabolise lignocaine to monoethylglycine xylidide, with 
fasting serum bile acids and with the PGA index. While the 
measurement of the N-terminal propeptide of procollagen III 
revealed significant differences between subjects with and 
without liver disease, the results correlated less well with the 
ultrasound score. Abnormalities documented by quantitative 
hepatobiliary scintigraphy also correlated well with the 
ultrasound based scoring system. 
Having established suitable criteria for diagnosing chronic liver 
disease in cystic fibrosis the systemic and pulmonary 
2 
circulations of patients with and without liver disease were 
evaluated non-invasively. The results confirm the presence of a 
hyperdynamic circulatory state in patients with chronic liver 
disease with significant elevations of cardiac output and left 
ventricular stroke work index and reductions of mean arterial 
pressure and systemic vascular resistance index. There were no 
differences in the peripheral circulatory status of the two 
cohorts. 
Evaluation of the pulmonary circulation was made using shunt- 
perfusion scans and the 100% oxygen re-breathing technique. 
Significant pulmonary arterio-venous shunting, consistent with a 
diagnosis of the 'hepato-pulmonary' syndrome, was only 
detected in the cohort with liver disease (36% of those studied). 
The results of studies presented within this thesis suggest that 
chronic liver disease can be confidently detected using 
ultrasound criteria, is important in the prognosis of patients with 
cystic fibrosis due to its covert adverse effect on survival, and 
may exert some of these effects through systemic and 
pulmonary circulatory changes. 
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Levison, 1990). 
Ethical approval for studies within this thesis 
Ethical permission for the study was obtained from the Riverside 
Medical Ethics Committee and informed consent was obtained 
from each subject prior to the study. Where paediatric subjects 
were studied permission was obtained from both patient and 
% guardian. 
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CHAPTER 1 
INTRODUCTION 
Cystic fibrosis and chronic liver disease 
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Cystic fibrosis, an introduction 
I 
Cystic fibrosis is the commonest autosomal recessive condition 
affecting white populations (Porteous & Dorin, 1990). It affects 
about 1: 2,500 live births (Boat et al., 1989) and approximately 
1: 25 of the population are carriers of the mutation which is 
found on Chromosome 7 (Riordan et al., 1989). 
Heterozygotes have none of the clinical manifestations of the 
disease which affects exocrine gland secretions with changes in 
the sodium, chloride and calcium composition and results in 
changes in the mucus which is then capable of blocking 
secretory ducts. In homozygotes this results in bronchiectasis, 
pancreatic exocrine insufficiency and an elevation of sodium and 
chloride concentrations in the sweat. 
This last abnormality has been used as the most reliable marker 
of the disease (MacLusky & Levison, 1990), although the recent 
discovery of the affected gene and multitude of mutations 
associated with it have allowed genotyping to be introduced as 
diagnostic test where the results of the sweat test are equivocal 
(Porteous & Dorin, 1990). 
Cystic fibrosis is usually diagnosed soon after birth with the 
development of the characteristic meconium ileus (intestinal 
obstruction), or later with recurrent chest infections or failure to 
thrive and steatorrhoea. Chest infections lead to bronchiectasis 
which accounts for the most disabling symptoms of the disease 
and for the majority of deaths which are due to respiratory 
failure or cor pulmonale (MacLusky & Levison, 1990). 
Recent advances in the management of the pulmonary 
complications of cystic fibrosis have resulted in increasing 
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longevity (British Paediatric Association Working Party on Cystic 
Fibrosis, 1988; MacLusky & Levison, 1990) and in increasing 
numbers of patients with other complications of cystic fibrosis 
such as hepatic disease and diabetes mellitus. 
1.1. Cvstic fibrosis related chronic liver disease 
Historical Review 
liver cirrhosis has been a recognised manifestation of cystic 
fibrosis since its earliest descriptions. In the original report of 
cystic fibrosis Andersen described three case of biliary cirrhosis, 
several cases of mild portal fibrosis and many patients with 
fatty livers (Andersen, 1938). 
The earliest descriptions of liver histoPathology in cystic fibrosis 
are from Farber who described small bile ducts blocked by 
eosinophilic material resembling that found in the pancreatic 
ducts and acini of cystic fibrosis patients (Farber, 1944) and 
from Bodian who noted the patchy distribution of hepatic 
changes in cystic fibrosis and coined the term "focal biliary 
cirrhosis" (Bodian, 1952). Progression of this focal lesion to 
'I multi-focal disease and established cirrhosis has been termed 
"multilobular biliary cirrhosis" (di Sant'Agnese & Blanc, 1956). 
The evolution of the focal lesion to multilobular biliary cirrhosis 
was demonstrated by Oppenheimer and Esterly (Oppenheimer & 
Esterly, 1975a). 
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Eathogenesis of liver d 
1.3.1. Histology 
Postmortem studies reveal the presence of the pathognmonic 
histological lesion of focal biliary cirrhosis in up to 72% of 
patients over 24 years old (Vawter & Shwachman, 1979). 
Focal biliary fibrosis is characterised by oedema, chronic 
inflammatory cell infiltration, bile duct proliferation, and 
increased fibrosis in some portal tracts with the accumulation of 
amorphous PAS positive diastase-resistant material 
(Oppenheimer & Esterly, 1975a). These changes are consistent 
with the lesion of partial biliary obstruction. 
In time focal lesions coalesce in some patients, progressing to a 
multilobular biliary cirrhosis characterised by irregular nodules 
larger than those seen in other forms of biliary and portal 
cirrhosis (Figure 1.1. ) and with regenerative microscopic 
nodules, massive foci of necrosis, and bile duct proliferation 
adjacent to areas of preserved hepatic lobular architecture (di 
Sant'Agnese & Blanc, 1956; Oppenheimer & Esterly, 1975a). Bile 
plugged ducts may still be present, but bile stasis within lobules 
Ik is uncommon even in advanced liver disease (Craig et al., 1957; 
Oppenheimer & Esterly, 1975a) (Figure 1.2. ). 
Obstructive plugging of the biLiary ductules has been well 
documented in cystic fibrosis. Such changes are found at post 
mortem in 11% of cystic fibrosis patients at 3 months, 27% at 
one year, and 72% of those aged over 24 years (Vawter & 
Shwachman, 1979). Whether obstructive plugging of the bile 
29 
ducts is alone sufficient to explain the development of biliary 
cirrhosis in cystic fibrosis remains a matter of controversy. A 
recent light and electron microscopic study detected little 
evidence of cholestasis in liver biopsies obtained from patients 
with cystic fibrosis, with the most prominent histological feature 
being evidence of bile duct destruction and associated collagen 
deposition. The authors hypothesise that the damage may be 
mediated by a bile-related toxin (Lindblad et al., 1992). 
Support for a bile-related toxin comes from studies of bile acids 
in cystic fibrosis. A change in the bile acid pool consequent upon 
malabsorption of bile acids (Colombo et al., 1984; O'Brien et al., 
1993) causing excessive faecal loss of primary and secondary 
bile acids and taurine conjugates, results in an increase in the 
preponderance of hydrophobic glycine conjugates in the bile acid 
pool in cystic fibrosis (Setchell et al., 1985; Thompson, 1988). 
These hydrophobic bile acids are potentially hepatotoxic (Attili 
et al., 1986). 
Subsequent exposure of the hepatocytes to lipophilic bile acids 
(chenodeoxycholic acid, deoxycholic acid and lithocholoic acid) 
exacerbated by bile acid reflux in the presence of a partiaUy 
obstructed biliary system may result in hepatocyte injury and 
constitute part of the mechanism for the development of cystic 
fibrosis related liver disease. 
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Figure 1.1. Photograph showing the macroscopic 
appearances of the macronodular cirrhosis of 
cystic fibrosis 
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Figure 1.2. Typical microscopic appearances of 
the cirrhotic liver in cystic fibrosis 
E- Eosinophilic material plugging the biliary ductules 
Bile pigment 
F- Fibrosis 
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1.3.2. The Cystic Fibrosis Transmembrane Regulator 
Cystic fibrosis is characterised by a number of mutations in the 
cystic fibrosis transmembrane regulator gene (CFrR), which 
encodes a protein of 1480 amino acid residues that function as a 
chloride channel regulated by cyclic adenosine monophosphate 
(cAMP) (Anderson et al., 1991). Determining the relevance of the 
CFrR to the pathogenesis of the liver disease of cystic fibrosis 
has proved harder than in some of the other tissues affected in 
cystic fibrosis. 
Primary bile is manufactured within the canaliculus, as a result 
of the active transport of solutes by the hepatocytes followed by 
the passive flow of water. Bile is modified by secretion and 
absorption in the intrahepatic bile ducts with some substances 
undergoing biliary-hepatic re-circulation. The larger ducts have 
two diametrically opposed rows of glands which produce both 
serous and mucous secretions (Psacharopoulos & Mowat, 1983) 
with sodium, potassium, chloride and bicarbonate accounting for 
most of bile osmolality. 
Recent studies have suggested the presence of the CFrR at or 
near the apical, plasma membrane of the biliary epithelium 
I (Mulberg et al., 1993; Cohn et al., 1993). While most studies of 
the function of the CFrR have concentrated on its role as a cAMP 
dependent chloride channel (Welsh, 1990), it has also been 
shown to act as a cAMP bicarbonate (Smith & Welsh, 1992) and 
cAMP water (Hasegawa et al., 1992) transporter. 
33 
The role of the CFTR as a chloride transporter in bile duct cells is 
supported by evidence in the rat that secretin can increase 
cAMP levels (Lenzen et al., 1992), which can stimulate chloride 
channel opening (Fitz et al., 1993) and chloride/bicarbonate 
exchange (Strazzabosco et al., 199 1). While extrapolation of these 
animal studies to the human bile duct cell should be made with 
caution, it may be hypothesised that secretin stimulated 
increases in intracellular cAMP open the CFTR-associated 
chloride channels and result in the efflux of chloride with 
i 
concomitant movement of sodium and water and dilution of bile. 
In addition, the increased intraluminal chloride concentration 
may favour alkalinisation of bile through activation of 
chloride/bicarbonate exchange if this also occurs at the apical 
membrane (Strazzabosco et al., 199 1). If this hypothesis applies 
to the human bile duct cell in cystic fibrosis then absence of the 
CFTR would lead to viscid bile which might cause obstruction of 
the intrahepatic ducts and may constitute part of the mechanism 
in the pathogenesis of the liver lesion of cystic fibrosis 
(Oppenheimer & Esterly, 1975a). 
Alternatively there is evidence to support active bicarbonate 
secretion as an important process in the formation and flow of 
bile. If the defective CFrR fails to act as a bicarbonate 
transporter (Smith & Welsh, 1992) it provides an alternative 
mechanism for the production of viscid, low flow bile. 
Support for this mechanism is derived from studies involving 
the administration of ursodeoxycholic acid. Unconjugated 
ursodeoxycholic acid has been shown to induce a bicarbonate 
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rich choleresis (Erlinger & Dumont, 1990) which may be the 
result of direct stimulation of hepatocyte bicarbonate transport 
(Erlinger & Dumont, 1990; Kitani, 1990). The improvement i 
both biliary excretion and the standard biochemical tests of liver 
function with ursodeoxycholic acid administration suggest that 
this mechanism may be important in the pathogenesis of cystic 
fibrosis liver disease (Colombo et al., 1992a). 
IL 
1.3.3. Common Bile Duct Stenosis 
A further mechanism proposed for the development of chronic 
liver disease in cystic fibrosis is stenosis of the intra-pancreatic 
portion of the common bile duct in association with the 
pancreatic disease of cystic fibrosis. Initial reports that this 
lesion was present in over 9011/6 of cystic fibrosis patients with 
chronic liver disease (Gaskin et al., 1988) have not been 
confirmed by other investigators (Nagel et al., 1989; O'Brien et 
al., 1992b). Nevertheless isolated reports of secondary biliary 
cirrhosis caused by this lesion (Vitullo et al., 1978; Lambert et 
al. 9 198 1; Bass et al., 1983) , with improvement following surgical 
intervention (Gaskin et al., 1988), suggest that it is an 
aetiological. factor in a minority of patients and that its presence 
should be excluded in all patients with cystic fibrosis related 
chronic liver disease. 
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1.4. Genetic asvects of cystic fibrosis related 
liver disease 
The relationship of hepatic involvement in cystic fibrosis to 
current knowledge about specific cystic fibrosis gene mutations 
on chromosome 7 is unclear. 
Studies evaluating the severity of liver disease and the 
prevalence of patients homozygous and heterozygous for the 
commonest gene deletion, &F508, do not agree about whether or 
not homozygotes for this deletion are at greater risk of 
developing liver disease (Johansen et al., 199 1; Ferrari et al., 
1991; De Arce et al., 1992). One study looking at three of the 
commoner gene mutations - AF5 08 ý G5 51D and R5 53X- found no 
correlation between the frequencies of each mutation and the 
presence or absence of liver disease (Duthie et al., 1992) as did 
another which looked at the frequencies of six defined CFTR 
gene mutations (Colombo et al., 1994a). A more recent report 
with a more detailed evaluation of currently identified 
mutations found no increase in the prevalence of any genotype 
in patients with liver disease. However, the prevalence of liver 
disease was low in the cohort of 798 patients studied (The Cystic 
Fibrosis Genotype-Phenotype consortium, 1993). 
The report by Duthie et al, in agreement with others (Schuster et 
al. 9 1977; Scott-jupp et al., 1991; De Arce et al., 1992), also noted 
some familial concordance in patients with liver disease 
suggesting the influence of genes outside the cystic fibrosis locus 
or an effect of environmental factors in the pathogenesis of the 
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disease. Further evidence for the influence of genes outside the 
cystic fibrosis locus is provided by a reported increase in the 
prevalence of liver disease in adolescent males (Scott-jupp et al., 
199 1; Feigelson et al., 1993; Colombo et al., 1994a). 
liver damage may also be associated with an HLA-associated 
genetic factor controlling the lymphocyte-mediated immune 
response to liver antigens. There is an increased frequency of 
the HIA antigens A2, B7, DR2(DRwlS) and DQw6 in those 
patients with liver disease which is probably due to an increase 
in the frequency of the HLA A2-B7-DR2-DQw6 haplotype (Duthie 
et al., 1990). The relative risk for liver disease increases from 
HIA A2 to DQw6, with 65.2% of patients with liver disease 
having DQw6 compared to 32.5% without, suggesting that the 
disease associated allele may lie near the DQB locus. 
Lymphocytes play a key role in stimulating, via cytokines, the 
production of collagen and other macromolecules of the 
extracellular matrix during fibrogenesis (Friedman, 1990; 
Gressner & Bachem, 1990). Detection of a sub-population of 
lymphocytes, cytotoxic to hepatocytes and directed towards 
liver-specific lipoprotein gives further evidence for a role for 
immune mechanisms in the pathogenesis of liver disease (NIieli- 
Vergani et al., 1980). 
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1.5. Epidemiology of Cystic fibrosis related 
chronic liver disease 
Historical postmortem data shows that the incidence of liver 
disease rises steadily with age from 10.8% in infants less than 
three months old, to 15.3% in those 3 months to one year and 
26.8% in those older than one (Salh et al., 1988). 
A recent retrospective analysis of the case notes of 1100 
children in central England revealed clinically overt liver disease 
in 4.2% of patients. The incidence rose from 0.3% in the 0-5 age 
group, to a peak of 8.7% in the 16-20 year old age group and in 
those over 20 years old it fell to 4.1%. There was a marked 
preponderance of affected males (5.4% of males compared with 
2.6% of females), being most pronounced in the 11 to 15 year 
age group where three times as many boys as girls were 
affected (Scott-jupp etaL, 199 1). 
The correlation between liver function tests, which were 
abnormal in 12.9% of those in whom they had been measured, 
and clinical evidence of liver disease was poor. Normal serum 
liver enzyme activities were seen in 6 of 46 patients (13%) with 
hepatosplenomegaly, while 50 of 524 (10%) had abnormal 
hepatic enzyme activities in the absence of clinical evidence of 
liver disease (Scott-jupp et aL, 1991). Subsequent clinical re- 
appraisal of a selected cohort of patients in the study revealed 
considerable under diagnosis of liver disease, but confirmed the 
male adolescent peak (Tanner, 1992). 
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The authors suggest that the reduced prevalence of liver disease 
in patients aged over 20 may be explained by selectively 
increased mortality in the liver disease group, but suggest that 
this is unlikely as liver related deaths due to such complications 
as hepatic failure and variceal haemorrhage were rare (7.8%). 
Their alternative explanation that this is a cohort effect, which 
will result in the peak age of liver disease steadily increasing, 
remains to be proven by a longitudinal study (Scott-jupp et al., 
1991). 
1.6. Clinical Presentation of chronic liver disease 
in cvstic fibrosis 
Focal and multi-lobular biliary cirrhosis are the characteristic 
lesions of cystic fibrosis (di Sant'Agnese & Blanc, 1956) and tend 
to present late in the natural history of the disease. Other 
manifestations may rarely present in infancy. 
Neonatal presentations of liver disease include deep cholestasis 
due to inspissated bile in the common bile duct which may have 
to be cleared by laparotomy and biliary lavage (Furuya et al., 
199 1) and presentation with haemorrhagic disease of the 
newborn due to vitamin K malabsorption (Torstenson et al., 
1970). In malnourished infants fatty infiltration of the liver, 
massive hepatomegaly and hypoglycaernia, with carnitine 
deficiency as a possible exacerbating factor, has been reported 
(Treem & Stanley, 1989). Neonatal giant cell hepatitis has also 
been reported (Resti et al., 1990). 
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More commonly the features of biliary cirrhosis develop at any 
time from infancy to adult life. Clinically evident liver disease 
has been reported in only 20-30% of cystic fibrosis patients 
(Feigelson et al., 1975; Schuster et al., 1977; Nagel et al., 1989) 
with overt hepatic decompensation in only 2-5% (Psacharopoulos 
& Mowat, 1983). However, the prevalence of liver involvement 
is likely to increase as the care of the respiratory disease 
continues to improve and survival is extended (British Paediatric 
Association Working Party on Cystic Fibrosis, 1988; MacLusky & 
Levison, 1990). It is, therefore, likely to become a more 
significant management problem in cystic fibrosis. 
A striking feature of cystic fibrosis related chronic liver disease 
is the paucity of clinical signs (Roy et al., 1982). Liver 
involvement is usually detected on the basis of abnormalities of 
the standard biochemical tests of liver function or hepato- 
splenomegaly in the patient under observation. Hepatomegaly 
has been shown to correlate well with histology and in particular 
fibrotic changes (Gaskin et al., 1988). Characteristically both 
lobes of the liver may be palpable when liver enlargement is 
first detected, but as the disease progresses the right lobe 
involutes while the left remains prominent (Vawter & 
Shwachman, 1979; Romano, 1981). 
Evidence of decompensation in the form of jaundice, ascites or 
encephalopathy is unconunon, either as a presenting feature or 
as part of the natural history of the disease (Park & Grand, 
1981). Similarly, variceal haemorrhage is a rare complication of 
cystic fibrosis but may occur in up to 30% of patients with 
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established focal or diffuse cirrhosis (a figure similar to 
cirrhotides of other aetiologies) (Navasa et al., 1987). However, 
variceal haemorrhage may be the presenting feature of 
underlying liver disease and may occur in the absence of any 
other signs of decompensation (Psachoropoulos et aL, 198 1; 
Penketh et al., 1987; Sinaasappel, 1989). Such early variceal 
bleeding may reflect the pre-sinusoidal component of portal 
vascular resistance which is well recognised in biliary cirrhosis 
and can occur in the pre-cirrhotic phase of the disease (Navasa 
et al., 1987). 
The overall picture is, therefore, of a benign disease process 
which is similar in many respects to the other biliary cirrhotides, 
(primary biliary cirrhosis (Dickson et aL, 1989) and primary 
sclerosing cholangitis (Farrant et al., 1991)), with a long history 
of evolution. However, the premature mortality caused by the 
pulmonary complications of cystic fibrosis may be a major factor 
reducing the incidence of decompensated cystic fibrosis liver 
disease (Scott-Jupp et al., 199 1). 
Diagnosing liver disease in cystic fibrosis 
1.7.1. Standard laboratory biochemical tests 
Standard biochemical tests of liver function have proved 
disappointing as predictors of underlying liver disease, and may 
even be normal in the presence of overt cirrhosis (di 
Sant'Agnese & Blanc, 195 6; Stem et al., 1976). In addition, many 
series evaluating indirect measures to detect liver disease are 
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limited by lack of definitive parameters with which to compare 
them. 
Previous reports have suggested that liver function tests become 
abnormal late in the disease (Feigelson et al., 1975; Park & 
Grand, 198 1), but this contention has been challenged by a 
recent report which indicates that biochemical changes precede 
abnormalities on imaging in the majority of cases (Feigelson et 
al., 1993). v 
in a recent epidemiological survey 13% of those with clinical 
liver disease had normal biochemical tests of liver function 
while 13% with no clUnical evidence of liver disease had 
abnormal blood tests (Scott-jupp, et al., 199 1). In another series 
30% of cystic fibrosis patients had transient moderate increases 
in circulating enzymes over a 38 year follow up period but did 
not go on to develop multilobular biliary cirrhosis (Feigelson et 
al., 1993). Histology for this sub-group of patients, when 
available, suggested focal biliary cirrhosis (Feigelson et al., 
1993). 
The pattern of blood tests is also variable with some patients 
with cirrhosis having entirely normal amino-transferase levels 
(Schwarz et al., 1978) and modest elevations frequently 
observed in the absence of liver disease (Kattwinkel et al., 1973; 
Feigelson et al., 1975). The reasons for this are unclear, but 
various explanations including chronic infection, hypoxaemia 
and drug ingestion have been proposed (Isenberg, 1982). 
Elevations of the liver iso-enzyme of alkaline phosphatase and 
gamma glutamyl transpeptidase (yGT) also have little specificity 
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(Feigelson et al., 1975; Scott-Jupp et al., 199 1) , although 
elevations of these enzymes to values four times above the 
normal level is almost always associated with some degree of 
biliary related disease. 
The measurement of alkaline phosphatase is particularly 
problematic in cystic fibrosis where many patients have delayed 
puberty and the hepatic iso-enzyme may be elevated in the 
presence of a normal total serum alkaline phosphatase (Schwarz 
et al., 1978). 
More refined analysis of alkaline phosphatase, by measurement 
of its high-molecular-mass iso-enzyme, has been proposed as a 
more sensitive test of hepato-biliary disease (Schoenau et al., 
1989). However, while serum concentrations of this iso-enzyme 
correlated with other abnormalities of standard serologic liver 
function tests the authors provide no data on the patients 
clinical status with regard to hepatic disease, making informed 
evaluation of their data difficult. 
The measurement of other parameters which are used to assess 
hepatic synthetic function are also unreliable in the early 
detection of the disease. The prothrombin time is usually normal 
in patients with liver disease, but when abnormal may be 
prolonged due to a due to a number of factors including reduced 
oral intake of vitamin K, reduced absorption of vitamin K and 
hepatic disease (Feigelson et al., 1970; Feigelson et al., 1975). 
More detailed analysis of the clotting cascade has been 
undertaken with conflicting results. The measurement of Factor 
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VII levels in ninety one cystic fibrosis patients revealed low 
Factor VII levels, that failed to correct with vitamin K 
administration, in all six subjects with cirrhosis and twelve of 
twenty four subjects with other evidence of liver injury 
(Dominick & Sutor, 1981). In contrast a study of Factor H 
coagulant activity and immunoreactive prothrombin protein 
ratios in twenty four cystic fibrosis patients often found a low 
ratio that responded to vitamin K administration (Corrigan et al., 
1981). 
The serum albumin and bilirubin concentrations are further 
markers of hepatic dysfunction, but these tend to remain normal 
until late in the disease (Schwarz et aL, 1978). While 
hypoalbuminaemia may be a marker of advanced liver disease 
(Feigelson et al., 1975; Green et al., 1960), it may also reflect the 
general nutritional status of the cystic fibrosis patient. 
Given the disappointing results obtained with individual blood 
tests an alternative approach, using the inununoglobulin A (IgA) 
to transferrin ratio and the yGT concentration, has been proposed 
(Feigelson et al., 1975). When the ratio was high (> 1.9) cirrhosis 
was indicated, but the yGT could be normal. Alternatively a low 
ratio (<1.0) was associated with a raised yGT suggesting 
cholestatic liver involvement. However, the ratio rose markedly 
in one patient shortly before death due to respiratory disease, 
because of an increase in IgA, suggesting that the applicability of 
the ratio is limited and while other investigators have suggested 
that serum IgA is related to liver involvement in cystic fibrosis 
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there is no data to support this contention (Dietzsch et al., 
1980a). 
1.7.2. Bile acids 
Bile acids have been evaluated as markers of liver disease i 
cystic fibrosis following an initial report that fasting serum bile 
acids were elevated in three of six patients, two of whom had 
evidence of cirrhosis (Goodchild et al., 1975). 
The fasting serum conjugated cholic acid has been proposed as a 
marker of early liver involvement in cystic fibrosis with 
elevated levels in patients with hepatomegaly (Davidson et a]., 
1980). However, subsequent work on fasting serum cholic and 
chenodeoxycholic acid concentrations suggested a lack of 
correlation with liver histology obtained percutaneously 
(Strandvik & Samuelson, 1985). 
The divergent results obtained in these and other studies of 
serum bile acids in cystic fibrosis highlight the compleNity of bile 
salt metabolism, where associated pancreatic insufficiency and 
intestinal malabsorption may also influence the serum levels of 
bile acids in each individual patient (Colombo et aL, 1984; 
O'Brien et al., 1993). 
Detailed evaluation of urinary bile acids has also been 
undertaken following the observation that the urinary excretion 
of trihydroxy bile acids in cystic fibrotic patients was 
significantly higher and the monohydroxy bile acids lower than 
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in the control group (Arborgh et al., 1980). Correlating their 
findings with histology the investigators noted that those 
patients with liver disease had elevated urinary 
chenodeoxycholic acid, while liver disease patients, cystic 
fibrosis controls and normal controls excreted similar amounts of 
cholic acid. In addition, the cirrhotics had elevated 
chenodeoxycholic acid to 3p-hydroxy-5 cholenoic acid ratios. 
Patients with normal biopsies or portal changes alone had ratios 
that were similar to the control subjects. The authors concluded 
that detection of elevated urinary chenodeoxycholic acid could 
be an early marker for cystic fibrosis liver disease (Arborgh et 
al., 1980). Difficulties in interpreting these data arise from the 
fact that the whole study group had normal galactose 
elimination, 24/25 had normal brom-sulph-phthalein (BSP) 
retention, there were no patients with clinical evidence of 
established liver disease and the histology specimens were 
obtained percutaneously (see below). 
Quantitative liver function tests 
Quantitative liver function tests have not been extensively 
evaluated in the detection of cystic fibrosis liver disease. BSP 
retention is reduced in advanced disease (di Sant'Agnese & 
Blanc, 1956; Feigelson et al., 1972; Feigelson et al., 1975). In 
addition, one report of BSP plasma clearance, using computerised 
BSP excretion curves, suggested that this technique can be used 
to detect early hepatic disease (Grand et al., 1978). It was, 
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however, evaluated on a relatively small cohort of patients (20), 
and has not been substantiated. 
More recently the galactose elimination capacity, 14C- 
aminopyrine breath test and BSP clearance tests have been used 
in the sequential monitoring of the response of cystic fibrosis 
patients with liver disease to treatment with ursodeoxycholic 
acid, but have not been evaluated as a diagnostic tool for cystic 
fibrosis liver disease (Cotting et al., 1990). 
1.7.4. Imaging techniques 
1.7.4.1 Ultrasound 
Real-time ultrasound scanning in cystic fibrosis allows the 
detection of hepatic parenchymal abnormalities and particularly 
the development of muld-lobular biliary cirrhosis (McHugo et 
al., 1987). 
It also allows detailed evaluation of the splanchnic vasculature 
and in particular the portal vein, splenic size and whether or not 
portal-systemic collaterals are present suggesting the presence 
of portal hypertension (Vergesslich et al., 1989). It has been 
suggested that the portal vein diameter may be a useful marker 
for the early detection of portal hypertension in cystic fibrosis 
(Kumari-Subaiya et al., 1987). Patency of the portal and splenic 
veins, which may become thrombosed in the presence of cystic 
fibrosis related chronic pancreatitis, can also be determined. 
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Ultrasound is also valuable for assessing the biliary tree and, in 
the context of liver disease, for excluding dilatation of the 
common bile duct secondary to a biliary stricture in the intra- 
pancreatic portion of the duct (Lambert et al., 198 1; Gaskin et al., 
1988). 
1.7.4.2 Computed tomography 
Computed tomography has been shown to successfully detect 
both hepatic parenchymal abnormalities and evidence of 
elevated portal pressure, but in reality is felt to add little to the 
clinical data (Cunningham et aL, 1980). It may be useful in 
evaluating the occasional patient in whom clinical and diagnostic 
doubt persists. 
1.7.4.3. Endoscopic Retrograde Cholangiography 
Cholangiography, most Often using the endoscopic route, has also 
provided important diagnostic information (Nagel et al., 1989; 
O'Brien et al., 1992b), and in patients with common bile duct 
calculi and stenosis of the distal portion of the common bile duct 
can be employed for therapeutic intervention. Calibre 
irregularities of the intra-hepatic ducts, similar to those 
observed in patients with primary sclerosing cholangitis, appear 
to be specific for established chronic liver disease (Nagel et al., 
1989; O'Brien etaL, 1992b) (Figure. 1.3. ) 
48 
IL 
Figure 1.3. Endoscopic retrograde cholangiogram 
in a patient with cirrhosis and cystic fibrosis 
showing the typical changes of the intrahepatic 
bile tree 
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1.7.4.4. Colloid liver scans 
Radionuclide colloid (gold or technetium. labelled) liver scans 
have been proposed as a useful adjunct in the diagnosis and 
monitoring of patients with cystic fibrosis liver disease 
(Feigelson et al., 1972). Scans reveal patchy uptake in the liver, 
an enlarged spleen and in the presence of marked liver damage 
increased isotope uptake by the vertebral column. In practice 
the anatomical data obtained adds little to the clinical 
information available (Smith et al., 1977). 
1.7.4.5. Hepatobiliary scintigraphy 
V. 
'D, -% 
.. dionuclide imaging using iminodiacetic acid (IDA) derivatives 
labelled with 99m Technetium have been used to assess both 
the biliary tree and hepatobiliary function (Chervu et al., 1988) 
as IDA is taken up by the hepatocytes and then rapidly cleared 
in the We. 
A number of recent studies have utilised these derivatives as a 
means of assessing biliary function and have confirmed 
impaired drainage in patients with chronic liver disease (Gaskin 
et al., 1988; Nagel et al., 1989). Delay of excretion was 
documented in both intra, and extra-hepatic sites, in keeping 
with delayed bile flow, rather than a single site of obstruction. 
Semi-quantitative application of these techniques has shown 
delayed time to maximal uptake (Tmax) and percentage 
excretion at 45 and 60 minutes in subjects with hepatic disease, 
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but while statistically significant differences in these parameters 
were documented, between those with and without liver disease, 
their applicability in facilitating the diagnosis of liver disease 
was not assessed(O'Brien et al., 1992b) 
Further use of semi-quantitative IDA imaging has allowed 
objective documentation of the response of individual patients to 
treatment with ursodeoxycholic acid. In one study the half-time 
of hepatic washout and time to appearance in the intestine 
improved with ursodeoxycholic acid therapy (Colombo et al., 
1992a), while in another the time to Tmax, and excretion at 45 
and 60 minutes were not improved following treatment (O'Brien 
et al., 1992a). More detailed application of these techniques may 
allow more accurate monitoring of deterioration in liver disease 
or response to therapy. 
IDA scanning has also been used to image the extrahepatic 
biliary tree. The results are contradictory with evidence of 
common bile duct stenosis reported in both patients with 
(Gaskin et A, 1988; O'Brien et al., 1992b) and without (O'Brien et 
al., 1992b) liver disease. Subsequent retrograde cholangiography 
in this latter study failed to demonstrate common bile duct 
strictures or dilatation in any of the patients with a dilated bile 
duct on IDA scanning. This discrepancy probably reflects biliary 
stasis or adherence of the tracer to abnormal mucous within the 
biliary tree and highlights the inaccuracy of this technique in 
diagnosing common bile duct stenosis. 
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1.7.5. liver biopsy 
liver histology forms a comer-stone for the assessment of 
patients with most forms of liver disease. However, a sampling 
error as high as 66% has been reported in the diagnosis of 
cirrhosis by needle biopsy (Soloway et al., 197 1) and the use of 
liver biopsies in the diagnosis of liver involvement in cystic 
fibrosis is controversial. 
While some investigators have advocated the use of serial 
percutaneous liver biopsies for diagnosing and monitoring the 
progression of liver disease (Dietzsch et al., 1980a; Dietzsch et al., 
1980b), it is accepted that the focal nature of the early lesion 
cystic fibrosis associated chronic liver disease makes 
percutaneous liver biopsy an unreliable diagnostic tool (Schwarz 
et al., 1978; Psachoropoulos et al., 198 1; Gaskin etaL, 1988). In 
addition the risk of a pneumothorax in a patient with impaired 
pulmonary function is not, generally, deemed acceptable 
(Wilson-Sharp et al., 1984). It is possible that the use of 
ultrasound guided percutaneous biopsies would improve the 
diagnostic yield while nuinhimising risks, but this remains to be 
prospectively evaluated. 
In contrast the histology obtained from open or wedge liver 
biopsies taken at laparotomY is reliable for the diagnosis of liver 
disease (Tyson et al., 1968; Gaskin et al., 1988). One study has 
compared the histology obtained by open biopsy with that 
obtained percutaneously and confirms gross sampling error 
using the percutaneous approach (Gaskin et al., 1988). 
Consequently open liver biopsy has been advocated as the 
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method of choice for obtaining tissue (Schwarz et al., 1978), but 
the risks of the operative approach and of a general anaesthetic 
in patients with pulmonary disease appear to make this 
approach unacceptable. 
Treatment 
The treatment for cystic fibrosis related chronic liver disease " 
falls into two areas. Firstly therapy directed at the complications 
of liver disease and secondly treatment for the liver disease 
itself. 
1.8.1. Complications of liver disease 
1.8.1.1. Specific Nutrients 
In the presence of established cirrhosis the protein calorie 
requirements are frequently increased (Levine et al., 1994), so 
that attention to nutrition is important. Deficiencies of fat- 
soluble vitamins may occur, particularly in the cholestatic 
patient, so supplementation may be required. Caution should, 
however, be exercised with vitamin A replacement as 
complications related to hyper-vitaminosis have been 
documented even in the absence of overt over-dosage (Eid et al., 
1990). 
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1.8.1.2. Portal hypertension 
Variceal haemorrhage represents the most frequent serious 
complication of chronic liver disease and should be managed in 
the same way as it is in other forms of liver disease (Westaby, 
1992). 
Ascites is uncommon, and is usually accompanied by other 
evidence of decompensated liver disease such as jaundice and 
impaired synthetic function. This too should be treated in the 
conventional way (Moore et al., 1992). 
IL 
Gross sPlenomegaly is an infrequent complication of portal 
hypertension (Psachoropoulos et al., 198 1). Hypersplenism is a 
frequent incidental observation, but the low white cell and 
platelet counts are usually of no clinical significance and are not 
an indication for splenectomy. Left upper quadrant pain is the 
most troublesome symptom, but can usually be managed with 
simple analgesics. Splenectomy is reserved for those patients 
with intractable symptoms. 
1.8.2 Treatment of cystic fibrosis related chronic liver 
disease 
1. Ursodeoxycholic acid 
There has been increasing interest in oral bile acid therapy for 
chronic liver diseases. Despite their essential function as 
detergents and key modulators of hepatic excretory function, 
bile acids are cytotwdc molecules and may cause cell death when 
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at high concentrations. Bile acid cytotoNicity is inversely related 
to the degree of hydrophilicity, which is in turn determined by 
their molecular structure (Attili et al., 1986). Hydrophilicity 
increases with the number of hydroxyl groups in the bile acid 
steroid nucleus and also whether or not it is conjugated, 
particularly with taurine. Ursodeoxycholic acid is very 
hydrophilic and non toxic due to the presence of an hydroxy 
group in the 7p position. In contrast, hydrophobicity and 
cytotoxicity is highest in the monohydroxy, dihydroxy, glycine- 
conjugated and free bile acids (Attili et al., 1986). 
Ursodeoxycholic acid changes the relative concentrations of toxic 
and non-toxic bile acids in the bile acid pool. The mechanism for 
this is unclear but it may compete with endogenous bile acids 
for active ileal re-absorption resulting in reduced circulating 
concentrations of hepatotoxic bile acids (Marteau et al., 1990), or 
it may expand the overall bile acid pool size and diminish the 
relative concentrations of toxic bile acids (Beuers et al., 1992). 
As well as protecting the hepatocyte from the toxicity of 
hydrophobic bile acids, ursodeoxycholic acid induces a 
bicarbonate rich choleresis (Renner et aL, 1980), which should 
be of particular value in a cholestatic liver disease. However, this 
effect is mediated by unconjugated ursodeoxycholic acid which 
does not increase in concentration in duodenal bile when 
ursodeoxycholic acid is given to patients with cystic fibrosis 
(Roseau, 1990), suggesting that this effect may not occur in vivo. 
However, chole-hepatic recycling may result in the unconjugated 
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bile acid failing to appear in the fmal bile, so this mechanism 
cannot be discounted (Erlinger & Dumont, 1990). 
A further mechanism for ursodeoxycholic acid efficacy may be 
via an immunomodulatory effect (Yoshikawa et al., 1992). 
'Dý 
Beneficial effects of ursodeoxycholic acid administration have 
been reported in children (Colombo et al., 1990) and young 
adults (Cotting et al., 1990) with cystic fibrosis associated liver 
disease. The drug appears to be well tolerated and to have 
beneficial effects on standard and quantitative (BSP retention at 
45 minutes and the aminopyrine breath test) liver function tests 
(Cotting et al., 1990). Dose response studies have shown that due 
to problems with ursodeoxycholic acid absorption encountered 
in cystic fibrosis 20 mg/Kg ursodeoxycholic acid must be 
administered to achieve similar biliary concentrations of 
ursodeoxycholic acid as those achieved with smaHer doses in 
other chronic liver diseases (Colombo et al., 1992b). 
Subsequent studies have confirmed the documented 
improvement in standard liver function tests reported by these 
early studies (Colombo et aL, 1994b) but, while they are 
encouraging, long-term studies with data on clinically relevant 
events are still required before ursodeoxycholic acid can be 
accepted as an established form of treatment. Early data 
suggests that ursodeoxycholic acid therapy vvill not arrest 
disease progression in those patients who already have 
I 
advanced chronic liver disease (Colombo et aL, 1993), suggesting 
that intervention at the focal stage or even earlier in the disease 
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process wiH be necessary if ursodeoxycholic acid is to confer any 
benefit. 
1.8.2.2. Somatic gene transfer 
Following the identification of the cystic fibrosis gene attempts 
have been made to deliver a recombinant gene to the lung 
epithelium using adenovirus and liposome vectors. 
Until recently attempts at delivering the recombinant gene to 
the liver have been focused on the hepatocyte (Wilson et al., 
1992; Kay et al., 1992). However, the demonstration of the 
presence of the CFrR close to or in the apical membrane of the 
biliary epithelium (Cohn et al., 1993) has recently led to 
attempts at delivering liver-directed gene therapy to the biliary 
epithelium using recombinant adenoviruses (Yang et al., 1993). 
The adenoviruses were infused retrogradely into the biliary 
tract via the common bile duct using endoscopic retrograde 
cholangiography, and resulted in widespread expression of the 
CIFTR gene throughout the biliary tract. This expression persisted 
for 21 days suggesting that this is a promising approach to the 
treatment of cystic fibrosis related chronic liver disease if the 
absence of the CFTR is the major pathogenetic defect related to 
the development of liver disease. 
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1.8.2.3. Transplantation 
Orthotopic liver transplantation is being increasingly used to 
treat monogenetic liver-based metabolic disorders as the 
outcome following transplantation improves (Cohen et al., 1991). 
1 year survival rates of over 85% are reported, with up to 78% 
surviving 5 years (Busuttil etaL, 199 1) and an annual attrition 
rate of 2-3%. The longest surviving recipient is reported to be 
well 20 years after transplantation (Salt et al., 1992). 
liver transplantation has been reported in about 35 cystic 
fibrosis patients, with 50% surviving with a very good quality of 
life (Starzl et al., 1989). However, progression of the lung disease 
may be anticipated after liver transplantation giving rise to 
further difficult management decisions. 
For many patients who might be considered for liver 
transplantation the severity of lung disease precludes this 
approach. Combined heart-lung-liver transplantation has been 
reported, with limited success (Cox et al., 1987; Mieles et al., 
1989; Madden et al., 1992; Feigelson et al., 1993). Success rates 
are unlikely to improve while small numbers of patients are 
being transplanted, and rates of triple organ transplantation are 
unlikely to increase while the shortage of donor organs exists. 
Heart-lung or double-lung transplantation is now widely used as 
treatment for end-stage pulmonary disease in cystic fibrosis, 
with 50% 3 year survival reported (Madden et a]., 1992). 
There has been no systematic study assessing the influence of 
established liver disease upon survival. While most transplant 
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programmes have excluded patients with overt complications of 
liver disease, the occult nature of cystic fibrosis liver disease has 
resulted in patients with established focal or multi-lobular 
cirrhosis undergoing heart-lung transplantation. There is little 
evidence that the procedure causes hepatic decompensation in 
the short term, although this has been a complication in patients 
undergoing portal-systemic shunting (Tyson et al., 1968) , and an 
uncomplicated post-operative course has been documented in 
some patients with a previous history of variceal bleeding 
(Williams et al., 1992). It, therefore, seems reasonable to offer 
heart-lung transplantation to all those patients with liver 
disease unless they have persistent jaundice, ascites or 
encephalopathy. 
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1.9. Aim of Studies Presented here 
liver disease in cystic fibrosis remains one of the less well 
studied manifestations of the disease. This has resulted from the 
apparent benign nature of the disease process and unavailability 
of an effective treatment for liver disease coupled with the fact 
that most of the significant morbidity and mortality in cystic 
fibrosis has been due to the pulmonary manifestations and their 
complications. 
Following the report of Scott-jupp et al suggesting a possible 
adverse effect of liver disease on prognosis in cystic fibrosis 
(Scott-jupp et al., 1991) the initial aim of this thesis was to 
evaluate the prognostic significance, if any, of chronic liver 
disease in the cohort of cystic fibrosis patients attending The 
Brompton Hospital, London, UK 
The finding of a significant influence of liver disease on survival 
coupled with the anticipated increase in the prevalence of liver 
disease as longevity improves suggest that liver disease in cystic 
fibrosis may become central to the long-term management of 
people with cystic fibrosis. This prompts a number of questions 
some of which have been addressed in the further studies 
presented in this thesis: 
(i) The need for an accurate, preferably non-invasive, test to 
accurately establish the diagnosis of liver disease is of 
paramount importance to allow the correct management of 
individuals with cystic fibrosis. This thesis evaluates a number 
of biochemical and imaging approaches to this problem. 
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(ii) Given that liver disease appears to indirectly influence 
survival in cystic fibrosis studies have been performed to 
attempt to elucidate a mechanism/mechanisms through which 
this effect might be mediated. 
T. 
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CHAPTER 2 
PREDICTING SURVIVAL IN CYSTIC FIBROSIS 
Development of a prognostic model and the influence of liver 
disease. 
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2.0. Introduction 
Survival of patients with cystic fibrosis has improved 
considerably in recent years, predominantly as a result of 
improved respiratory care (British Paediatric Association 
Working Party on Cystic Fibrosis, 1988; MacLusky & Levison, 
1990). Death however, continues to be due, in the majority, to 
respiratory failure associated with cor pulmonale and 
pulmonary hypertension (MacLusky & Levison, 1990). 
Transplantation (double-lung, heart-lung or occasionally heart- 
lung-liver) remains the cornerstone of treatment in the terminal 
phase of the disease (Madden et al., 1992) and results, which 
include enhanced survival and improvement in lung function, 
have been encouraging in both adults (Scott et al., 1988) and 
children (Whitehead et al., 199 1b). 
To optimise the timing and results of transplantation, 
particularly in the presence of a donor shortage, there is a need 
for an accurate prediction of patient survival. Current 
recommendations for transplantation include those patients 
whose quality of life is severely impaired and whose life 
expectancy is less than two years (Whitehead et al., 1991a). 
Current criteria suggested for recommending transplantation 
include percentage predicted forced expiratory volume in one 
second (%PFEV1) < 30% and significant carbon dio. -dde (C02) 
retention (Kerem et al., 1992). 
There have, however, been no assessments of the influence of 
liver disease upon survival despite the results of a large 
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retrospective study suggesting a possible covert influence of 
liver disease upon survival (Scott-jupp et al., 199 1). 
The aim of the present study was, therefore, to document 
predictors of short and medium term survival in cystic fibrosis 
and to further evaluate the importance of liver disease in 
determining prognosis in cystic fibrosis. 
The analysis was perfonned on a prospectively collected data 
base of patients seen at The Royal Brompton Hospital, London. 
Following initial screening for variables significantly associated 
with survival by log rank analysis and univariate Cox regression 
analysis, significant variables were entered into a time 
dependent multivariate Cox regression analysis to select the 
subset of variables which best predict survival (Christensen et 
al., 1986). 
These variables were combined to create a prognostic model 
which was then internally validated using split-sample testing 
(Christensen et aL, 1986). 
Data from a second cohort of patients also seen at The Royal 
Brompton Hospital after completion of the original study cohort 
were then used to externally validate the model. 
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Methods 
2.1.1. Study Population 
The study cohort consisted of 403 patients with cystic fibrosis 
seen at The Royal Brompton Hospital, London between 1969 and 
1987, and followed up until death or 1989. 
I& 
All patients underwent an initial assessment upon referral to the 
hospital and subsequent annual assessments. Evaluation of 
routine haematology and serum biochemistry, pulmonary 
function, nutritional and hepatic status were performed during 
periods of stability. 
These data were collected prospectively on a computerised data 
base, with pulmonary function and weight expressed as a 
percentage of the expected value (Society of Actuaries (Chicago), 
195 9; Bates et al., 197 1). 
The year of entry to the study, considered to be the date of first 
full assessment at the Brompton Hospital, was included in all 
analyses to allow for the possible effect of changes in referral 
patterns and for the development of improved treatment 
regimes. In addition, as the diagnosis of cystic fibrosis had been 
made sometime prior to the initial assessment for the majority 
of the study population, the time from diagnosis to entry was 
calculated and entered into the analysis. 
Sixteen patients were lost to follow-up but were included in the 
analysis until the date they were last known to be alive. 3 of 
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these patients returned to their homes abroad, 11 were 
transferred to other hospitals and no inforniation is available for 
the other 2. 
2.1.2. Statistical analysis 
Variables were initially screened using two statistical tests: 
(i) Log rank analysis was used to screen twenty static and 
continuous variables for correlation with survival. Median 
values were used as cut points for the continuous variables. 
IL 
(ii) Univariate Cox regression analysis was performed separately 
on twelve variables as they changed with time. Those with a 
skewed distribution were transformed into a Gaussian 
distribution using a log transforination. 
All significant variables identified by these initial screening tests 
were then entered in a stepwise manner into both forward and 
backward stepping, time dependent, multivariate Cox regression 
analysis to select the subset of variables which best predict 
survival (Christensen et al., 1986). 
At each step only the significant variables were retained such 
that variables which did not add further information about 
survival were excluded. 
Multivariate time dependent Cox regression analysis requires 
that all patients be represented by a complete set of data at the 
time of entry to the study. Thus as variables with missing data 
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were analysed and were excluded from the model, so more 
patients could be included in the final analysis. 30 patients had 
one or more variable in the final model missing and so the final 
analysis was performed on 373 patients. The significant 
variables were combined into a predictive index and used to 
produce estimates of survival. 
2.1.3. Validation of the model 
2.1.3.1 Internal Validation (within the study 
population). 
The model was validated using split-sample testing (Christensen 
et al., 1986). The database of 373 patients was divided into two 
parts. The model was regenerated using the first 3/4 of the 
database and applied to the remaining 1/4. A predictive score 
was generated, at all time points, for each of the remaining 
patients using the model and, in combination with the 
underlying hazard function, used to calculate the probability of a 
particular patient dying within one year: 
Probabflity of death =1- exp-(hazard x time x exp(PI)) 
where 
exp = exponential 
haz = underlying hazard function 
time = period of prediction (years) 
PI = predictive score for a particular set of observations 
The sum of these probabilities represents the expected number 
of deaths within one year. Any death which occurred less than a 
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year after the observation was counted as an observed death. 
Only one set of observations per year per patient was used in 
the analysis. 
The process was repeated by regenerating the model using the 
last 3/4 of the data base and applying it to the first 1/4. 
The observed and expected totals were compared using the X2 
test. 
IL 
2.3.1.2. External validation (using a cohort recruited 
between October 1988 and September 1993). 
The predictive index (PI) was generated for each patient and the 
probability of dying within 1 year calculated using the same 
fonnula as above (Christensen et al., 1986). 
The patients were then divided into three groups by PI, and the 
probabilities of death calculated for each group to give the 
expected number of deaths for that group. A comparison with 
the actual number of deaths was made using the X2 test. 
A further comparison of observed and expected deaths, as 
predicted by the model, was made by subdividing the observed 
deaths into PI ranges such that equal numbers of patients died 
in each of the three sub-divisions. The expected number of 
deaths for each of these ranges was calculated and comparison 
made using X2. 
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2.2. Results 
Statistical analyses. 
The patient characteristics are shown in Table 2.1 (pancreatic 
replacement being those subjects taking pancreatic enzyme 
supplements; malabsorption defined as frequent, loose, pale or 
offensive stools that were difficult to flush away). 373 patients 
were included in the final analysis of which 188 (50.411/6) died. 
The median age was 20 years (range 11 - 63 years ) with 169 
males and 204 females. 
it 
54 (14.5%) had hepatomegaly at entry to the study and a further 
74 (19.8%) developed hepatomegaly during follow-up. 24 (6.4%) 
had splenomegaly at entry and 89.7% were on pancreatic 
enzyme supplements. 
The factors significant by either log rank analysis or univariate, 
time dependent, Cox regression analysis are shown in Table 2.1. 
Eleven variables were significant by Cox regression analysis. 
Age, gender, the year of entry into the study and time from 
diagnosis to entry into the study were not significant after the 
final analysis. 
Time dependent multivariate Cox regression analysis revealed 
hepatomegaly (as defined by palpable liver, confirmed by span 
> 12 cm in the mid-clavicular line), height (m), percentage 
predicted forced vital capacity (%PFVC), percentage predicted 
forced expiratory volume in 1 second (%PFEVl), white blood 
count (WBQ W09/1), serum albumin (g/1), and serum alkaline 
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phosphatase (ALP) (iu/1), as factors significantly associated with 
survival. 
Serum albumin and ALP were excluded from the final model. 
The former because its coefficient within the predictive model 
was only 0.0001 and the latter because for individual patients 
there was concern that bone related ALP might introduce 
considerable inaccuracy. 
IL The remaining significant variables were combined to produce 
the fmal model (table 2.2. ): 
PI = (0.99 x hepatomegaly) - (3.41 x height) - (0.03 8x %PFVQ - 
(0.0590 x %PFEV1) + (0.090 x WBQ 
(presence of hepatomegaly =1; absence = 0) 
2.2.2. Application of the model 
Multivariate Cox regression analysis produces a model of two 
parts. The first part is related to the current medical status of 
the cohort and the second is a multiplying hazard function which 
is constant for all patients (the underlying hazard function) 
(Christensen et al., 1986). The hazard for this cohort of patients 
was constant as it changed over time (r=0.996), deviating only as 
the numbers of patients become small at 7 years (Figure 2.1. ). 
As the aim of the analysis was to evaluate short and medium 
term predictors of survival, this line represented the underlying 
hazard function of the model well. 
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A linear hazard function implies a risk of death that is 
independent of time, and allows graphs relating the predictive 
index and the probability of surviving set periods of time to be 
generated (Figure 2-2. ). 
Using the model it is possible to calculate a predictive index (PI) 
for any patient with cystic fibrosis at any stage of their disease 
and to use it to obtain estimates of their predicted survival using 
the survival curves (Figure. 2.2). 
2.2.3. An example of model application: 
A patient presents with 
Height = 1.54 
Hepatomegaly =1 (present) 
%PFVC =50 
%PFEV1 = 35 
WBC = 20 
IL 
The predictive index for this patient is obtained by multiplying 
each variable by its coefficient 
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Pi =-3.410 x 1.54 
0.990 x1 
- 0.038 x 50 
- 0.059 x 35 
0.090 x 20 
=-6.4 
Using figure 2.2. it can be seen that this patient has a 75% 
estimated chance of surviving 6 months and a 56% chance of 
surviving 12 months. 
2.2.4. Results of the validation 
2.2.4.1. Internal Validation 
IL 
The validation was performed twice. Once using the top 3/4 of 
the data, and once using the bottom 3/4. 
'k 'n In the first case the observed number of deaths was 65 and we 
expected number 60 (Chi squared = 0.41; p>0.4 (ns)). In the 
second there were 33 observed and 33.65 expected deaths (Chi 
squared = 0.012; p>0.8 (ns)). 
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2.2.4.2. External Validation 
There were one hundred patients, fifty of each sex aged between 
13 and 45 years old, recruited between October 1988 and 
September 1993. All had at least one years follow-up, or died 
soon after referral. Comparison of observed and expected deaths 
using sub-division according to PI and sub-division to ensure 
that all groups contained the same number of observed deaths 
confirms the ability of the prognostic model to accurately predict 
1 year survival in this cohort of cystic fibrosis patients (Tables 
2.3. and 2.4. ). 
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Median (n) 10-90% Range Log Rank 
(p) 
Univariate Cox 
Regression (p) 
Age (years) 20.17(373) 16.0-27.0 p=0.421 N/A 
% Pred PEFR 61(364) 25.5-98.2 ". 0001 P<0.001 
% Pred FVC 62(373) 31.4-99.1 ". O()Ol P<0.001 
% Pred FEV1 43(373) 19.3-86.0 P<0.0001 P<0.001 
Height (m) 1.63(373) 1.51-1.78 p<0.0003 p<0.001 
% Pred weight 82.0(351) 71.1-100 ". 0001 "-. 001 
Alk Phos (iu/1) 225(365) 130-571 p=0.897 ". 05 
Albumin (g/1) 38(354) 32-46 p=0.0007 P<0.001 
Bilirubin 
(JAMOI/1) 
7(359) 3-16 p=0.968 O. lq3<0.2 
WBC (x1O9A) 10.8(373) 6.9-17.0 p=0.189 p<0.001 
Haemoglobin 
(g/dl) 
13.5(364) 11.8-15.4 p=0.0006 p<0.001 
Follow-up 
(years) 
3.5(373) 1.0-7.0 N/A N/A 
Sex male=169, female=204 P=0.556 N/A 
Splenomegaly no splenomegaly=349, 
splenomegaly=24 
P<0.0001 P<0.001 
Hepatomegaly no hepatomegaly=319, 
hepatomegaly=54 
P=0.010 p<0.001 
Malabsorption no malabsorption= 148, 
malabsorption=218 
p=0.095 
Diabetes no diabetes=326, diabetes=47 p=0.005 
Ascites no ascites=365, ascites=8 p=0.469 
Varices no varices=367, varices=4 p=0.027 
Pancreatic 
replacement 
no replacement=40, 
replacement=331 
p=0.022 
* These variables were recorded only at entry to the study. 
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V 
Variable Coefficient SE Coef/SE p-value Relative 
Risk 
Height -3.41 0.828 -4.12 P<0.0001 0.033 
(M) 
Hepmeg 0.99 0.154 6.48 P<0.0001 2.69 
(091) 
% Pred -0.038 0.009 -3.27 P<0.0001 0.963 
FVC 
% Pred -0.059 0.013 -4.46 P<0.0001 0.943 
FEV1 
WBC 0.090 0.014 6.40 P<0.0001 1.095 
(X109/1) 
Table 2.2. Details of variables significant by 
multivariate Cox regression analysis and 
included in the final model 
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PI < -9.0 PI 2 -9.0 - PI 2 -6.5 
PI < -6.5 
Observed 0 13 26 
Expected 0.20 6.42 21.7 
X2 0.20 6.7 0.85 
Total X2 = 7979; p>0.05 
Table 2.3. External validation sub-dividing 
patients by PI 
PI < -6.5 PI ý: -6.5 - PI ý: 5.4 
PI < -5.4 
Observed 13 13 13 
Expected 6.6 9.6 12.1 
X2 6.2 1.2 0.07 
Total X2 = 7.47; p>0.05 
Table 2.4. External validation sub-dividing 
patients to ensure equal numbers of observed 
deaths within each sub-group 
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2.3. Discussion 
2.3.1. General 
This analysis has enabled the construction of a model to predict 
short and medium term survival in patients with cystic fibrosis. 
The model was validated within the study population and a 
cohort recruited after October 1988. Its application to other CF 
populations remains to be assessed, but its support by the 
results of the external validation, suggests wide applicability. 
This presumption is supported by reported similarities in the 
median survival for cystic fibrosis patients in the United 
Kingdom (British Paediatric Association Working Party on Cystic 
Fibrosis, 1988), United States of America (Corey et al., 1988), 
Canada (Corey et al., 1988) and Denmark (Niellsen & Schiotz, 
1982). 
The results of the external validation confirm the accuracy of the 
model in predicting the prognosis of cystic fibrosis patients who 
are particularly unwell. Sub-division by PI results in less 
accurate prognostic prediction for the intermediate category 
while sub-division to ensure equal numbers of observed deaths 
in the three groups results in successively less accurate 
prediction of survival in the intermediate and well sub-groups. 
The purpose of this prognostic model is, however, to identify 
patients in need of transplantation and the results of the 
79 
validations showing accurate prediction of survival in the least 
well patients suggest that it will, in general, fulfil this aim. 
The characteristics of the cohort within this study were 
determined by hospital referral patterns and resulted in the 
analysis being of a predominantly adult population. This does 
not diminish its value, although its extrapolation to a paediatric 
population remains to be evaluated. 
While there have been marked improvements in the 
management of patients with cystic fibrosis over the 
considerable time period of recruitment to this study, and also 
changes in the pattern of referral to the Brompton Hospital 
resulting more recently in a sicker patient population 
(predominantly those with complications of the disease that 
have proved difficult to manage or those in need of transplant 
assessment; the result of the development of specialist centres 
for the management of cystic fibrosis outside London), the 
failure of the year of entry to the study to reach statistical 
significance in the multivariate analysis suggests that 
improvements in patient management are accounted for by the 
variables included in the model. These changes do not, therefore, 
reduce the applicability of the prognostic model to patients 
diagnosed more recently. Furthermore, the prognosis of patients 
recruited more recently, whose prognosis is likely to reflect 
these changes in management and referral practice, appears to 
be well modelled by the predictive index as demonstrated by 
the results of the external validation. 
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Several previous reports have centred on the predictors of long- 
term survival and the factors associated with improved long- 
term outcome in cystic fibrosis (Corey, 1980; Wood, 1984; Phelan 
& Hey, 1984; Hudson & Phelan, 1987; Huang et al., 1987; British 
Paediatric Association Working Party on Cystic Fibrosis, 1988; 
Corey et al., 1988; Britton, 1989). Only one has attempted to 
address the issue of predictors of short term survival. (Kerem et 
al, 1992). 
IL 
The failure of both the age and sex of the patients to reach 
statistical significance within the model is at variance with some 
(British Paediatric Association Working Party on Cystic Fibrosis, 
1988; Britton, 1989; Elborn et al., 199 1; Kerem et al., 1992), but 
not all (Huang et al., 1987; Hudson & Phelan, 1987), previous 
reports. It has been suggested that the influence of both these 
factors on survival is related to the nutritional status of the 
patient (Corey et aL, 1988). The inclusion of patient height, 
which may reflect nutritional status (see below), in this model 
may have resulted in the exclusion of both age and gender from 
the prognostic index. However, this inter-relationship between 
age, sex and nutrition has not been reported universally with 
the most recent report of predictors of prognosis suggesting an 
increased risk of death in young females with cystic fibrosis 
even when allowance is made for weight differences (Kerem et 
aL, 1992). 
While pulmonary function has not always correlated with 
survival (Huang et al., 1987), other reports have documented the 
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importance of deteriorating FEV1 and Of C02 retention (Wagener 
et al., 1980; Kerem et al., 1992). 
Kerem et al. found that a %PFEV1 below 30% was the best 
predictor of survival, with other significant factors including a 
partial pressure of arterial oxygen below 55 mmHg, a partial 
pressure of arterial carbon dioxide above 50 mmHg. Within this 
model a reduced %PFEV1 and reduced %PFVC are positively 
correlated with shorter survival. Although a reduction of both , 
variables reflects pulmonary outflow obstruction the inclusion of 
both by the statistical analysis suggests that each provides 
additional prognostic information. 
Oxygen saturation and arterial blood gas analysis were not 
included in this analysis as these were not routinely performed 
before the mid 1970s. 
Nutritional status, including short stature and reduced weight 
percentile, have also been documented as important predictors 
of prognosis (Huang et a]., 1987; Corey et al., 1988), although 
there are no studies showing that nutritional intervention leads 
to an improved long-term survival (Levy et al., 1985). In the 
current analysis taller patients survived longer. The precise 
relationship of height to survival remains unclear, but failure of 
statural. growth probably reflects a degree of malnutrition 
(Editorial, 1988) and may, therefore, be a longer term marker of 
disease severity. 
The prognostic model also includes two factors that have not 
previously been reported as predictors of outcome: 
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The negative correlation of a high WBC with survival may reflect 
chronic on-going sepsis, presumably of pulmonary origin. The 
observation that WBC and pulmonary function are independent 
prediction variables suggests that mechanisms other than 
pulmonary disease alone may be involved. It may be speculated 
that inflammatory mediators secondary to sepsis, such as 
turnour necrosis factor a, may have a systemic adverse effect 
(Elborn et al., 1993). 
Established chronic liver disease, as manifest by hepatomegaly, 
also proved to be an important negative correlate with survival. 
This previously largely unsuspected influence of chronic liver 
disease upon survival highlights two areas which may become 
increasingly important in the longer-term management of cystic 
fibrosis patients: firstly the accurate documentation of those 
cystic fibrosis patients with and without significant hepatic 
involvement (without the need to resort to a liver biopsy) and 
secondly the identification of a therapeutic agent effective for 
the treatment of cystic fibrosis related chronic liver disease. 
Concerns that hepatomegaly might represent a poor predictor of 
chronic liver disease with inter-observer variation may have 
credence for individual patients (Tanner, 1992) but has proved 
of value both when compared with histological evidence of liver 
disease in cystic fibrosis (Gaskin et al., 1988) and within this 
statistical model (relative risk 2.69). Further support comes from 
two other cholestatic liver diseases: primary sclerosing 
cholangitis (Farrant et al., 1991) and primary biliary cirrhosis 
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(RoH et al., 1983) for which hepatomegaly has been shown to 
correlate significantly with reduced survival. 
The importance of liver disease as a predictive factor is further 
supported by the finding that ALP was a significant variable. 
2.3.2. Possible mechanisms for the influence of liver 
disease upon survival 
In the present series very few deaths were directly attributable 
to overt complications of liver disease (2.2%). This observation is 
in keeping with a recent retrospective analysis of a cohort of 
1100 cystic fibrosis patients in which only 7.8% of deaths in 
those patients with liver disease were directly related to the 
liver disease (Scott-jupp et al., 199 1) and suggests a covert 
influence of liver disease upon survival. 
There are a number of potential mechanisms by which this 
effect could be mediated, including an adverse effect upon 
nutritional status (although liver disease and nutrition are 
independent variables within the prognostic model) (Sproul & 
Huang, 1964; Sokol & Stall, 1990); abnormalities of the immune 
system, both humoral (Feizi, 1968) and cell mediated (Webb et 
al. ý 1980), and changes in the pulmonary and systemic 
haemodynamics which occur in cirrhosis of other aetiologies and 
have resulted in hypoxaemia, a relative tissue oxygen debt and a 
detrimental effect on major organ systems (Bosch et al., 1983; 
Rodriguez-Roisin et al., 1988). 
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The documentation of the factors determining the adverse effect 
of liver disease upon survival would offer a potential for 
therapeutic intervention. 
2.4. Conclusions 
The importance of the accurate prediction of survival to 
facilitate assessment for lung transplantation is well recognisecl 
(Whitehead et al., 1991a; Kerem et al., 1992). This model 
represents a simple method, which should be applicable to other 
cystic fibrosis populations, for timing assessment for 
transplantation, and should be a valuable addition to the 
available criteria for judging the short and medium term 
management of cystic fibrosis patients. 
The identification of chronic liver disease as an important factor 
reducing longevity in cystic fibrosis highlights a number of 
issues that have already been discussed. The simple, non 
invasive diagnosis of chronic liver disease (given the inaccuracy 
of percutaneous liver biopsy) and some of the possible 
mechanisms for its covert effect upon survival are central to 
further work conducted as part of this thesis. 
In addition, the identification of an effective treatment for cystic 
fibrosis related chronic liver disease would appear to be 
essential for the prospects of further improving longevity in 
cystic fibrosis. 
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CHAPTER 3 
AN ULTRASOUND SCORING SYSTEM FOR THE 
DIAGNOSIS OF LIVER DISEASE IN CYSTIC 
FIBROSIS 
and a detailed evaluation of the biliary tree. 
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3.0. Introduction 
The prevalence of liver disease in cystic fibrosis has been 
estimated at up to 72% in postmortem studies (Vawter & 
Shwachman, 1979) and although clinical estimates of established 
chronic liver disease are lower at up to 25% of cases (Nagel et al., 
1989) it is likely that improvements in the management of the 
pulmonary complications of CF and consequent increasing 
longevity (British Paediatric Association Working Party on CysAc 
Fibrosis, 1988; MacLusky & Levison, 1990) will result in more 
patients developing significant hepatic involvement. 
The anticipated increase in prevalence coupled with the results 
of the multivariate Cox regression analysis presented in chapter 
2 of this thesis suggest that the presence of liver disease may be 
important in the future management of patients with cystic 
fibrosis and highlights the need for a simple and accurate test 
for confirming the presence of established chronic liver disease. 
Clinical examination and conventional biochemical tests of liver 
function are neither sensitive nor specific enough, in the 
individual patient, to confirm the diagnosis of established cystic 
fibrosis related chronic liver disease (Tanner, 1992). 
In hepatological practice percutaneous liver biopsy is the 
standard for evaluating liver pathology (Van Ness & Diehl, 1989) 
as well as for guiding and monitoring treatment (Sherlock & 
Dooley, 1993b). However, liver biopsy has an associated 
morbidity (3%) and mortality(O. 03%) (Garcia-Tsao & Boyer, 
1993). This is further increased in cystic fibrosis because of the 
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risks of pneumothorax and the likely increase in mortality 
should any complication occur. 
Percutaneous liver biopsy is subject to sampling error which 
may be as high as 66% (Soloway et al., 19 7 1). In cystic fibrosis 
related chronic liver disease liver biopsy is particularly open to 
sampling error due to the patchy distribution of the early 
hepatic lesion (Bodian, 1952) and the macronodular pattern of 
the established cirrhosis (di Sant'Agnese & Blanc, 1956). 
Considerable discrepancy has been documented between liver 
biopsies taken percutaneously and wedge biopsies obtained 
laparoscopically in the same cystic fibrosis patients (Gaskin et 
al., 1988) with those obtained percutaneously being 
unrepresentative of the severity of the underlying liver lesion. 
This, coupled with the potential complications of the procedure, 
has made liver biopsy, in cystic fibrosis, unacceptable to many 
experts (Wilson-Sharp et al., 1984). 
These major limitations have resulted in the evaluation of 
imaging techniques to detect evidence of liver disease. Reports 
of hepatic ultrasound (Wilson-Sharp et al., 1984; Graham et al., 
1985; McHugo et al., 1987) and the measurement of the portal 
vein diameter (Kumari-Subaiya et al., 1987) in cystic fibrosis 
have supported the value of this non-invasive investigation. 
In cystic fibrosis it might be reasonable to assume that the vast 
majority of chronic liver disease will be of biliary origin, and as 
such ultrasound does not need to be capable of providing a 
histological diagnosis, but rather to assess (and grade) the 
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degree of architectural disruption. Such assessment appears well 
within the capacity of modem ultrasound technology. 
One small study (9 patients) has addressed the issue of an 
ultrasound diagnosis of liver disease in cystic fibrosis by 
comparing ultrasound findings with open or laparoscopic liver 
biopsies. This study showed that, in the few patients evaluated, 
ultrasound detected hepatic parenchymal abnormalities 
consistent with abnormal liver histology (Willi et al., 1980). In, 
addition ultrasound abnormalities did not parallel histological 
change in the one patient who underwent a percutaneous liver 
biopsy (Willi et al., 1980). 
The aim of this study was, therefore, to document the detailed 
clinical, biochemical and ultrasound characteristics of a cohort of 
cystic fibrosis patients in order to establish ultrasound criteria 
which could be applied universally for the diagnosis of cystic 
fibrosis related liver disease. Each of these parameters, if 
considered alone, would not be considered very specific or 
sensitive for the diagnosis of liver disease, but when combined 
represent the best 'guess'. This may provide problems for the 
individual case but overall provides a basis for statistical 
assessment. 
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Patients and Methods 
1.1. Patients. 
68 stable adult cystic fibrosis patients attending the out-patient 
clinics at The Royal Brompton Hospital were investigated. 
The majority of patients were prospectively evaluated, although 
not all were randomly selected as some were known to have 
liver involvement prior to this study, and as such the cohort is 
not a truly representative cross-section of the cystic fibrosis 
patients attending The Royal Brompton Hospital. 
3.1.2. Methods. 
1. Clinical Examination 
T. 
Subjects were examined for evidence of the peripheral stigmata 
of chronic liver disease (SCID) (Saraky, 1987), hepatomegaly 
(palpable liver with span > 12 cm in the mid-clavicular line) and 
splenomegaly. 
3.1.2.2. Haematological tests 
Blood was taken for routine haematological and biochemical 
testing and was also screened for other aetiological factors of 
chronic liver disease in young adults/adolescents (Hepatitis B 
and C, autoimmune liver disease, al-antitrypsin and Wilson's 
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disease). Where these were detected the patient was excluded 
. C-- - 
from the study. 
3.1.2.3. Ultrasound scanning 
The subjects underwent a detailed ultrasound scan following a4 
hour fast, using a realtime electronic curved array scanner 
(Ultramark 9-HDI, ATL, USA) and 3.5 MHz transducer, to asses§ 
the liver, spleen and portal circulation. Scanning was perfonned 
in the supine, right anterior oblique and left lateral positions by 
a single observer blinded to the available clinical and 
biochemical data. 
3.1.2.3.1. Ultrasound scoring system 
Dv-, n * 
I. evious studies have identified three ultrasound characteristics 
particular to liver disease in cystic fibrosis. These are 
parenchymal change similar to that observed in other forms of 
chronic liver disease (Wilson-Sharp et al., 1984), periportal 
fibrosis (increased periportal echoes) (Willi et al., 1980; Graham 
et al., 1985) and irregularity of the liver edge consistent with 
the macronodular pattern of cirrhosis in cystic fibrosis (McHugo 
et al., 1987). 
Based on these criteria an initial cohort of 20 subjects was 
scanned to assess inter-subject variation in these features which 
were then used to develop an ultrasound based scoring system 
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for the objective diagnosis of liver disease (Table 3.1.; Figures 
1. to 
A total score of 3 generated by the scoring system (Table 3.1. ) 
was consistent with no liver abnormality (NLD group), while 
higher scores were indicative of a degree of hepatic abnormality 
up to a score of 9 which suggested established cirrhosis. All 
subjects with a score of four or more were allocated to the liver 
disease (ID) group. % 
The remaining 48 adult subjects were then evaluated 
prospectively, together with a cohort of 16 pre-pubertal subjects 
from the paediatric cystic fibrosis clinic who underwent hepatic 
ultrasound scanning to confirm the applicability of the scoring 
system to younger cystic fibrosis patients. 
3.1.2.3.2. Validation of the scoring system 
Inter-observer reproducibility of this scoring system was 
assessed by three independent radiologists, blinded to the 
patient's status, who used the scoring system to score hardcopy 
scans obtained from each of 52 ultrasound examinations. 
3.1.2.3.3. Measurement of liver volume 
The liver volume was estimated, f6flowing a small inspiratory 
breath, by measuring (in cm) the cranio-caudal (c-c) and antero- 
posterior (a-p) diameters of the liver in the mid-clavicular line 
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and by measuring the latero-lateral (1-1) diameter of the liver 
after rotating the ultrasound probe through 900. The liver 
volume was calculated using the formula: 
Volume (ml/Kg) = (133.2 + 0.422(c-c x a-p x 1-1))/patients 
weight (Kg) (Zoli et aL, 1989) 
3.1.2.3.4. Measurement of the splanchnic vessels I& 
The diameter of the splanchnic vessels were measured following 
a small inspiratory breath. The portal vein at the porta hepatis, 
the splenic vein where it crosses anterior to the superior 
mesenteric artery and the superior mesenteric vein 1 cm 
proximal to its confluence with the splenic vein to form the 
portal vein. Doppler signal analysis was used to confirm Patency 
of the splanchnic vessels and hepatic veins and to assess the 
direction of blood flow within the splanchnic vessels. 
The porta hepatis, splenic hilum and gastric cardia were 
examined for the presence of portal-systemic collaterals and the 
longitudinal length of the spleen was measured. 
3.1.2.3.5. The Biliary Tree 
The biliary tree was evaluated to document intrahepatic and 
extrahepatic bile duct abnormalities. These included the 
diameter of the common bile duct and the status of the 
gallbladder, including whether or not it contained stones or 
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debris. When the gall-bladder was visualised it was classified as 
a micro-gaflbladder when < 1.5-2.0 cm in width and < 3.0 cm in 
length (Kramer et al., 198 3). 
The pancreas was examined, when not obscured by bowel gas, 
for dilatation of the main pancreatic duct and increased 
echogenicity which suggests fibrosis. 
3.1.3. Statistical analysis 
Results for the adult subjects with a normal distribution are 
expressed as mean + SEM, while those without a normal 
distribution and the results of the paediatric subjects are 
expressed as median (range). 
Differences between the NID and LD groups (as defined by the 
ultrasound scoring system) were calculated using the X2 test for 
static variables and unpaired t tests for normally distributed 
and the Mann-Whitney U test for non-normally distributed 
continuous variables. Ap value of <0.05 for a two-tailed test was 
considered statistically significant. 
To assess the validity of the scoring system comparisons were 
made between the NLD and ID groups with respect to the results 
of their clinical examinations, haematological. tests and 
ultrasound measurements . Correlation between the liver score 
and other measured variables was calculated using Spearman's 
Rank correlation co-efficient. 
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Inter-observer reproducibility of the ultrasound scoring system 
was calculated using Kendall's co-efficient of concordance W 
which allows comparisons to bemade between observations 
made by more than two observers. 
WA 
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W. 
Characteristic 1 
SCORE 
3 2 
Hepatic Normal Coarse Irregular 
Parenchyma 
I 
liver Edge Smooth Nodular 
Periportal Fibrosis None Moderate Severe 
Table 3.1. The ultrasound scoring system 
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Figure 3.1. Hardcopy ultrasound scan of normal 
hepatic parenchyma and normal periportal 
echoes. 
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3.2. Results 
3.2.1. Ultrasound scanning 
Eighty four patients with cystic fibrosis underwent ultrasound 
assessment. Sixty eight were post-pubertal and sixteen pre- 
pubertal. These were sub-divided into NLD and LD groups on the 
basis of ultrasound criteria. 
The post-pubertal group consisted of 35 NLD subjects (14 female 
and 21 male) with an average age of 24.5 + 1.1 years and 33 LD 
subjects (12 female and 21 male) with an average age of 23.4± 
0.9 years. These differences were not statistically significant. 
The ultrasound results for the adult patients are shown in Table 
3.2.3 patients in the LD group had had a splenectomy: 1 for a 
childhood lymphoma, and 2 for symptoms related to 
splenomegaly. The splanchnic vessel diameters and blood count 
results for these three patients were excluded from further 
analysis. 
Comparison of the ultrasound characteristics between the two 
groups shows no difference in the liver volume, but significant 
% differences for the spleen length (NID vs 1D: 10 (8-12.5) vs. 16.8 
(10.6-26) cm; p=0.0001) and the diameters of all the splanchnic 
vessels, and in particular the splenic vein (5.9 (3-12) vs. 11 (4-5- 
29.1) mm; p=0.0001). 
Doppler assessment confirmed patency of hepatic veins in all 
patients, and patency of all splanchnic vessels although intra- 
abdominal gas limited visualisation of the splenic and superior 
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mesenteric veins in some subjects (numbers visualised given in 
Table 3.2). The direction of blood flow was hepatofugal in two of 
the patients in the LD group and a further patient in this group 
had cavernous transformation of the portal vein. 
Portal-systemic collaterals were documented in seventeen of the 
ID group and none of the NID group. 
The pre-pubertal group consisted of nine NLD (3 females; age 10 
(5-15)) and 7 [5 females; age 11 (5-15)] LD subjects. These 
differences were not statistically significant. 
Ultrasound scanning identified changes identical to those of the 
post-pubertal subjects. The ultrasound characteristics of this 
cohort are shown in Table 3.3. The only significant difference 
between the two groups was in spleen size (9 (5.8-11) vs. 12.7 
(8.6-17.4); p<0.02), with none of the other differences reaching 
statistical significance. 
Following stratification into N1D and LD group on the basis of 
ultrasound scanning, a comparison of other group characteristics 
was possible: 
t 
3.2.2. Clinical findings 
Examination of the adult patients for clinically detectable 
evidence of chronic liver disease: SUD, hepatomegaly and 
splenomegaly, revealed no patients in the NID group with any 
markers that are associated with liver disease. Seven of the LD 
group had palmar erythema (p=0.004 for LD vs NLD), and five of 
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the LD group had other SCID (3 gynaecomasU 1 spider naevi 
and 1 petechiae) (p<0.01 vs. NID), although the subject with 
petechial haemorrhages was on long-term steroid therapy for 
allergic bronchopulmonary aspergillosis. 
Seventeen of the LD group had hepato-splenomegaly, four had 
isolated hepatomegaly, and four LD patients had isolated 
splenomegaly. All these differences were significant when 
compared to the NLD group (p 10.05). 
Comparison of the clinical findings in the pre-pubertal cohort 
revealed the expected differences in hepatomegaly +/- 
splenomegaly between the two groups (Table 3.3. ). One subject 
in each group had palmar erythema and there were no other 
SC1D. 
3.2.3. Haematological and Biochemical laboratory 
results 
Comparison of measured haematological variables in the adults 
is given in Table 3.4. The LD subjects had significant elevations 
of the conventional biochemical tests of liver function, a 
significantly higher serum bilirubin (17 (5-71) vs 7 (4-44) 
Rmol/l; p=0.0001) and significantly lower albumin (35 (25-44) 
vs. 39 (27-45) g/l; p<0.003) and platelet counts (120 (33-384) 
vs. 351 (215-834) x109/1; p=0.0001). The international 
normalised ratio (INR), a test for coagulopathy, was not different 
between the two groups and was within the normal range (< 1.3) 
for the majority of the subjects. 
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3.2.4. Regression analyses between ultrasound score 
and other variables 
Least-squares regression analysis confirmed significant 
correlations between measured variables and the ultrasound 
score (Table 3.5. ). In particular increasing ultrasound score 
correlated with increasing splenic length (R, =0.86, p=0.0001), 
increased splenic vein diameter (Rs=0.74, p=0.0001) and the 
presence of portal-systemic collaterals (Rs=0.80, p=0.0001). Thq 
majority of patients with varices (15/17; 88%) had marked 
ultrasonographic changes (score 8 or 9). There were weaker 
associations documented between ultrasound score and 
increasing portal vein diameter and superior mesenteric vein 
diameter (Table 3.5. ). 
Correlation with haematological/biochemical variables revealed 
three associations of note. Increasing ultrasound score correlated 
with reduced albumin (R, = -0.30, p=0.0008), increased serum 
bilirubin (Rs=0.69, p=0.0001), and a reduced platelet count (Rs= 
-0.60, p=0.0001) (Table 3.5. ). Further inspection of the data 
confirmed a predominance of the patients with a reduced serum 
albumin (<35 g/1) and elevated bilirubin (>17 gmol/1) in patients 
scoring 8 or 9 on ultrasound. All four subjects with prolonged 
INRs (> 1.3) scored 8 or 9 with the ultrasound scoring system. 
Furthermore, correlation of clinical data with ultrasound score 
revealed correlations between increasing score and the SCLD 
(Rs=0.70, p=0.0001), and with the number of subjects with 
hepato-splenomegaly (Rs=0.769 p=0.0001) (Table 3.5. ). Ten of the 
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twelve subjects with SCLD (83%) and 13/17 (76%) with hepato- 
splenomegaly scored 8 or 9 when ultrasounded. 
3.2.4. Ultrasound score reproducibility 
The inter-observer scores for the hardcopy scans were strongly 
correlated confirming the reproducibility of the ultrasound 
scoring system ('W' = 0.92; p=0.0000 1). I. 
3.2. S. The Biliary Tree 
Evaluation of the biliary tree in the adult cohort revealed only 
one dilated common bile duct, and this in a patient who had had 
intrahepatic cholelithiasis treated by endoscopic sphincterotomy, 
basket retrieval of stones and who had had a pigtail prosthesis 
left in situ. There was no evidence of intra-hepatic bile duct 
dilatation. 
The gaU-bladder was visible in 31 (9 1%) of the NLD patients 
(one patient had had a cholecystectomy for symptomatic 
cholelithiasis), and 27 (82%) of the ID patients. 6 (17%) of the 
NLD group and 9 of the 1D subjects (27%) had a micro-gall 
bladder. 5 (15%) of the N1D and 7 (21%) of the ID group had 
gall-stones identified by ultrasound scanning. None of these 
differences were statistically significant. 
The pancreas was only visualised in 50 of the 68 adult subjects 
scanned. 24 of the 29 patients in the NLD group in whom the 
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pancreas was visualised had a pancreas of increased 
echogenicity, whereas aH 21 visualised in the LD group were 
bright. No dilatation of the main pancreatic duct was 
documented. 
In the pre-pubertal subjects there was no evidence of dilatation 
of the biliary tract. The gall bladder was visible in all nine of the 
NID group, and only six of the ID group. 2 patients in each group 
(22% of the NM and 2W6 of the ID group) had a micro gall- 
11 
bladder. 
The pancreas had increased echogenicity in all thirteen subjects 
in whom it was visualised, but was obscured by bowel gas in 
two of the NLD and one of the LD patients. 
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GROUP 
NLD LD p-value 
Number (n) 35 33 
Volume (ml/Kg) 20.4(11.7- 18.5 (7.6- NS 
33.6) 44.6) 
Spleen length 10(8-12.5) 16.8 (10.6-26) 0.000 1 
It (cm) 
Portal vein 
Number 35 (100%) 30 (10011/o)* 
visualised 
Diameter (mm) 12.2 (5-15) 14.5 (8-26) <0.002 
Splenic vein 
Number 30(86%) 26 (87%)* 
visualised 
Diameter (mm) 5.9(3-12) 11 (4.5-29.1) 0.0001 
Superior 
mesenteric vein 
Number 27(77%) 19 (63%)* 
visualised 
Diameter (mm) 7 (3-12) 9(6-18) <0.006 
* Three cases, who had previously undergone splenectomy, 
deleted from the analysis of the LD group 
Table 3.2. Ultrasound characteristics for the 68 
adults (median (range)) 
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GROUP 
IL 
NLD LD p-value 
Number (n) 97 
Volume (ml/Kg) 24.9(17.4- 18.8(6.4- NS 
32.4) 33.7) 
Spleen length 9(5.8-11) 12.7(8.6- < 0.02 
(cm) 17.4) 
Portal vein 10(6-12) 10.3 (8-17.2) NS 
diameter (mm) 
Splenic vein 4(2.7-8) 6.3(4.7-9) NS 
diameter (mm) 
Superior 5 (3-8) 7(5-9.7) NS 
mesenteric vein 
diameter (mm) 
Table 3.3. Ultrasound characteristics for the pre- 
pubertal subjects (median (range)) 
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GROUP 
NLD LD p-value 
Number 35 
Alkaline phosphatase 241(113- 
(iu/l) 647) 
(NR 90-250) 
33 
1074(217- 
3950) 
I& 
0.0001 
Gamma glutamyl 14 (5-13.8) 169 (18-776) 0.0001 
transferase (iu/1) 
(NR 0-32) 
Aspartate 28 (13-371) 72 (25-196) 0.0001 
aminotransferase 
(iu/1) (NR 10-50) 
Alanine 24(5-89) 92.5 (16- 0.0001 
aminotransferase 289) 
(iu/1) (NR 5-40) 
Total bilirubin 7(4-44) 17 (5-71) 0.0001 
(1, tmol/1) (NR 0-17) 
Albumin (g/1) 39 (27-45) 35 (25-44) <0.003 
(NR 33-47) 
Platelets (x109/1) 351 (215- 120 (33-384) 0.0001 
(NR 150-400) 834) 
Table 3.4. Haematological and biochemical values 
for subjects with and without ultrasound 
evidence of liver disease (median (range)) 
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Variables Correlation coefficient p-value 
(Rs) 
Ultrasound 
Splenic length 0.86 0.00*0 1 
Portal vein diameter 0.42 <0.003 
Splenic vein diameter 0.74 0.0001 
Superior mesenteric vein 0.45 <0.001 
diameter 
Portal-systemic collaterals 0.80 0.0001 
Haematological 
Alka. Une phosphatase 0.76 0.0001 
Gamma glutamyl transferase 0.74 0.0001 
Bilirubin 0.69 0.0001 
Albumin -0.30 0.0008 
Platelet count -0.60 0.0001 
Clinical 
Signs of chronic liver disease 0.70 0.0001 
Hepato-splenomegaly 0.76 0.0001 
Table 3.5. Correlations between clinical, 
biochemical and ultrasound parameters and the 
ultrasound scoring system. 
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3.3. Discussion 
3.3.1. The ultrasound scoring system 
This study describes an ultrasound scoring system which allows 
the identification of patients with cystic fibrosis related chronic 
liver disease. It is based upon three characteristics which are 
particularly prominent in the liver disease of cystic fibrosis - the 
coarse liver parenchyma (Wilson-Sharp et al., 1984), nodularivy 
of liver edge (McHugo et al., 1987) and increased periportal 
echoes (Willi et al., 1980; Graham et al., 1985) 
The reproducibility of the scoring system has been 
independently validated by three blinded observers scoring 
hardcopy scans, which is more difficult than assessing realtime 
images (Joseph et al., 199 1). 
Support for an ultrasound based scoring system is provided by 
the reported sensitivity and specificity of ultrasound scanning in 
detecting hepatic fibrosis (Joseph et al., 199 1) (although its 
limitations in detecting mild hepatic fibrosis are acknowledged), 
together with reports that abnormal hepatic ultrasonography 
represents strong evidence for significant hepatic pathology in 
chronic liver disease of other aetiologies (Bloom et al., 1992) 
While no direct comparisons with previous studies can be made 
of scanning technique and assessment of hepatic parenchyma, 
detailed comparison of splanchnic vessel visualisation rates and 
vessel diameter measurements gives some comparison of the 
technical aspects and success of ultrasound scans in this series. 
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The visualisation rates of the splanchnic vessels were 
comparable with published series both in groups with (Wilson- 
Sharp et al., 1984; McHugo et al., 1987) and without (Bolondi et 
al., 1982) cystic fibrosis. In addition, comparison of the 
splanchnic vessel measurements with data from normal controls 
(Strohm et al., 1983; Zoli et al., 1985) reveals that the vessel 
diameters of the NLD subjects are very similar. Likewise the 
portal vein, splenic vein and superior mesenteric vein diameters 
of the LD group are similar to those reported for patients with 
chronic liver disease of other aetiologies (Zoli et al., 1985; Rector 
et al., 1986). 
The optimal criteria to validate this scoring system would have 
been histological. However, as already discussed, percutaneous 
and open liver biopsy are unacceptable in cystic fibrosis due to 
the associated morbidity and mortality. In addition, as a result 
of sampling error, multiple percutaneous biopsies would have to 
be obtained. This approach would be unethical. We have, 
therefore, made an extensive and detailed comparison of the 
scoring system with potential markers of liver disease (markers 
of portal hypertension, clinical evaluation and conventional 
biochemical tests) as we believe this represents the best option 
available for validation. 
Markers of portal hypertension including splenic size, splenic 
vein diameter (Doust & Pearce, 197 6; Matsutani et al., 199 1) and 
the presence of portal-systemic collaterals (Lebrec et al., 1980; 
Garcia-Tsao et al., 1985; Cales & Pascal, 1988) correlate strongly 
ill 
with the scoring system as do the clinical, haematological and 
biochemical parameters. 
The strong correlation of splenic vein diameter with ultrasound 
score is in keeping with reports that the splenic vein diameter is 
the best marker of portal hypertension (Doust & Pearce, 1976; 
Matsutani et al., 1991). Portal vein measurements, suggested by 
others to be an early marker of liver disease in cystic fibrosis 
(Kumari-Subaiya et al., 1987), correlated less well with 
ultrasound score. This observation is in keeping with reports 
that portal vein diameter correlates poorly with portal pressure 
in liver disease of other aetiologies (Bolondi et al., 1982; 
Subramanyam et al., 1983). 
The positive correlation of the ultrasound score with the serum 
bilirubin and negative correlation with serum albumin, a marker 
of hepatic synthetic function which may reflect more advanced 
liver disease (Green et al., 1960; Feigelson et al., 1975), also 
suggest that increasing ultrasound score indicates more severe 
liver disease. 
On this basis the scoring system identifies cystic fibrosis patients 
without liver disease (score 3) and with established cirrhosis 
(score 8-9). It also identifies a group of patients with definite 
but less advanced, possibly non-cirrhotic, liver disease (score 4- 
7). 
Further analysis of the data according to these sub-groups would 
seem to confirm this distinction as the patients scoring 3 have 
normal biochemistry, those scoring 4-7 have normal hepatic 
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synthetic function but have conventional biochemical tests of 
hepatic function that mirror those of the more advanced group 
who scored 8-9. This last grouphave significant elevations of 
serum bilirubin. and reductions of serum albumin (Table 3.6. ). In 
addition there is a predominance of patients with varices, SCID 
and hepato-splenomegaly in the patients scoring 8-9. 
q& 
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Ultrasound score 
Variable 3 (NLD) 4-7 (ILD) 8-9 (SLD) 
. 
Number 35 14 
a, bAlkaline 241 (113- 1085.5 (217- 
phosphatase (iu/1) 647) 2830) 
a, 
l%, 4- 
14(5-138) 168 (18-776) Ciamma glutamyl 
transferase (iu/1) 
c, dAspartate 28 (13-371) 67.5 (42- 
aminotransferase 135) 
(iu/l) 
apbAlanine 24(5-89) 101 (24-220) 
aminotransferase 
(iu/l) 
b, eTotal bilirubin 7(4-44) 10.5 (5-55) 
(UM01/1) 
b, eAlbumin (g/1) 39 (27-45) 36.5 (30-43) 
19 
1047 (255- 
3950) 
199 (33-662) 
72 (25-196) 
83 (16-289) 
23 (11-71) 
31 (25-44) 
a)b, fPlatelets (x109/1) 351 (215- 281 (107- 75 (33-383) 
834) 384) 
a Differences significant (p<0.001) for NLD vs ILD. 
b Differences significant (p<0.001) for NLD vs SLD. 
c Differences significant (p<0.05) for NlD vs ILD. 
d Differences significant (p<0.01) for NLD vs SID 
e Differences significant (p<0.01) for ILD vs SlD 
f Differences significant (p<0.001) for ILD vs SID 
Table 3.6. Results of haematological. and 
biochemical tests for the three groups as defined 
by the ultrasound scoring system (median (range)) 
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3.3.2. The Biliary Tree 
This study has allowed detailed evaluation of the biliary tree 
and gallbladders of patients with cystic fibrosis. The absence of 
demonstrable dilatation of the biliary tree (apart from the 
subject with a pig-tail stent in situ) on ultrasound confirms that 
there is no evidence in this study to support bile duct 
obstruction in the intrapancreatic portion of the duct as an 
important mechanism for the development of liver disease in 
the majority of cystic fibrosis patients (Gaskin et al., 1988; Nagel 
et al., 1989; O'Brien et al., 1992b). 
The gallbladder visualisation rates (81%-91%) and the 
frequency of micro-gallbladder (17%-29%) are consistent with 
other reported series which document micro-gallbladder in up to 
18% in clinical series and 30% at post mortem (Isenberg et al., 
1976; L'Heureux et al., 1977). 
Gallstones were detected by ultrasound in none of the paediatric 
subjects and in 15% of the NID and 21% of the LID adult patients. 
This increase in the prevalence of gallstones with age in cystic 
fibrosis is well recognised (Warwick et al., 1976) and the 
prevalence rates are comparable with those published in the 
literature (Vawter & Shwachman, 1979). 
3.4. Conclusions 
The need for an early, accurate, diagnostic test for liver disease 
in cystic fibrosis is highlighted by the possibility of an occult 
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adverse effect of liver disease on survival, the potential for an 
increased prevalence of liver disease as survival improves and 
the availability of potential therapeutic agents such as 
Ursodeoxycholic acid (Cotting et al., 1990; Colombo et aL. 1992b) 
and other anti-fibrotic agents such as colchicine (Burt, 1992) and 
the prolyl-4 hydroxylase inhibitors (Clement et al., 199 1) which 
are as yet untried in cystic fibrosis liver disease. The ability to 
identify patients with earlier hepatic disease may be important 
as they may form a sub-group more likely to respond to therapy 
as compared with patients with advanced cirrhosis (Colombo et 
al., 1993). 
Percutaneous liver biopsy is inaccurate and correlates poorly 
with open biopsy and ultrasound. Obtaining tissue for histology 
by either route is likely to be unacceptable. 
The ultrasound scoring system reported here, which is 
supported by clinical, biochemical and ultrasound markers of 
liver disease, is probably useful for detecting and grading the 
severity of liver disease in cystic fibrosis. It may also allow the 
objective evaluation of response to therapy. 
This study suggests that an ultrasound scan, preferably 
performed by a single experienced ultrasonographer using this 
scoring system, should be incorporated into the routine, regular 
assessments of all cystic fibrosis patients to allow early detection 
of hepatic disease and early institution of therapy. 
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Chapter 4 
QUANTITATIVE HEPATOBILIARY SCINTIGRAPHY 
for the diagnosis and assessment of disease severity in cystic 
fibrosis related chronic liver disease. 
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4.0. Introduction 
Hepatobiliary scintigraphy represents an alternative means of 
imaging and evaluating liver disease (Heyman, 1994). 
The present study evaluated this technique, which involves the 
use of Technetium labelled iminodiacetic acid derivatives to 
evaluate the integrity of the hepatobiliary system, for the 
detection of liver disease in cystic fibrosis and for the 
assessment of disease severity. 
The handling of the isotope allows the measurement of both 
hepatic parenchymal and biliary excretory function. Measures of 
hepatic uptake may be a particularly useful marker of disease 
severity in patients with cystic fibrosis related chronic liver 
disease as the conventional parameters used to assess disease 
progression (hepatic decompensation and impairment of hepatic 
synthetic function) rarely occur until late in the disease process. 
Similarly, measures of hepatic excretion may be particularly 
useful in a disease which is believed to evolve from biliary 
obstruction. 
Calculated measures of hepatic isotope uptake include the 
hepatic extraction fraction which is calculated using 
deconvolutional analysis and may be a useful estimate of hepatic 
reserve. In addition, other measures of hepatic isotope uptake 
(the half-time of hepatic uptake and time to maximal hepatic 
activity) and measures of biliary excretion (half-time of hepatic 
excretion and percentage retention of the isotope at particular 
time points) can be calculated from a non-linear least squares fit 
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to a background corrected liver time-activity curve. 
Furthermore, the anatomy of the biliary tree (both intra- and 
extra-hepatic) can be delineated. 
For the purposes of this study a cohort of cystic fibrosis subjects 
who had already undergone hepato-biliary ultrasound scanning 
were evaluated. Normal ranges for the measured scintigraphic 
variables were established using ten normal healthy volunteers. 
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4.1. Patients and Methods 
4.1.1. Patients and methods 
Following an overnight fast 30 subjects underwent quantitative 
hepatobiliary scintigraphy (Brown et al., 1988; Howman-Giles et 
al., 1993). Of 20 subjects with cystic fibrosis, 13 had abnormal 
hepatobiliary ultrasounds (ID group) and 7 normal ultrasounds 
(NID group), and there were 10 healthy Control subjects, with no 
clinical or laboratory evidence of hepato-biliary disease, who 
were recruited from the medical staff at Charing Cross Hospital. 
150 MBq of technetium-99m labelled N, a-(2,6- 
diethylacetanflide)-iminodiacetic acid (EHIDA, Amersham 
Laboratories, Amersham, UK) was injected as an intravenous 
bolus. The dose was reduced for the paediatric subjects as 
appropriate for weight and age. 
Serial analogue 64 x 64 matrix images were obtained every 
minute for 60 minutes by a wide field of view gamma camera 
(Scintronix, Aura Ltd., UK) fitted with a low energy general 
purpose collimator, that was interfaced to a dedicated computer 
system (Micas 5, Bartec). The spectrometer was set at a photon 
energy level of 140 KeV, with a 20% window. 
The images were analysed by drawing regions of interest over 
the right lobe of the liver and the left ventricle of the heart. Care 
was taken to ensure exclusion of the major hepatic ducts, 
gallbladder and scatter from the heart from the liver region of 
interest, and to exclude the aorta and scatter from the liver from 
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the left ventricular one. A further area of interest was drawn 
over the spleen to give a measure of vascular background 
activity. The spleen was selected as background as it has a 
common arterial supply with the liver. Time-activity curves 
were generated from each of the areas of interest (Figure 4.1. ). 
These time-activity curves were used by a single observer, who 
was blinded to the clinical status of each subject, to calculate 
measures of hepatic uptake and excretion. 
4.1.2. Calculation of the hepatic extraction fraction 
The heart curve was used as the input function and the liver 
curve as the output function for deconvolutional analysis 
(Gflbert et al., 1987; Hownian-Gfles et al., 1993). 
The matrix algorithm of deconvolution (Valentinuzzi & Montaldo 
Volachec, 1975) was used to calculate the deconvolved liver 
curve. The resultant deconvolved liver curve is a hypothetical 
true liver response representing a direct bolus injection into the 
hepatic artery. 
An exponential best-fit curve was matched to the deconvolving 
liver curve over the first 30 minutes of the study and 
extrapolated to time zero. The point where the curve crosses the 
y-axis is proportional to hepatocyte function and used to give a 
measure of the hepatic extraction fraction (HEF) by comparing 
the y-intercept of the fitted curve to the actual maximum value 
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of the deconvolved liver curve. 
HEF = (y-intercept/y-max of liver response curve) x 100 (%) 
4.1.3. Calculation of other measures of hepatic uptake 
and excretion 
A further time-activity curve was generated by subtracting the 
background counts, measured over the spleen, from the liver L 
time-activity curve. This background corrected liver curve was 
modelled by an uptake-excretion (bi-exponential) 
compartmental model: 
L(t) = k(e-(). 693. t /TE - e0.693. t /TU) 
where L is the number of counts at time t, TE is the excretion 
half-time and TU is the uptake half-time (Brown et aL, 198 1). 
The best fit was determined by a non-linear least squares 
technique (Bevington, 1969). 
The background corrected liver curve was used to estimate the 
half-time of hepatic uptake (tup) 9 the time to maximal 
hepatic 
activity (Tmax), the half-time of hepatic excretion (tEX) and to 
estimate the percentage radio-isotope retained at 45 and 60 
minutes (E45 and E60 respectively). 
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4.1.4. Calculation of hepatic output efficiency 
The output efficiency of the liver was calculated using a 
modification of a technique usually applied to renal studies 
(Britton & Brown, 197 1). 
The liver region of interest was modified to include both left and 
right lobes of the liver, but excluding scatter from other regions 
such as the major intrahepatic bile ducts. The integrated input 
(heart) curve was fitted to the first 5 minutes of the hepatic 
time-activity curve using a correction factor and the assumption 
that excretion from the liver over this time was zero. The counts 
from the actual hepatic time-activity curve were subtracted 
from this hypothetical fitted curve, which assumes that no 
isotope is excreted from the liver over the time course of the 
study, to produce a hypothetical curve of the cumulative amount 
of radio-isotope excreted by the liver. 
The output efficiency was calculated from the average readings 
for the last 2 minutes of each curve and expressed as a 
percentage: 
(Mean t58-60 excretion curvel X 100 
. 2a" -- (Mean t58-60 integrated input curve) 
4.1.5. Assessment of the biliary tree 
Subjective observations were also made, by a single blinded 
observer, of whether there was delayed excretion of the radio- 
isotope from the liver and whether this delay was intra- or 
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extra-hepatic. In addition the images were analysed for 
abnormalities of the common bile duct including dilatation, 
stricture and stenosis and for whether or not the gallbladder 
was visualised. 
4.1.6. Statistical analysis 
Differences between the three groups were analysed using X2 for 
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static variables and one-way analysis of variance (ANOVA) for 
continuous variables. When significant differences were detected 
between the three groups by ANOVA the results were analysed 
further using Fisher's t-based least significant difference. 
Where comparisons were made between the 20 subjects with 
cystic fibrosis the Mann Whitney U test was used as the total 
numbers analysed were small. 
A probability value <0.05 was considered statistically significant 
for a two-tailed test. 
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Figure 4.1. Regions of interest over the heart 
(pink), right lobe of liver (white) and spleen 
(green) and time-activity curves for each of 
these regions (as labelled) for quantitative EHIDA 
uptake and excretion analysis 
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4.2. Results 
4.2.1. Subjects 
30 subjects underwent EHIDA scanning. 13 had evidence of 
cystic fibrosis related chronic liver disease detectable on 
ultrasound scanning (ID) (mean age 19.8 + 2.2 years; 6 males: 7 
females), 7 had completely normal ultrasounds (N1D) (mean age 
19.3 + 3.9 years; 3 males: 4 females) and 10 were normal 
Controls (mean age 27.4 + 1.8; 5nuales: 5 females). These 
differences in age and sex were not statistically significant. 
4.2.2. Clinical, biochemical and ultrasound 
characteristics of the two cystic fibrosis groups. 
The two groups had broadly similar characteristics to those 
already described in the ultrasound analysis. 
There were significantly more subjects with hepato- 
splenomegaly (7/13 vs. 0/7; p<0.02) in the ID cohort (Table 
4.1. ). 3 of the LD group also had portal-systemic collaterals 
detectable on ultrasound against none in the NLD group, 
although this difference was not statistically significantly. 
Routine haematological and biochemical laboratory tests 
revealed a significant elevation of AST, ALT and yGT in the LD 
group (Table 4.1. ). While statistically significant differences in 
the bilirubin and INR results were detected for the two groups, 
the results were predominantly in the normal range suggesting 
that these differences were of no clinical relevance. 
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The median ultrasound score for the 1D cohort was 8 (range 4- 
9), with five subjects scoring 7 or less. The ultrasound 
characteristics confirmed splenomegaly in the 1D patients and a 
significant difference in the splenic vein diameter (Table 4.2. ). 
None of the cystic fibrosis patients had abnormalities of the 
intra- or extra-hepatic bile ducts on ultrasonography. The gall- 
bladder was visualised, in 5/6 (83%) of the NLD group (one of the 
NLD subjects had previously undergone cholecystectomy) and 
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9/13 (69%) of the 1D group. Three subjects in the NLD and three 
in the LD group had micro gall-bladders (see above). These 
differences were not statistically significant. 
4.2.3. Quantitative hepato-biliary scintigraphy 
An example of an EHIDA scan in a cystic fibrosis subject without 
liver disease is shown in figure 4.2. There is rapid excretion of 
the isotope, whereas figure 4.3. shows a similar scan in a subject 
with liver disease and demonstrates marked retention of the 
EHIDA late in the time course of the study. 
Overall there were no differences between the results for any 
parameter between the normal Controls and the N1D cystic 
fibrosis subjects. However, the LD subjects differed significantly 
from both the other groups for a number of uptake and 
excretion variables. 
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Parameter Controls NLD LD 
a, bAST (iu/1) 24.8+3.3 25.9+2.5 83.2+ 9.7 
cýdALT (iU/1) 30.2+9.5 49.7+26.6 78.0+ 13.6 
b, eyGT (iu/1) 6.8+2.3 22.4+9.5 204.2+ 67.5 
tgBilirubin 8.9+1.7 7.7+0.9 15.2+ 2.2 
(Rmol/l) % 
Albumin (g/1) 38.9+2.2 34.9+ 1.1 
INR 1.1+0.0 1.0+0.0 1.2+0.1 
fPlatelets 250.7+7.7 297.3+51.9 193.4+31.4 
(X109/1) 
Clinical Finding 
c, hHepato- 0/10 0/7 7/13 
splenomegaly 
a p=0.004 N1D vs ID 
b P=0.0001 Controls vs 1D 
c p<0.02 NID vs LD 
d p<0.005 Controls vs LD 
e p<0.002 NID vs LD 
f p<0.05 NID vs 1D 
g p<0.05 Controls vs LD 
h p<0.01 Controls vs LD 
Table 4.1. Clinical, haematological, and biochemical 
variables for the subjects included in the EHIDA 
study 
(Statistical comparison by ANOVA and Fisher's t-based least significant 
difference; no significant differences between Controls and NLD subjects) 
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IL 
Variable NID ID p value 
liver volume (ml/Kg) 23.8+2.4 
Spleen (cm) 9.9+0.7 
Portal vein diameter 9.6+1.1 
(mm) 
Splenic vein diameter 5.3+0.6 
(mm) 
Superior mesenteric 5.9+0.9 
vein diameter (mm) 
19.4+2.1 NS 
15.5+1.0 <0.003 
12.7+1.1 NS 
9.0+0.8 <0.01 
8. l+O. 3 NS 
Varices 0/7 3/13 NS 
Table 4.2. Ultrasound characteristics of the 
cystic fibrosis subjects included in the EHIDA 
study 
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Figure 4.2. Hepato-biliary scintigram in an NLD 
subject 
Ij Appearance in the heart in the first minute 
1,4 Rapid uptake into the liver by the end of the fourth minute 
19 11 Rapid excretion, with radio-isotope in the small bowel at 
eleven minutes 
1,27 Excretion almost complete by the twenty seventh minute 
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Figure 4.3. Hepato-biliary scintigram in an LD 
subject 
2.1 Appearance in the heart and spleen after one minute 
2,4 Uptake by the liver by the fourth minute 
2,27 Marked intra-hepatic retention of the radio-isotope at 
twenty seven minutes with some excretion into the small bowel 
2,60 Continued intra-hepatic retention at sixty minutes with 
more isotope excreted into the small bowel 
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4.2.3.1. Uptake (Table 4.3. ) 
Time to maximal uptake was significantly longer in the ID 
patients (p<0.02), although the delay in absolute terms was only 
a mean of 4 minutes with considerable overlap for the 
individual values of Tmax for the three groups (Figure 4.4. ) 
Deconvolutional analysis revealed no overall significant 
difference in HEF between the three groups. However 5/13 
It 
(38%) of the patients with hepatic disease, all of whom scored 8 
or 9 on ultrasound, had a reduced HEF (<93.7%, or mean + two 
standard deviations less than the normal controls; Figure 4.5. ). 
Uptake half-time was not different between the groups. 
4.2.3.2. Excretion (Table 4.4. ) 
In the ID group there was a significant increase in retention of 
the radioisotope at both 45 and 60 minutes as well as a 
prolonged excretion half-time and reduced output efficiency 
(p<0.000 1 for all comparisons) - 
Examination of the individual results shows an almost clear 
separation between the EHIDA retention at 45 minutes (Figure 
4.6. ) , and 
60 minutes (Figure 4.7. ) and the hepatic output 
efficiency (Figure 4.8. ) between NID and 1D cystic fibrosis 
groups. 
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W. 
Controls NLD LD p-value 
(ANOVA) 
Number (n) 10 7 13 
HEF (%) 98.9+0.8 100.0+0.0 93.7+2.7 NS 
*Tmax (min) 11.0+0.8 10.1+1.0 14.6+1.2 <0.02 
Uptake ti/2 4.5+0.4 3.9+0.3 4.6+0.6 NS 
Table 4.3. Parameters measuring EHIDA uptake 
in the three groups (mean ± SEM) 
*Significant differences between LD and NID (p<0.02) and LD 
and Controls (p<0.05) 
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Figure 4.4. Scattergram of time to 
maximal hepatic uptake (Tmax) 
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Figure 4.5. Scattergram of hepatic 
EHIDA extraction fraction (HEF) 
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CONTROLS NLD LD 
IL 
Controls NLD LD p-value 
(ANOVA) 
Number (n) 10 
*E45 (%) 26.1+4.3 
*E60 (%) 15.4+3.4 
*Excretion 14.7+2.0 
tl/2 (Min) 
13 
18.4+3.5 50.8+3.2 0.0001 
10.9+2.9 39.0+4.0 0.0001 
11.9+1.7 28.0+2.6 0.0001 
*Output 93.7+1.5 93.6+1.4 85.1+1.1 0.0001 
efficiency (%) 
Table 4.4. Parameters measuring EHIDA 
excretion in the three groups 
* Significant differences (p<0.001) between LD and both NID and 
Control groups 
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Figure 4.6. Scattergram of EHIDA 
retention at 45 minutes 
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Figure 4.7. Scattergram of EHIDA 
retention at 60 minutes 
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Figure 4.8. Scattergram of hepatic 
output efficiency 
GROUP 
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CONTROLS NLD LD 
4.2.3.3. Assessment of the biliary tree 
Intrahepatic delay of EHIDA excretion was detected in none of 
the Control group, 1/7 of the N1D group and 7/13 of the LD 
group on subjective examination of the images. The differences 
between Control and LD groups was statistically significant 
(p<0.006), but all other inter-group comparisons were not. 
Extrahepatic delay was detected in 2/10 of the Controls, 1/7 of 
the NID group and 1/13 of the LD group. Delay in excretion was, 
not associated with dilatation or tapering of the common bile 
duct, but did correlate with rapid filling of the gallbladder. These 
differences were not statistically significant. The single NLD 
subject had both intrahepatic and extrahepatic delay. The radio- 
isotope cleared rapidly from all four subjects with extrahepatic 
delay following presumed relaxation of the sphincter of Oddi. 
The gallbladder was visualised in 9/10 of the Controls, 4/6 of 
the N1D cohort and 5/ 13 of the ID group. The reduction in 
gallbladder visualisation rates in the ID group was statistically 
significant when compared with the Control group (p<0.02). 
The two NLD subjects whose gall bladders were not visualised 
had micro-gallbladders on ultrasound scanning, as did one of 
those in whom it did fill with radio-isotope. Similarly, a further 
five of the LID cohort had gallbladders visualised on ultrasound. 
Only two of these had a micro-gallbladder which was also found 
in one of the LD subjects whose gallbladder was visualised using 
both techniques. Three of the LD group had no identiflable 
gallbladder either by EHIDA or ultrasound scanning. 
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4.3. Discussion 
The results of EHIDA scanning have demonstrated delayed 
uptake and excretion of the radio-isotope in patients with the 
biliary cirrhosis of cystic fibrosis. In contrast those subjects who 
had normal hepato-biliary ultrasound scans extracted and 
excreted EHBDA at similar rates to the normal Controls. These 
results suggest that quantitative hepatobiliary scintigraphy may 
be useful for the identification of cystic fibrosis patients with , 
significant hepatic involvement. The results also provide further 
support for the ultrasound based scoring system. 
Iminodiacetic acid (IDA) compounds are transported bound to 
plasma proteins and in particular albumin. They enter the space 
of Disse through fenestrations in the endothelial cells and the 
IDA complex is extracted by the hepatocyte using a non-sodium 
dependent carrier mediated organic anion pathway (Gilbert et 
al., 1987). In health this process is completed rapidly, but it is 
impaired in hepatocellular disease (Howman-Giles et al., 1993). 
The IDA molecule is transported to the canaliculus by an 
unknown mechanism and then excreted in the bile along with 
the hepatic bile. Intra- and extra-hepatic biliary disease results 
in impaired excretion (Brown et al., 1988). 
The use of IDA derivatives in the quantitative assessment of 
hepatic and biliary function is dependent on their uptake and 
excretion via the liver. The loss of large amounts of the radio- 
isotope via the kidneys, for example, would invalidate 
quantitative measurements. More than 97% of administered 
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EHIDA is removed via the liver in animal studies (Wistow et al., 
1977), supporting its use as an agent for the quantitative 
esdmtion of hepatobiliary function. 
Hepatobiliary scintigraphy has previously been used in cystic 
fibrosis to evaluate the biliary tree (Gaskin et aL, 1988; Nagel et 
al., 1989; Semith Dogan et al., 1994) and to assess the response 
to therapy of patients with chronic liver disease (Colombo et al., 
1992a; O'Brien et al., 1992b). V 
The study by Colombo et al. evaluated quantitative measures of 
biliary clearance only with respect to the half-time of hepatic 
washout and the time of appearance of isotope within the gut. 
They did not evaluate parameters of hepatic uptake. More 
recently a study detailing parameters representative of hepatic 
uptake and excretion has been reported (O'Brien et al., 1992b), 
with the baseline results similar to those obtained in the current 
study. However HEF and output efficiency were not calculated. 
The HEF may accurately reflect hepatocyte function in adults 
(Brown et al., 1988; Doo et al., 199 1) and children (Howman- 
Giles et al., 1993), falls with ischaemic liver injury (Tagge et al., 
1987) and has also been used to serially monitor liver transplant 
function (Reichle et al., 1986). In this series 5/13 (38%) of the 
liver subjects, all of whom scored 8 or 9 on ultrasound, had an 
abnormally low HER 
It is well recognised that patients with cystic fibrosis related 
liver disease rarely develop hepatic decompensation. 
Consequently conventional tests such as the bilirubin and INR 
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are rarely helpful in detecting advanced disease. Similarly there 
are no available criteria for evaluating liver disease in subjects 
who may require lung transplantation. It is possible that 
measurement of HEF will allow identification of a sub-group 
with more advanced parenchymal liver disease who are more 
likely to develop hepatic decompensation, particularly in 
relation to pulmonary transplantation. 
While there are also significant differences in the time to IL 
maximal hepatic activity (Tmax) between the LD subjects and 
the other two sub-groups the mean delay of four minutes in the 
LD cohort is of doubtful clinical significance. The scattergram 
confirms marked overlap in this parameter for the three groups 
studied. 
The differences in excretory parameters are similar to those 
previously documented (O'Brien et al., 1992b). However, the 
scattergrams of the excretory parameters do show good 
discrimination between cystic fibrosis subjects with and without 
liver disease. Measurement of these variables may supplement 
ultrasound for the diagnosis of liver disease particularly in 
subjects in whom doubt persists following baseline investigation. 
Repeated documentation of these measures of hepato-biliary 
excretory function may also allow accurate monitoring of disease 
progression and the response to therapy. 
The demonstration that the excretory delay is predominantly 
. trahepatic is in keeping with previous studies (Nagel et al., 
1989; O'Brien et al., 1992b). In addition, the results of the 
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present study fail to provide evidence of common bile duct 
stenosis as a potential aetiological factor for chronic liver disease 
(Gaskin et al., 1988; Nagel et al., 1989; O'Brien et al., 1992b). 
Extrahepatic delay was observed in all three groups. The delay 
appeared to be secondary to contraction of the sphincter of Oddi 
as evidenced by rapid filling of the gall bladder in all four cases 
and rapid clearance with appearance of the radio-isotope within 
the gut following presumed relaxation of the sphincter. 
Interestingly the NLD subject also had pooling of the radio- 
isotope in the intrahepatic biliary tree in a pattern similar to 
that previously described (Gaskin et al., 1988) and rapidly 
cleared it following relaxation of the sphincter. The detection of 
this pattern of abnormality in all three groups suggests that, 
contrary to previous reports (O'Brien et al., 1992b), biliary 
hypomodlity and viscid mucous within the common bile duct 
may not be important mechanisms promoting the development 
of chronic liver disease. 
The gallbladder abnormalities detected by biliary scintigraphy 
also show considerable inter-patient variation. The detection of a 
small gallbladder on ultrasound does not appear to imply that it 
is non functioning, and likewise the finding of a gallbladder with 
normal appearances on ultrasound does necessarily indicate a 
normally functioning organ as some of these were not 
demonstrated by biliary scintigraphy. However, it is recognised 
that a normal gall-bladder filled with bile following a prolonged 
fast may not be visualised using biliary scintigraphy (Larsen et 
aL, 1982). 
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Other potentkd reasons for these variations in gallbladder 
visualisation are unclear but they may all ýpAy reflect different 
parts of the spectrum of the same disease process. At post 
mortem. shrunken hypoplastic gallbladders with cystic duct 
obstruction due to plugging with mucous and sludge, mucosal 
hyperplasia, stenoses and even atresia have been demonstrated 
(Oppenheimer & Esterly, 1975a; Roy et al., 1982). These changes 
may result in non-visualisation of the gallbladder by both 
imaging techniques, or alternatively demonstration of a micro- 
gallbladder on ultrasound. Visualisation of an intact gallbladder 
by ultrasound but not by scintigraphy may reflect occlusion of 
the cystic duct by mucous at an early stage in the evolution of 
these changes or alternatively a gallbladder filled with bile 
following the pre-investigation fast. 
4.4. Conclusions 
Quantitative hepato-biliary scintigraphy may be of value in 
patients with cystic fibrosis where doubt about the hepatic 
status of the patient persists after more conventional tests and 
an ultrasound have been performed. 
In addition the uptake parameters, and in particular the HEF, 
may prove of value in the assessment of disease severity pre- 
transplantation. Repeated measurement of both the uptake and 
the excretory parameters may allow the objective monitoring of 
disease progression or the response to therapeutic agents. 
These potential applications require prospective evaluation. 
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CHAPTER 5 
THE EVALUATION OF BIOCHEMICAL TESTS FOR THE 
PRESENCE AND SEVERITY OF LIVER DISEASE IN 
CYSTIC FIBROSIS. 
146 
5.0. Introduction 
Individual biochemical tests of liver function (the transaminases, 
alkaline phosphatase and gamma glutamyl. transferase) have 
proved disappointing markers for underlying liver disease in 
cystic fibrosis, and may be normal in the presence of overt 
cirrhosis (di Sant'Agnese & Blanc, 1956) (Stem et aL, 1976). 
In a recent epidemiological survey 13% of those with clinical 
liver disease (hepatomegaly ± splenomegaly) had normal 
conventional biochemical tests of liver function and conversely 
13% with no clinical evidence of liver disease had abnormal 
blood tests (Scott-jupp et al., 199 1). 
The purpose of the present study was to assess four alternative 
biochemical parameters as markers of liver disease in cystic 
fibrosis: the levels of monoethylglycinexylidide (MEGA) 
f6flowing the administration of lignocaine was used as an 
estimate of functioning hepatic ceR mass (Oeflerich et al., 1989); 
fasting serum bile acid concentrations were measured as a 
marker of biliary liver disease (Cravetto et al., 1985); the 
measurement of the concentration of the amino terminal 
propeptide of type III procollagen (PIIINP) was used as an 
estimate of ongoing liver fibrosis (Babbs et al., 1988); 
apolipoprotein Al was measured and incorporated into an index 
for the detection of liver disease (the PGA index; P=prothrombin, 
G=gamma-glutamyl transpeptidase and A=serum apolipoprotein 
Al concentration (Poynard etaL, 199 1)). 
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The MEG-X test is a quantitative liver function test (Reichen, 
1993) and has been advocated as a useful test for the diagnosis 
of hepatic disease. It offers the potential of assessing disease 
severity (Huang et al., 1993) and may be of prognostic value 
(Salhe et al., 1991). MEGA, the primary metabolite of hgnocaine, 
was measured 15 minutes after a bolus injection of lignocaine 
using a fluorescence polarisation immunoassay (OeHerich et al., 
1989). 
IL 
Fasting serum bile acids have been advocated as a sensitive and 
specific test for liver disease (Cravetto et al., 1985), although 
they may not be sensitive enough to detect mild liver disease 
(Ferraris et al., 1987). Their concentration was measured using 
an enzyme linked immunosorbent assay. 
Serum levels of PIIINP correlate with histological parameters in 
many forms of liver disease including primary biliary cirrhosis 
(Babbs et al., 1988; Mutimer et al., 1989) which suggests that 
serum concentrations may be of value in the assessment of the 
biliary cirrhosis of cystic fibrosis. PIIINP concentration was 
measured using a radio-immunoassay. 
Hepatic fibrosis has also been estimated using a scoring index 
that has previously been validated in patients with alcoholic 
liver disease. The serum concentration of apolipoprotein A 1, 
measured using rate nephelometry, gamma glutamyl 
transpeptidase and prothrombin time (expressed as the 
international normalised ratio (INR)) were assigned a score and 
the scores were combined (the PGA index). This index has been 
advocated as a sensitive test for the detection of liver fibrosis in 
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alcoholic liver disease (Poynard et al., 199 1) , and has been 
reported to correlate with disease severity, as judged by the 
Mayo score, in primary biliary cirrhosis (Teare et al., 1993). 
It 
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Patients and Methods 
1.1. Patients 
Subjects were drawn from the pool of cystic fibrosis patients 
studied in chapter three. In addition twenty seven Control 
subjects with no clinical or laboratory evidence of hepatobiliary 
disease were recruited from the medical staff at Charing Cross 
Hospital. % 
All subjects undergoing hepatobiliary ultrasound evaluation 
provided fasting blood samples for the measurement of the 
standard biochemical tests of liver function (the transaminases, 
alkaline phosphatase, gamma-glutamyl transpeptidase) and for 
PIIINP, serum bile acid and apolipoprotein Al measurement. 
Similar fasting samples were obtained from the Control subjects. 
The MEGA test was not performed on the normal healthy 
controls, although the safety of the test is well recognised. 
5.1.2. Methods 
All blood samples obtained for analysis were allowed to stand 
for 30 minutes and then centrifuged at 1,800 r. p. m. for 15 
minutes to separate the serum. This was then decanted and 
stored at -20cC until analysed. 
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5.1.3. Monoethylglycinexylidide measurement. 
lignocaine hydrochloride (2% aqueous solution) was given as a 
slow intravenous bolus (1 mg/Kg body weight) over 2 minutes. 
Blood samples were drawn before and 15 minutes after the 
completion of lignocaine administration (OeUerich et al., 1989). 
The serum concentration of the lignocaine metabolite 
monoethylglycinexylidide (MEG-X) was determined, after 
thawing the stored serum samples, using a fluorescence 
polarisation immunoassay and an automated analyser (TDx 
analyser, Abbott Laboratories, Maidenhead, UK). 
The TDx analyser was calibrated using standard samples 
f. 
obtained from the manufacturer to create a reference curve. The 
analyser automatically estimated the sample serum MEGA 
concentration. 
The MEGA to values were subtracted from the t 15 values to give 
the serum MIEG-X concentration (ng/ml). 
5.1.4. Total fasting serum bile acid assay 
3a-hydroxy bile acid concentration was estimated using a 
commercially available kit (Enzabile, Nycomed Pharma, Oslo, 
Norway). The bile acids were reduced by 3a-hydroxysteroid 
dehydrogenase to produce 3a keto bile acids and NADH. Reaction 
of NADH and nitroblue tetrazolium salt, catalysed by diaphorase, 
resulted in the production of formazan which has a stable blue 
colour and a maximum spectophotometric absorption at 540nm. 
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For each serum sample three nlicrocuvettes were prepared. Two 
each containing SOOR1 of reconstituted sample reagent (Sample 
tubes), and one containing 500 td of reconstituted blank reagent 
(Blank tube). 200gl of the serum was pipetted into each tube 
and mixed thoroughly. The time of addition was recorded and 
the mixture was incubated at room temperature (20-250C) for 
20 minutes. At the end of this period stop reagent was added to 
each of the micro-cuvettes and the tube mixed once more. 
ý 
Aý)rbances of the sample and blank tubes were read in pairs at 
540 nm (PU 8800 UV/VIS spectrophotometer, Phillips, Holland). 
The average of the absorbance recorded for the two sample 
tubes was used to estimate the serum bile acid concentration by 
reference to a standard curve constructed using standard 
samples obtained from the manufacturer (Enzabile standards, 
Nycomed Pharma, Oslo, Norway). The method shows a linear 
relation between absorbance at 540 nm and 3a-hydroxy bile 
acid concentration up to 200 Rmol/l. 
S. 1.5. N-terminal procollagen III propeptide 
measurement 
Serum samples were analysed for PIIINP using a commercially 
available radioimmunoassay kit, (RIA-gnost PHIP, 
Behringwerke AG, Marburg, Germany), in which anti-PIIINP 
antibodies coated on a test-tube combine with PIIINP in the 
sample. 
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20R1 of standard or serum was pipetted. into the bottom of the 
coated test tube and mixed with 40ORI of buffer. The tubes were 
incubated in a horizontal shaker, at room temperature, for 2 
hours and then washed twice with 1ml of wash buffer. The 
mixture within the tubes was discarded after each wash. After 
washing 40(ýd of 1251-labelled monoclonal antibody to PIIINP 
was pipetted into each tube and incubated for a further three 
hours in a horizontal shaker. The tubes were washed two further 
times with 1ml. of wash buffer, with the contents of the tubes 
being decanted at each stage. 
The amount of tracer specifically bound after washing was 
quantified by counting with a gamma scintillation counter (1261 
Multigamma, Wallac UCB, Turku, Finland) over a two minute 
period. The content of unknown samples was estimated by 
reference to a standard curve constructed under identical 
conditions using standard samples provided by the 
manufacturer and the results expressed as serum PIIINP 
concentration (u/ml). 
5.1.6. Apolipoprotein Al and the PGA index 
Apolipoprotein A-1 (APA) concentrations were measured by 
rate nephelometry using a commercially available kit (Beckman 
APA, Beckman Instruments Inc., Galway, Ireland) and a 
Beckman Array Protein System analyser (Beckman Instruments, 
High Wycombe, UK). 
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The analyser was calibrated using a calibrator, diluted 1: 32ý 
supplied by the manufacturer (APO Cal). 42 [tl of the sample, 
also diluted 1: 32, was mjected into a cell and 42 [d of 
apolipopretein A-1 antibody was added. The fight scatter caused 
by the antigen-antibody complexes formed was detected by the 
analyser and converted to a peak rate signal which is a function 
of the sample APA concentration. 
The gamma-glutamyl transferase concentration and INR were 
measured using standard laboratory techniques, and the thr e 
values were combined to produce the PGA index by scoring the 
results according to the table below and combining the scores to 
give a PGA value between 0 and 12 (Table 5.1. ) (Poynard et al., 
1991). 
Score P (INR) G (YGT) iu/I A (apo Al) 
0 <1.25 <20 z200 
1 1.25-1.41 20-49 175-199 
2 1.42-1.65 50-99 150-174 
3 1.66-1.99 100-199 125-149 
4 z2.00 z200 <125 
Table 5.1. Scoring for the PGA index 
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5.1.7. Statistical analysis 
The results were expressed as mean + SEM. 
Differences in the gender ratios of the groups studied were 
compared using X2 and the results for all assays were compared 
between the two cystic fibrosis groups and Controls using 
ANOVA. When ANCIVA was statistically significant (p<0.05), the 
results were further analysed by Fisher's t based least 
significant difference test. Where no control group was analysezi 
(the MEG-X test) the results were compared using an unpaired t 
test. 
Results were considered significant with a p-value of <0.05 for a 
two-tailed test. 
Receiver operating characteristic curves were constructed, 
where appropriate, to estimate the optimal sensitivity and 
specificity of each test. Each curve was constructed by 
calculating the sensitivity (proportion of positives correctly 
identified) and specificity (proportion of negatives correctly 
identified) by the test at a particular value and plotting the 
sensitivity against (1-specificity) at each value (Poynard et al., 
1991). The best cut-off point is that which maximises the sum of 
the sensitivity and specificity and corresponds to the point 
nearest the top left-hand comer of the curve (Altman, 1991). 
Correlations between results for the four assays and the 
ultrasound score documented from chapter three were made 
using Pearson's simple least-squares regression analysis to 
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provide further analysis of the effectiveness of the ultrasound 
assessment. 
5.2. Results 
The diagnosis of cystic fibrosis related chronic liver disease and 
the sub-division into NIA and LD was made on the basis of the 
ultrasound scoring system reported in chapter 3. 
IL 
3.5.2.1. Conventional biochemical tests of liver function 
The biochemical test results of the 68 adult subjects included in 
the ultrasound study have sensitivities and specificities as 
detailed in Table 5.2. when the results are analysed relative to 
the laboratory upper limit of normal (U1N). The greatest 
sensitivity was found for the alkaline phosphatase concentration 
which correctly identified 97% of the subjects with ultrasound 
evidence of liver disease, but was only 57% specific. The gamma- 
glutamyl transferase had the best combined sensitivity and 
specificity (85% and 89% respectively) corresponding to a 
positive predictive value of 88% and a negative predictive value 
of 86%. 
When the data for these conventional tests of liver function 
were evaluated for their capacity to differentiate between the 
three ultrasound categories (NLD, ELD and SLD) none of them 
(except the platelet count) were able to adequately differentiate 
those patients with more severe hepatic involvement (Table 
5.3. ). The platelet counts are all within the normal range. 
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5.2.2. Monoethylglycinexylidide 
Forty nine subjects underwent the MEGA test. Serum MEGA 
concentrations were measured before and fifteen minutes after 
the injection of lignocaine to give the corrected MEGA 
concentration (t15 - to). 
Thirty one subjects had liver disease (ID group) and nineteen qo 
significant hepatic involvement (NID). There was no significant 
difference in their ages (19.6 + 1.1 vs 19.7 + 2.2 years 
respectively) or gender distributions (18 males and 13 females 
vs 9 males and 9 females) - 
Corrected serum MEGA concentrations for the LD group were 
significantly lower than those of the NLD group (3 8.5 + 3.7 vs 
67.0 + 4.2 ng/ml; p<0.0001). 
Eleven of the LD group fell into the intermediate ULD) and 
twenty into the severe (SLD) sub-group as defined by the 
ultrasound scoring system. Sub division into NID, IID and SLD 
sub-groups revealed significantly different corrected MEGA 
concentrations (67.0 + 4.2; 52.0 + 5.6; 31.1 + 4.1 respectively; 
p<0.0001; (ANOVA)). Further analysis with Fisher's t-based least 
significant difference confirms statistically significant 
differences between all groups: NLD vs ILD, p<0.05; NID vs SLD, 
p<0.001 and ILD vs ID, p<0.01. A scattergram. of these data for 
the three sub-groups is shown in figure 5.1. 
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Construction of a receiver operating curve revealed the 'best' 
discrimination between the NID and LD subjects at a corrected 
MEG-X concentration of 160 ng/ml. At this concentration the 
assay is 84% sensitive and 78% specific for an ultrasound based 
diagnosis of liver disease in cystic fibrosis (fig 5.2. ). This 
corresponds to a positive predictive value of 87% and a negative 
predictive value of 74%. 
Simple least squares regression analysis of corrected MEG-X 
concentration against the ultrasound score revealed a good 
correlation (r=0.7 1; p=0.000 1). 
5.2.3. Fasting serum bile acids 
Ninety four subjects had their total 3a-hydroxy bile acid 
concentration measured. The Control group consisted of twenty 
seven volunteers (15 females and 12 males) with an average age 
of 26.9 + 0.7 years. This group did not differ significantly from 
the thirty two NLD subjects (23.9 + 1.4 years; 14 females and 18 
males), but was significantly older than the thirty five ID 
subjects (average age 22.7 + 0.9 years; p<0.005). The gender 
distribution of the LD subjects (14 females and 21 males) was 
well matched with the Controls. The NLD and LD groups were 
well matched with respect to age and sex. 
There was no significant difference in the mean fasting bile acid 
concentration for the Controls (2.4 + 0.5 [tmol/1) and the NLD 
group (6.4 + 0.7 Rmol/1). Both groups differed significantly from 
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the ID group (mean concentration 3 6.1 + 5.3 jAmol/1) (p<0.001 for 
both comparisons) - 
Sub-division of the LD group into ILD and SLD sub-groups 
revealed a fasting bile acid concentration of 17.5 + 3.7 [Lmol/I for 
the 16 subjects in the 11D group and 51.9 + 7.7 ltmol/l for the 19 
subjects in the SID group. Comparison between these groups by 
ANOVA revealed a statistically significant difference between 
the three sub-groups (p=0.0001), with significant differences 
(p<0.001) between the NLD and SlD and between the IIJD and 
SID groups when the data was analysed further. The differences 
in fasting bile acid concentration were not statistically different 
between NLD and IID sub-groups. A scattergram of these data 
for the three sub-groups is shown in figure 5.3. 
Construction of a receiver operating curve using 1 Rmol/I cut-offs 
revealed that, at a cut-off of 8[tmol/l, the serum fasting 3a- 
hydroxy bile acid concentration was 86% sensitive and 78% 
specific (positive predictive value 81%, negative predictive value 
83%) (Fig 5.4. ). 
Simple regression analysis of fasting bile acid concentration 
against ultrasound score for the 67 cystic fibrosis subjects 
evaluated revealed a good correlation between increasing fasting 
serum bile acid concentration and ultrasound score (r)=0.72, 
P=0.0001. 
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5.2.4. N-terminal procollagen III propeptide 
Due to the variation in serum PHINP during childhood (Trivedi 
et al., 1989) data for subjects under 20 years of age was 
analysed separately. 
The cohort of subjects 20 years or over consisted of 27 controls, 
34 NLD subjects and 28 LD subjects. The groups were well 
matched for age (26.9 + 0.7,26.7 + 1.1 and 25.3 + 0.9 years 
respectively) and gender (12 males: 15 females; 19 males: 15 
females, 17 males: 11 females respectively). 
Comparison of the fasting serum PIIINP concentrations between 
the three groups revealed significant differences for all 
comparisons. The Control group (mean concentration 0.48 + 0.03 
u/ml) differed significantly from the NLD (0.59 + 0.02 u/ml; 
p<0.05) and the ID (0.81 + 0.04 u/ml; p<0.001) groups. Similarly 
the NLD and LD groups had significantly different PHINP 
concentrations (p<0.001) (Fig 5.5. ). 
Further analysis of the cystic fibrosis cohort incorporating the 
severity of the liver disease into the analysis revealed a 
significant difference in the NLD PIIINP concentrations with 
those of the ILD (0.79 + 0.06 u/ml; p<0.01) and the SLD (0.82 + 
0.06 u/ml) groups (p<0.001 for both comparisons). There was, 
however, no significant difference between the ILD and SLD 
PIIINP concentrations (Fig 5.6. ). 
Construction of a receiver operating curve for the PIIINP 
concentration, using 0.1 u/ml cut-off points from 0.2 u/ml to 1.0 
u/ml, revealed an optimum performance of the PIIINP assay in 
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detecting liver disease at 0.7 u/ml. The sensitivity at this 
concentration was 68% and the specificity 82% (Fig 5.7. ). This 
corresponds to a positive predictive value of 76% and a negative 
predictive value of 76%. At 0.6 u/ml the sensitivity was 86% but 
the specificity fell to 59%. 
Simple regression analysis of PIIINP concentration against the 
ultrasound score gave an r value of 0.42. This relationship was 
statistically significant (p=0.01). 
Analysis of the data for the subjects aged between 15 and 20 
and those aged under 15 revealed no significant difference in 
age, gender or PIIINP concentrations (Tables 5.4. and 5.5. ). 
5.2.5. Apolipoprotein Al and the PGA index 
IL 
80 cystic fibrosis patients (42 NID and 38 LD) and 27 control 
subjects underwent measurement of APA and subsequent 
calculation of the PGA index. The groups were well matched for 
sex, but the controls were significantly older than the cystic 
fibrosis cohorts (Controls: 26.9 + 0.7; NID: 22.2 + 1.2; ID: 21.8 + 
1.1 years; p<0.0 1 for comparisons between controls and both 
cystic fibrosis groups). 
The mean APA concentration was not different between the 
three groups (150 + 6,170 + 6, and 170 +8 mg/dI respectively). 
The mean PGA index was not significantly different between the 
Controls and NM cystic fibrosis group (2-9 + 0.3 and 2.2 + 0.2 
respectively) - Both groups 
had a significantly lower PGA index 
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scores than the 1D cystic fibrosis group (5.1 + 0.2; p<0.001 for 
both comparisons). A scattergram detailing the distribution of 
the individual PGA index scores is shown in Figure 5.8. 
Sub-division of the LD group into ILD and SLD sub-groups 
revealed a PGA index score for the ILD group of 4.4 + 0.3 which 
differed significantly from the N1D group (p<0.001), and from 
the SID group (PGA index 5.7 + 0.3; p<0.01). Similarly there were 
significant differences between NID and SLD groups at the 
p<0.001 level. 
Construction of a receiver operating curve revealed a sensitivity 
of 87% and specificity of 76% at a cut-off PGA index score of 4. 
This corresponds to a positive predictive value of 77% and a 
negative predictive value of 86% (Fig 5.9. ) 
Simple regression analysis of the PGA index against the 
ultrasound score revealed a significant correlation (r=0.72; 
p=0.0001) between the two variables. 
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Test Sensitivity Specificity +ve predictive -ve predictive 
(CYO) (%) value value 
AST 68 97 95 77 
(ULN 50 u/1) 
ALT 84 81 82 83 
(ULN 40 u/1) 
yGT 85 89 88 86 
(ULN 50 u/1) 
ALP 97 57 68 95 
WIN 250 u/1) 
Bilirubin 42 91 82 63 
(ULN17 [tmol/1) 
Table 5.2. Table of sensitivity and specificity 
values for the conventional tests of liver 
function in the diagnosis of liver disease 
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I& 
Test Comparison 
NLD vs ILD NLD vs SLD ILD vs SLD 
AST <0.05 <0.01 NS 
ALT 90.001 <0.001 NS 
ALP <0.001 <0.001 NS 
yGT -4). 001 <0.001 NS 
Bilirubin NS <ü. 001 <0.01 
Albumin NS «). 001 <0.01 
Platelets <0.001 <0.001 <0.001 
Table 5.3. Results of comparisons by Fisher's t 
based least significant difference showing lack of 
discrimination between ultrasound sub-groups 
by the conventional biochemical tests of liver 
function. 
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Figure 5.3. Scattergram of the fasting 
bile acid concentrations (and mean ± SEM 
in control, NLD and LD groups 
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fasting bile acid concentration 
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Fig 5.5. Scattergram. and mean ± SEM 
of PIIINP concentrations 
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0 20 40 60 80 100 120 
qL 
NID 
Number (n) 6 9 
Age 
Sex 
17.5 (16-19) 
3 M: 3F 
17.6 (16-19) 
6 M: 3F 
. 
PIIINP (u/ml) 1.04 (0.81-1.2) 1.3 (0.48-1.9) 
Table 5.4. Age, gender and PIIINP (median (range)) 
data for the 15 to 20 year old cohort 
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W. 
NID ID 
Number (n) 
Age 
Sex 
12 (5-15) 13 (5-14) 
5 M: 2F 1 MAF 
PIIINP (u/ml) 1.05 (0.57-1.47) 1.46 (1.13-1.78) 
Table 5.5. Age, gender and PIIINP (median (range) 
data for the under 15 year old age group 
173 
'a 7- we 
ro CL, 6- %9010 
000 0 
4- 
3 00,04? 
*00 0%10000% *0 
00 0 
0 1 00900 1 CONTROLS NLD LD 
GROUP 
Figure 5.8. Scatte rgram of the PGA index 
results for the three groups 
IL 
174 
P-%, 
tot %%ýp 
0 
100 
80 
60 
40 
20 
0 
False-positive rate (%) 
Figure 5.9. Receiver operating curve for 
the PGA index 
It 
175 
0 20 40 60 80 100 
5.3. Discussion 
S. 3.1. Monoethylglycinexylidide 
The measurement of the lignocaine metabolite MEGA in this 
cohort has revealed reduced hepatic lignocaine metabolism in 
cystic fibrosis patients with chronic liver disease. In addition 
serum MEGA concentrations were successively significantly 
lower in the ILD and SLD sub-groups suggesting that the assay 
may be useful for the assessment of the severity of hepatic 
disease (based upon ultrasound assessment). 
The results of this study are in keeping with many previous 
reports of MEGA measurement in patients with chronic liver 
disease. The close correlation of MEGA concentration with 
histology in adults (Schiffman et al., 1994) and with a validated 
composite score in children (Gremse et al., 1990) provide 
support for this means of assessing liver disease in cystic 
fibrosis. 
The advantage of the test, when compared with other 
quantitative hepatic function tests, is that it is simple, rapid and 
reliable and that the assay is easy to perform using a 
commercially available kit (Schiffman et al., 1994). 
However, the pharacokinetics of lignocaine provide a number of 
limitations of this test. While only about 3% of lignocaine is 
excreted intact in the urine (Keenaghan & Boyes, 197 2) , and 
MEGA formation is not affected by renal dysfunction 
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(Collinsworth et al., 1975), the conversion of lignocaine to MOEGA 
is dependent on oscidative N-deethylation by cytochrome P-450 
IIIA (P-450 IIIA) (Bargetzi et al., 1989). This process can be 
influenced by the concomitant use of drugs that result in 
enzyme induction (phenobarbitone, dexamethasone, 
corticosteroids) (Guenerich, 1989) or substrate competition 
(Feely etaL, 1982; Conrad etaL, 1983). 
In addition, there is a wide variation in P450 IIIA activity in the 
V 
general population (Bargetzi et al., 1989; Waddns, 1990) that 
may have a genetic basis, and which probably accounts for the 
wide range of MEG-X concentrations obtained when the test is 
performed in normal controls (Thomson et al., 1987). 
Furthermore the presence of the P450 IIIA enzyme in the 
intestine (Kolars et al., 1992) might also contribute to lignocaine 
metabolism (Schiffman et al., 1994), although the high first pass 
hepatic metabolism would minimise this. This enzyme may, 
however, be important in patients with significant portal- 
systemic shunting (Schiffman et al., 1994). 
Despite these caveats, in the present study the range of MEG-X 
concentrations obtained in the NID group (27 - 107 ng/ml) 
corresponds well with other series (3 4- 111 ng/ml) (Thomson 
et al., 1987) as does the mean concentration for both NID and 1D 
groups (Huang et al., 1993). In addition, the MEGA value 
(60ng/ml in this study) which maximises the diagnostic 
sensitivity and specificity of the assay in detecting liver disease 
corresponds well with that previously reported (54 ng/ml) 
(Huang et al., 1993). 
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It should be noted that two of the LD subjects were on 
corticosteroids, which may in theory have resulted in enzyme 
induction and elevated concentrations of NEGA. However, the 
serum concentrations of MEG-X for these two subjects were very 
much at the low end of the spectrum of values (26.2 and 34.4 
ng/ml). None of the other patients were taking medications 
likely to affect lignocame metabolism. 
These results suggest that measuring the serum MEG-X 
concentration inno more sensitive or specific than some 
conventional biochemical tests of liver function in confirming an 
ultrasound based diagnosis of liver disease. However, its 
measurement in conjunction with ultrasound may give a 
measure of disease severity. 
The MEGA test may also predict the risk of developing the 
complications of cirrhosis (Schiffman et al., 1992) and may 
identify a cohort of patients more likely to die from their hepatic 
disease (Huang et al., 1993). It may also prove valuable in 
monitoring the response to therapy (Schiffman et al., 1994). 
These hypotheses remain to be prospectively evaluated. 
5.3.2. Fasting serum bile acids 
The measurement of serum bile acids in this cohort of cystic 
fibrosis patients revealed significant elevations in subjects with 
LD and significant differences between the ILD and SLD sub- 
groups as defined by the ultrasound scoring system. There was 
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also a highly significant correlation between increasing 
ultrasound score and the bile acid concentration. 
The assay had an 86% sensitivity and 78% specificity for the 
detection of liver disease in cystic fibrosis when a cut-off of 
8[tmol/I was used. This cut off value is higher than the upper 
limit of normal for the assay quoted by the manufacturer of the 
Enzabile kit (6ttmol/1), but is siniflar to the upper limit of the 
normal range quoted in other series (Rickers et al., 1982; 
Ferraris et al., 1987) and lower than the upper limit of the range 
of values obtained in the Control cohort in this study (9.76 
ttmol/l). 
While these results were obtained in a predominantly adult 
cohort previous reports showing that adult and paediatric cystic 
fibrosis patients have similar fasting bile acid concentrations 
(Strandvik & Samuelson, 1985) suggest that they can be 
extrapolated to the cystic fibrosis population in general. 
The sensitivity and specificity of fasting serum bile acids in the 
diagnosis of hepatic disease of aetiologies other than cystic 
fibrosis has been a matter of controversy. A 78% sensitivity and 
94% specificity has been reported for bile acids, measured by 
radioinununoassay, in detecting histologically proven liver 
disease (Ferraris et al., 1987). The poor sensitivity of the test 
was particularly marked in patients with histologically mild 
disease, in whom the serum aspartate aminotransferase was 
reported to be a more sensitive marker. In contrast Mannes et 
al. reported a 93% sensitivity of bile acids, measured by 
radioimmunoassay in detecting liver cirrhosis. This was 
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increased to 97% if the fasting and postprandial concentrations 
were used (Mannes et al., 1982). The sensitivity of the assay in 
this study is lower. This may be due to methodological 
differences, but may also be related to the fact that some of the 
cystic fibrosis patients may not have fasted. 
It has been suggested that enzymatic methods, such as the one 
employed in this study, are less accurate in detecting the 
concentration of bile acids in the low or normal range (Kaplowitz, 
et al., 1973). The sensitivity of enzymatic methods is increased 
by coupling the assay to a fluorescein indicator (Hofmann, 1982) 
as in the present study, but it is this proposed inaccuracy at low 
concentrations that have led to other techniques for measuring 
bile acids, such as radioimmunoassay and gas liquid 
chromatography, being advocated (Kaplowitz et al., 1973; 
Hofmann, 1982; Ferraris et a4 1987). 
In the present study the mean fasting bile acid concentrations 
for the controls and the mean concentration for the NLD group 
fall within the normal range suggested by the manufacturer of 
the assay. The differences between them (Control and NLD) can 
probably be explained by the possibility that some of the cystic 
fibrosis subjects were not in the fasting state. This is a well 
recognised limitation of this test (Hofinann, 1982). 
Some investigators have suggested that the inaccuracy of the 
assay at low concentrations might be reduced by using post- 
prandial bile acid concentrations (Kaplowitz et al., 1973; Fausa, 
1976). However, not all investigators have detected significant 
differences in pre- and post- prandial results (Pennington et al., 
180 
1977; Linnet et al., 1983) and it may be that a2 hour post- 
prandial concentration is less reliable as the post-prandial peak 
may be reached between 1 and 3 hours after the meal 
(Hofmann, 1982). 
The factors contributing to fasting serum bile acid concentrations 
include intestinal absorption and hepatic uptake (Gilmore & 
Thompson, 1981). In patients with hepatic disease their 
concentration reflects hepatocyte loss and dysfunction, as well as 
portal-systemic and intra-hepatic shunting (Hofmann, 1982). 
Their concentration is inversely proportional to indocyanine 
green clearance and as such the functional hepatic blood flow 
(Islam et al., 1985). 
In cystic fibrosis evaluation of fasting serum bile acid 
concentrations is further complicated by the evidence that Heal 
reabsorption of bile acids is abnormal (Fondacaro et al., 1982). 
More recently it has been suggested that terminal fleal 
malabsorption occurs predominantly in patients without chronic 
liver disease (O'Brien et al., 1993). These increased faecal losses 
of bile acids are compensated by increased hepatic bile acid 
synthesis and the resultant serum bile acid pool is of a similar 
size to that of normal controls (Setchell et al., 1985). However, 
the terminal Heal defect coupled with the high proportion of 
subjects with an abnormal gall bladder in cystic fibrosis 
(Isenberg et al., 1976) suggest that the post-prandial bile acid 
concentration is likely to be less accurate than the concentration 
estimated in the fasting state. 
181 
Previous reports evaluating the measurement of bile acids in 
patients with cystic fibrosis related chronic liver disease are 
hampered by the diagnostic criteria employed. An increased 
concentration has been reported in all those with palpable 
hepatomegaly and as a consequence the measurement of bile 
acids was advocated as a test for early liver involvement in 
cystic fibrosis (Davidson et al., 1980). However, more recent 
reports suggest that fasting serum bile acids correlate poorly 
with the degree of liver injury (Matsui et al., 1982; Roy et al., 
1982). Subsequent work on serum cholic and chenodeoxycholic 
acid concentrations confirmed the lack of correlation with liver 
disease (Strandvik & Samuelson, 1985) but these evaluations 
were based upon clinical, biochemical and histological 
parameters which, as has already been discussed, all have major 
limitations in confirming a diagnosis of liver disease in cystic 
fibrosis. 
The results obtained in this study suggest that the measurement 
of fasting bile acids correlates well with an ultrasound diagnosis 
of liver disease in cystic fibrosis. However, the fasting serum bile 
acid concentration did not distinguish between the NLD and ILD 
groups suggesting limited applicability of the assay in diagnosing 
early hepatic disease. In addition, the sensitivity of the test is 
httle better than some of the conventional hver function tests 
and the specificity is somewhat worse. 
Fasting bile acid concentration may be of prognostic significance 
in chronic liver disease of other aetiologies (Mannes et aL, 1986). 
Patients with a serum bile acid concentration less than 20 Rmol/I 
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may have a good prognosis, and those with a concentration over 
50 Rmol/I may have a poor prognosis. Whether these criteria 
have any applicability to prognosis in cystic fibrosis or to the 
assessment of the need for hepatic transplantation in patients 
undergoing lung transplant assessment requires prospective 
evaluation. 
5.3.3. N-terminal procollagen III peptide % 
The results of the measurement of serum PIIINP concentration 
in this study revealed (in subjects 20 years old and over) a 
significant difference between Controls, NID and ID groups. The 
PIIINP concentration did not, however, detect increasing liver 
disease severity as defined by the ultrasound score and was 
relatively poor at distinguishing between cystic fibrosis patients 
with and without liver disease on the basis of the sensitivity and 
specificity of the test as measured by the receiver operating 
curve. 
The results for the small cohort of subjects under 20 years old 
confirm the inapplicability of this assay to patients who are still 
growing due to the contribution to PIIINP concentrations by 
interstitial procollagen turnover attributable to growth (Trivedi 
et al., 1989). The median values obtained in this study in the 
under 15s correspond well to those reported by the 
manufacturer, while the values in the 15 to 20 year olds are 
higher (manufacturers median 0.76 u/ml; range 0.29-1.95 
U/ml). 
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The PIIINP concentration has been used as a means of 
monitoring veno-occlusive disease in children after bone 
marrow transplantation (Eltumi et al., 1993). To make it possible 
to make comparisons between subjects of differing age 
concentrations were standardised for age and sex by calculating 
a standard deviation score (Trivedi et al., 1989). While this 
approach may prove of value in comparing subjects of similar 
age with and without liver disease in cystic fibrosis, the detailed 
data necessary to make such standardised calculations are not 
currently available for the assay used in this study. 
Procollagen III peptide is enzymatically cleaved from 
procollagen during the formation of collagen (Fessler & Fessler, 
1978). Its serum concentration is also influenced by the 
breakdown of previously deposited procollagen III peptide and 
degradation by the liver (Alcorn & Chojkier, 1987; Bentsen et al., 
1988). The relative contribution of these factors to serum PIIINP 
concentrations is unknown but a good correlation with the 
activity of hepatic prolyl hydroxylase, the enzyme related to the 
rate of collagen synthesis (Mann et al., 1979), in man (Torres- 
Salinas et al., 1986) and the level of hepatic fibrogenesis in a rat 
model of hepatic fibrosis has been demonstrated (Hayasaka et 
al., 199 1). 
Studies in patients with liver fibrosis reveal two types of 
collagen in association with liver disease (types I and III) (Gay 
et al., 1975). with evidence that the deposition of type III 
precedes that of type I (Wick et al., 1978). A significant 
correlation between PIIINP concentration and histologically 
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determined collagen content has been demonstrated, although it 
has been suggested that type I coRagen may be a better marker 
of more advanced liver disease (Raedsch et al., 1982). PIIINP 
may, therefore, be a useful parameter for the assessment of less 
advanced liver disease in patients in whom a liver biopsy is not 
possible. 
Studies of PIIINP in patients with the other biliary cirrhotides 
have yielded conflicting results. In primary biliary cirrhosis 
It 
PIIINP correlates with survival (Schuppan, 1991) and with the 
Mayo Prognostic index score (Teare et al., 1993). An increase in 
PIIINP concentration with worsening histological stage in 
primary biliary cirrhosis has also been demonstrated, although 
the results were not statistically significantly different (Teare et 
al., 1993). 
In contrast, studies in patients with primary sclerosing 
cholangitis reveal a significant increase in PHINP concentration 
when compared with control groups, which correlated with 
hepatic fibrosis and portal tract inflammation but not with the 
Mayo histological stage (Mehal et al., 1992). In addition, the 
PIIINP level did not correlate with survival (Mehal et al., 1992). 
These results suggest that PIIINP measurements might have 
been of some value in the evaluation of hepatic involvement in 
cystic fibrosis. However, a major confounding factor is likely to 
be the documented elevation of PIIINP in about 20% of patients 
suffering from some forms of fibrotic lung disease (idiopathic 
pulmonary fibrosis and sarcoidosis) (Rohde et al., 1979; Low et 
al., 1992), and it is therefore not surprising that the results are 
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disappointing. Comparisons have not been made, however, with 
the amount of fibrosis on liver histology specimens. 
It should also be noted that the assay used for this study detects 
both intact circulating PIIINP and low molecular weight 
fragments (such as Col 1P Mr 10,000) produced by fibrinolysis 
(Schuppan, 199 1). Thus increased fibrinolytic activity might 
result in marked elevation of the PIIINP concentration 
measured by this assay. More sensitive assays are being V 
developed which measure intact fragments of PIIINP alone and 
may allow more accurate assessment of hepatic fibrogenesis and 
fibrinolysis (by allowing comparison with less sensitive assays, 
the difference being due to the products of fibrinolysis) 
(Schuppan, 199 1). The use of such assays may have improved 
the accuracy of the PIIINP level in detecting liver disease in this 
cohort. 
In summary, estimation of the serum PIIINP concentration in 
cystic fibrosis is of limited applicability as a means of detecting 
hepatic involvement due to the probable confounding influence 
of the relatively young age of many of the affected cohort and 
the presence of active fibrotic lung disease in many of the 
patients. 
It has been suggested that the measurement of other 
procollagen peptides such as the amino and carboxyl terminal 
propeptides of procol1agen type IV and the laminin P1 fragment 
may be better markers of fibrotic liver disease in younger 
patients (Schuppan, 1991). It is not known whether the use of 
such assays would have yielded more information in this cohort. 
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One possible application for PIIINP measurement may be in the 
assessment of disease progression and the monitoring of the 
response to therapy (Schuppan, 1991). This remains to be 
evaluated. 
5.3.4. Apolipoprotein Al concentrations and the PGA 
index. 
It 
This study reveals a poor correlation between the apolipoprotein 
Al concentration and the ultrasound evaluated hepatic status of 
the patients. The concentrations documented in all three groups 
are similar to those reported for controls in other series (males 
171 + 28, females 163 + 33 mg/dl (Poynard et al., 1986)) and 
also correlate well with concentrations of APA in healthy 
controls in our laboratory (158.6 mg/dl). 
Lipoprotein abnormalities in patients with liver disease are 
complex, but include a reduction in APA in patients with more 
advanced liver disease (Malmendier et al., 1983; Jahn et al., 
1985). It has been suggested that serum APA has a higher 
predictive value for fibrosis than serum laminin and procollagen 
III propeptide (Poynard et al., 1989). However, of particular 
relevance to the present study is the elevation of APA in stage I 
and II primary biliary cirrhosis (Jahn et al., 1985) (according to 
the classification of Scheuer (Scheuer, 1973)), together with the 
fact that the intestine is also a significant source of the protein 
(Poynard et al., 1986). 
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If the progression of liver disease in cystic fibrosis follows a 
similar pattern to primary biliary cirrhosis it might be expected 
to follow a similar pattern of APA changes. APA might then help 
discriminate the early and late stages of the disease process. The 
results presented here suggest that this is not the case and it is 
probable that the serum APA concentration reflects the well 
maintained synthetic function usually found in patients with 
cystic fibrosis related chronic liver disease. While the 
contribution of disordered intestinal function to serum APA 
concentrations may be abnormally high in cystic fibrosis this has 
not been formally investigated. 
The construction of the PGA index was based upon a study in 
patients with alcoholic liver disease in which APA, yGT and the 
prothrombin time were shown to be independent markers of the 
severity of liver disease (Poynard et al., 1986). Alcohol increases 
serum APA concentration early in the disease process, although 
the mechanism for this increase is unclear (Luoma et al., 1984; 
Poynard et al., 1986), suggesting that extrapolation of the index 
to populations of patients with other forms of liver disease may 
not be appropriate. 
However, its application in chronic liver disease due to alcohol, 
hepatitis B and primary biliary cirrhosis has recently been 
reported (Teare et al., 1993). The PGA index in patients with 
primary biliary cirrhosis correlated well with the Mayo 
prognostic index score, a well validated measure of disease 
severity (Dickson et al., 1989). 
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The results for the PGA index obtained in this study Confirm that 
it has some value in the discrimination between patients with 
and without liver disease in cystic fibrosis and that the PGA 
index increases as the ultrasound score of liver disease becomes 
more severe. However, the sensitivity and specificity of the 
index is not dissimilar from that of the standard biochemical 
tests of liver function in diagnosing liver disease. This probably 
reflects the similarity in NLD and ID APA concentrations, the 
fact that it is unusual for the INR to be elevated and the well 
recognised transient increases in yGT in cystic fibrosis patients 
without hepatic parenchymal involvement. 
Overall the applicability of the PGA index is, therefore, likely to 
be of limited value. 
5.4. Conclusiona 
This study has assessed four different biochemical measures of 
hepatic disease. Two are dependent on hepatic parenchymal 
function and two are markers of hepatic fibrosis. Their 
sensitivities and specificities for confirming an ultrasound based 
diagnosis of liver disease, which are no better than some of the 
conventional biochemical tests of liver function, are summarised 
in Table 5.6. 
The most valuable information may be derived from the MEGA 
assay, which has been shown to have a sensitivity and 
specificity similar to conventional biochemical tests of liver 
function while also allowing discrimination between patients 
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with mild and severe hepatic involvement as defined by the 
ultrasound scoring system. This discnimmiant capacity was not 
found for any other assay evaluated in this study. The use of the 
MEGA test in conjunction with ultrasonography may prove 
useful in confum-iing hepatic disease and estimating disease 
severity in cystic fibrosis. 
Of the other assays assessed both the fasting serum bile acid and 
PIIINP assays do not, in this study, distinguish between all suh- 
groups and the PGA index is, as already discussed, of limited use 
given the pattern of disease in cystic fibrosis. 
Both the fasting serum bile acid and MEGA assays may be of 
value in assessing the severity of hepatic disease in patients pre 
transplantation and these two assays together with the PIIINP 
concentration may allow the response to therapy to be 
monitored. 
It may be possible to combine some or all of these biochemical 
tests into a prognostic index allowing more sensitive and specific 
diagnosis of liver disease. However, their application, as 
evaluated in this study, will always be limited by the 
dependence on ultrasound criteria for the detection of hepatic 
disease. 
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Test Sensitivity Specificity +ve predictive -ve predictive 
(0/0) (IYO) value N value (%) 
MEG-X 84 78 87 74 
Bile acids 86 78 81 83 
PIIINP 68 82 76 76 
PGA index 87 76 77 86 
Table 5.6. Summary of sensitivity and specificity 
of the assays used to diagnose liver disease in 
cystic fibrosis 
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CHAPTER 6 
SYSTEMIC HAEMODYNAMIC CHANGES IN PATIENTS 
WITH CYSTIC FIBROSIS 
an adverse effect of underlying cystic fibrosis liver disease. 
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6.0. Introduction 
There are well documented circulatory changes associated with 
chronic liver disease, although their mechanism remains obscure 
(Reichen, 1992). The circulation becomes hyperkinetic with an 
increased cardiac output associated with decreased peripheral 
vascular resistance and a tendency towards arterial hypotension 
(Kowalski & Abelmann, 1953). 
T. 
Clinically there is evidence of increased peripheral blood flow 
(bounding pulse, capillary pulsations), and of increased cardiac 
output (tachycardia, active precordial impulse, ejection systolic 
murmurs) (Murray et al., 195 8). In addition, there is a 
documented reduction in oxygen consumption in spite of the 
increase in oxygen transport (Moreau et al., 1988), thought to be 
related to physiological shunting of blood through the tissues. 
It has been suggested that the hyperdynamic circulation, 
together with altered oxygen utifisation could be a factor in the 
pathogenesis of multiple organ failure in end-stage liver disease 
(Sherlock, 1990). 
Following the demonstration that chronic liver disease was an 
independent risk factor for increased mortality in cystic fibrosis 
(as described in chapter 2 of this thesis), it was hypothesised 
that the presence of a hyperdynamic circulatory state in patients 
with cystic fibrosis related liver disease might be a contributory 
factor to accelerated mortality. 
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The aim of the present study was to test this hypothesis by 
evaluating the circulatory status of a group of patients with 
cystic fibrosis, with and without liver disease, for evidence of 
the hyperdynamic circulation. 
Invasive measurement of circulatory parameters in cystic 
fibrosis patients was deemed unacceptable due to the small but 
appreciable risks involved - in particular the risk of 
pneumothorax from central vein cannulation and the likelihood 
that any complication associated with invasive evaluation was 
likely to be poorly tolerated. The study was designed, therefore, 
to use entirely non-invasive techniques. 
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6.1. Patients and methods 
1.1. Patients 
Fifty six stable cystic fibrosis patients attending the out-patient 
departments at The Royal Brompton Hospital were recruited for 
the study. Selection of patients was random in that all suitable 
candidates who attended the clinics were approached. Subjects 
known to have hepatic disease were selectively approached to,. 
ensure adequate recruitment to this cohort. Only subjects with 
very advanced pulmonary disease who were considered unlikely 
to be able to tolerate the exercise protocol were excluded. 
Patients were categorised into the LD group on the basis of an 
abnormal hepato-biliary ultrasound scan using the criteria 
documented in chapter three. 
The severity of liver disease was judged using the previously 
validated ultrasound scoring system (subjects were categorised 
into N1D, ILD and SLD groups on this basis (see Chapter 3)) and 
by using the Child-Pugh classification (a recognised system for 
grading severity of liver disease based upon five patient 
characteristics: encephalopathy, ascites, bilirubin, albumin and 
prothrombin time) (Pugh et al., 1973). 
6.1.2. Control subjects 
Mercury strain gauge plethysmography was performed on 12 
healthy adult Control subjects, who had no clinical evidence of 
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pulmonary or hepato-biliary disease and who were members of 
the Departments of Gastroenterology or Respiratory Medicine at 
Charing Cross Hospital. 
6.1.3. Methods 
6.1.3.1. Clinical history and examination 
Data on current clinical problems including whether or not the " 
subject had been admitted to hospital during the previous year 
for complications related to cystic fibrosis (e. g. respiratory 
exacerbations), and current drug history (on the day of the 
exercise test) were obtained for all subjects. 
Clinical examination placed an emphasis upon signs consistent 
with liver disease (hepatomegaly, splenomegaly or both) 
together with the peripheral stigmata of chronic liver disease 
(SCLD) (palmar erytherna, spider naevi etc. ) (Saraky, 1987) and 
any evidence of a hyperkinetic circulation (warm flushed 
extremities, bounding pulses etc. ). 
The subjects were weighed (Kg) and measured (m) using the 
same scales and height measure on the day of the test. 
6.1.3.2. Sputum colonisation 
The most recent sputum culture result was obtained for each 
subject. 
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6.1.3.3. Lung function tests 
The subjects underwent baseline lung function tests (forced 
expiratory volume in 1 second (FEV1) and forced vital capacity 
(FVQ) recorded on the day of haemodynamic assessment 
(Vitalograph spirometer, Vitalograph, Buckingham, UK). These 
were expressed as percentages of the predicted value for age 
and height (e. g. percentage predicted FEV1 (%PFEV1)) (Cotes, 
1991). % 
Other lung function parameters (Total lung capacity (TLC), 
residual volume (RV) (Body plethysmograph, Fenyves & Gut, 
Basel, Switzerland), transfer factor (TLCO) (Model B analyser, PK 
Morgan, UK) and transfer factor corrected for lung volumes 
(KCO)) were obtained from formal lung function tests performed 
as part of the patients' regular out-patient follow-up. These lung 
function tests were also expressed as percentage of predicted 
value (Cotes, 1991) and must have been recorded within six 
months of the study (without evidence of marked deterioration 
in the intervening period). 
6.1.3.4. Chest radiograph and electrocardiogram 
The most recent out-patient chest radiograph (CXR) and 12-lead 
electrocardiogram (ECG) were obtained for each subject to look 
for evidence of cor pulmonale (increased cardio-thoracic ratio, 
right axis deviation, right ventricular hypertrophy, peaked p 
waves). 
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6.1.3.5. Haemodynamic and ventilatory assessment 
Subjects had the following variables recorded in the 4th minute 
of a period at rest and then at steady state in the 4th minute of 
25 watt exercise seated on a bicycle ergometer (Lode, Holland) 
(Figure 6.1): 
(i) Heart rate was continuously recorded with a3 lead ECG 
(CASE, Marquette, USA). 
qL 
(ii) Blood pressure was recorded using a semi-automated 
sphygmomanometer (Narco, Houston, USA) pre set to make 
recordings every 11/2 minutes. Mean arterial pressure (MAP) 
was calculated using the formula MAP = diastolic blood pressure 
+ 1/3. pulse pressure. 
(iii) Respiratory airflow was measured using a heated 
pneurnotachorneter (Fleisch No. 2) mounted on a mouthpiece. A 
nose clip was applied to prevent nasal ventilation. From this 
flow signal, an automatic system (Ergostar, Fenyves & Gut, Basel, 
Switzerland) computed averages every 30 seconds of respiratory 
rate (f), tidal volume (VT) and minute ventilation (VE). Oxygen 
uptake W02) and carbon dioxide production (VC02) were 
calculated every 30 seconds from integrated measurements of 
airflow together with mixed expired carbon dioxide (FE C02) 
(infrared analyser) and expired oxygen (FE 02) (paramagnetic 
analyser) measured in a flow-weighted sample of expired gas. 
The system is able to derive volume from airflow over one 
breath and this function was used to calibrate the airflow: a 
known volume of air (1 litre) was passed, at physiological rates, 
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through the pneumotachometer and the amplifiers in the system 
were adjusted until the volume reported by the automated 
system equalled the volume used (± 3%). The gas analysers were 
calibrated before each study with air and two standard gas 
mixtures (100% N2; 5% C02/12% 02/balance N2). 
(iv) Arterial oxygen saturation was measured using a pulse- 
oximeter (Ohmeda Biox 3700, BOC Healthcare Ltd. ). A vasodilator 
(Finalgon ointment, Boehringer Ingelheim) was applied to the . 
left ear lobe and an ear probe attached. The pulse-oximeter was 
set to 'fast-response' mode to give a continuous reading of a3 
second moving average of the arterial oxygen saturation (Sa02). 
(v) End-tidal carbon dioxide, an estimate of arterial PC02. was 
measured from expired air sampled distal to the 
pneurnotachometer through an infrared gas analyser (Beckman 
LB-2, Beckman Instruments). This system was calibrated with 
room air (0.03% C02) and a standard gas containing 5% C02/12% 
02/balance N2. The ambient barometric pressure (PBAR) was 
used to convert FE-IC02 into PETC02- 
(vi) Cardiac output (I min7l) was estimated by measuring aortic 
blood velocity using a 2MHz pulsed Doppler supra-sternal 
ultrasound probe (Pedof, Vingmed, Norway) interfaced to a 
Discrete Fourier Transform analyser (Doptek, Chichester) (Innes 
et a], 1987). By observing a spectral display the probe was 
angled and the depth of measurement adjusted at rest until the 
highest detectable peak ejection velocity was found. This setting 
was maintained for recordings made at rest and during exercise. 
The audiofrequency Doppler signals representing flow towards 
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the probe were recorded on an analogue tape-recorder (Store 4 
DS, Racal Recorders Ltd. ) for off-line analysis (see below). 
A phonocardiogram. was simultaneously recorded from the aortic 
area precisely to define end-ejection from the aortic second 
sound during Doppler signal analysis. 
On a separate occasion, M-mode echocardiography was used to 
measure the diameter of the aortic root using the leading edge to 
S leading edge technique; this measurement is required to 
calculate the cardiac output (see below). 
Doppler signal analysis was performed off-line by replaying the 
taped audio-frequency signals through the spectrum analyser, 
and capturing the digital spectral data on a Research Machine 
380Z microcomputer. The person performing the off-line 
analysis was blinded to the status of the cases (NLD or LD). An 
ensemble-averaged sonogram was obtained for 30-60 
consecutive heart beats and the mean blood velocity for each 5 
ms during ejection was calculated, then integrated for the entire 
ejection period and multiplied by the aortic root cross-sectional 
area (calculated from the M-mode aortic root diameter) to give 
an estimate of stroke volume (SV). This method has been 
validated against simultaneous thermodilution and invasive 
aortic blood velocity measurements Unnes et aL, 1987). 
Cardiac output was calculated from the product of heart rate and 
Sv. 
Cardiac index (CI) (I min-1 M-2) was calculated from the cardiac 
output and surface area of each subject which was estimated 
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from the height and weight using a nomogram (Du Bois & Du 
Bois, 1916). 
6.1.3.6. Derived variables 
Two other haemodynamic variables were derived from the 
avaffable data: 
The left ventricular stroke work index (LVSWI) (gm. min. m-2; 
normal range 29-39) according to the formula: 
LVSWI = (SV/surface area) x (MAP - PAWP) x 0.0136 (Haupt & 
Rackow, 1983), where PAWP is the pulmonary artery wedge 
pressure. In the absence of a direct measurement of PAWP this 
was assumed to be zero. 
Systemic vascular resistance index (SVRI) (dynes. S. CM75. M72; 
normal value 2140 + 240) according to the formula: 
SVRI = (MAP - mean right atrial pressure) x 80/0 (Fromm et al., 
1987) 
In the absence of a direct measurement of right atrial pressure, 
and in the knowledge that there was no clinical evidence of cor 
pulmonale, ECG or CXR evidence of right heart strain for any of 
the subjects included in the study, the right atrial pressure was 
assumed to be zero. 
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6.1.3.7. Peripheral circulatory assessment. 
Forearm blood flow (FBF) in mls/100mls tissue/min was 
measured using mercury-in-Silastic (Sonicaid, UK) strain gauge 
venous occlusion plethysmography (Hewlett & Van 
Zwaluwenberg, 1909-10; Whitney, 1953). 
Measurements were made in a room kept at a constant 
temperature (20-210C) and with the subject lying with the 
upper body at approximately 30c) to the horizontal. The 
temperature and humidity of the room were recorded at the 
start of the study and the subjects' skin temperatures were 
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recorded at the start and finish of the study (EHab CTD 85, EHab, 
Copenhagen; accurate to + 0.1 OC, manufacturers data). 
The strain gauge was placed around the left forearm, at the 
point of its greatest circumference, and the forearm was 
supported on a piece of foam at about the level of the right 
atrium, such that the subject was comfortable and relaxed. An 
occlusion cuff was placed around the wrist and inflated to 200 
mmHg to exclude the circulation of the hand. Two further cuffs 
were placed proximal to the elbow. The most distal of these was 
used for venous occlusion by intermittent inflation to 60 mmHg 
(Whitney, 1953). A large pressurised reservoir was used for 
rapid inflation of the venous cuff. 
Changes in gauge resistance, consequent upon blood filling the 
capacitance vessels and stretching the gauge after venous 
occlusion, were recorded on a chart recorder (Mingograf 800, 
Seimens) with the paper speed set at 5mm/sec. and with the 
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gain adjusted to give an angle of about 45 degrees to the 
baseline of the recorded output of the strain gauge on venous 
ocdusion. 
To calculate the FBF the steepest straight line possible was 
drawn through the waveform produced by two beats at the 
same point in the cardiac cycle. This was either beats 1 and 2 or 
beats 2 and 3 (numbered from cuff inflation); beats 1 and 2 
were only used if beat 1 occurred after full cuff inflation and tj4e 
absence of cuff artefact had been demonstrated (Figure 6.2. ) 
(Wilkins et al., 1938). Ten recordings of baseline flow were made 
over a5 to 10 minute period, the angle of the slope was 
measured (to within +1 degree) and the results averaged. The 
product of the tangent of the angle of the slope and the paper 
speed (300mm/min) gives the change in limb circumference due 
to vascular filling following venous occlusion (divisions/min). 
The strain gauges were calibrated off the limb on a former 
(Roberts et al., 1986). The gauge was stretched and, when the 
stretch increased the resistance sufficiently to return the 
recording needle to the baseline reading for the study, the 
length of the gauge corresponded to the forearm circumference. 
The length of the gauge was measured (mm). 
It was then stretched further using a screw, whose pitch had 
been determined using a travelling microscope, to allow 
calculation of the number of divisions the record increased for a 
given stretch of the strain gauge (nim/division). The product of 
the calibration and change in limb circumference gives the gauge 
stretch (mm/min) and 
204 
FBF =2x Gauge stretch (mm/min) x 100 (ml/100ml tissue/min) 
limb circumference (mm) 
The second cuff on the upper arm (arterial occlusion cuff) was 
used in the assessment of the hyperaemic response to ischaemia 
of the forearm (Strandness & Sumner, 1975). This cuff was 
inflated to 200 mmHg for 4 minutes following the base line 
measurements. Before deflating the arterial occlusion cuff at the 
end of the 4 minute period the venous occlusion cuff (distal 
upper arm cuff) was inflated to 60 mmHg to allow measurement 
of forearm blood flow immediately following cuff deflation (to) - 
Further measurements of blood flow were made by inflating the 
venous occlusion cuff to 60 mmHg 30 and 60 seconds after 
deflating the arterial cuff and thereafter every minute for a 
further two minutes by which time the resting flow levels had 
been reached. Blood flow was calculated using the method 
described above. 
205 
. ....... ..... ; 
tZý 
pi 
49 64 
10 
Figure 6.2. Specimen plethysmography trace 
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6.1.3.8. Statistical analysis 
6.1.3.8.1. Systemic haemodynamic data 
The results are expressed as mean + SEM. 
Differences between groups were compared using X2 for 
categorical data and unpaired t tests for continuous variables. 
Discriminant function analysis was performed to define the v 
subset of variables which best described the differences 
between the NID and LD groups. 
As the data for the Child-Pugh grades did not have a Gaussian 
distribution, the effect of deteriorating hepatic status on 
haemodynamic variables was evaluated using the Mann- 
Whitney U test. 
Simple least-squares regression analysis (Pearson's correlation 
co-efficient) was used to assess correlations between 
deteriorating lung function (reduced FEV1) and worsening liver 
disease as judged by the ultrasound grade (NLD, ILD and SLD) 
and haemodynamic variables for the two groups. 
Forward stepping multivariate regression analysis of the resting 
data was used to assess whether or not the hepatic status (as 
judged by increasing ultrasound grade: NID, ELD, SID) and lung 
function status (as judged by worsening %PFEV1) of the subjects 
were additive in their effect on the haemodynarnic response at 
rest. 
207 
One-way analysis of co-variance (ANCOVA), where the baseline 
value of the variable was entered as a covariate, was used to 
compare the response to exercise between the two groups. 
6.1.3.8.2. Plethysmography data 
One-way ANOVA was used to compare the baseline 
plethysmography data. 
For the purposes of analysing the hyperaernic response the data 
was analysed in two phases: the initial hyperaemic blood flow 
and then the recovery phase. Log transformation of the data was 
necessary due to the non-Gaussian distribution of blood flow 
immediately and 30 seconds after cuff deflation. 
ANCOVA was used to compare the hyperaemic response (with 
the baseline value as the co-variate) and recovery phase (with 
the hyperaemic value as the co-variate). 
Significant differences detected using ANOVA or ANCOVA were 
analysed further using Fisher's t-based least significant 
difference to detect which paired groups were significantly 
different. 
p<0.05 for a two-tailed test was considered a statistically 
significant result for all comparisons. 
208 
6.2. Results 
6.2.1. Patients 
Fifty six patients were included: 28 with (LD) and 28 without 
(NLD) cystic fibrosis related liver disease. 
The exercise test was stopped early for two patients, one from 
each group. The NLD subject developed marked bronchospasm 
and the LD subject profoundly desaturated from a resting Sa02 
of 83%. 
Fourteen other studies were incomplete due to failure to obtain 
technically adequate Doppler signals (judged from the sonogram 
(Innes, 1987)) at rest and on exercise (11 studies: 5 NLD and 6 
1, D) or on exercise alone (5 studies: 2 NLD and 3 LD). Those 
studies where inadequate results were obtained both at rest and 
on exercise were excluded altogether (including ventilatory 
data) from further analysis, while those in which only the 
exercise data was inadequate were included in the evaluation of 
the resting data. Thus forty five resting (23 NLD; 22 LD) and 
forty paired rest and exercise (21 NID; 19 ID) studies were 
available for final analysis. 
Fifteen of the twenty two LD subjects included in the resting 
analysis were Child-Pugh grade A and seven were grade B (Pugh 
et al., 1973). There were no Child-Pugh grade C subjects. Two 
Child-Pugh grade A patients had technically inadequate Doppler 
recordings on exercise and one grade B subject failed to 
complete the four minute period of exercise. 
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Analysis of the data for the patients for whom resting 
haemodynamic data were available revealed that the two groups 
were well matched for age, sex, height, weight, body mass index 
and pulmonary function (Table 6.1. ). 
There were no significant differences, between the two groups, 
in the nature of pathogens isolated from the sputum (NIRID; 
non-mucoid Pseudomonas aeruginosa 13: 8; mucoid Pseudomonas 
aeruginosa 10: 13; Staphylococcus aureus 13: 11) , or in the 
number of subjects admitted for respiratory exacerbations 
(9: 12), distal Heal obstruction syndrome (meconium fleus 
equivalent) (2: 1) or variceal haemorrhage (0: 2) during the year 
preceding the study. There were significantly more subjects with 
diabetes mellitus in the LD group (7: 0; p<0.005). 
The regular medications, recorded on the day of the study, being 
taken by the two groups differed in a number of ways (Tables 
6.2. and 6.3. ). There were significantly more LD subjects on 
nebulised Gentamicin, vitamin K and iron supplements, H2 
antagonists and insulin injections. 
The number of subjects who were clubbed was not statistically 
different between the two groups (13 NLD vs. 14 LD), but the 
number of subjects with peripheral manifestations of liver 
disease (Saraky, 1987) and/or hepato-splenomegaly was 
significantly greater in the LD group. 
In the LD group there were twelve subjects with hepato- 
splenomegaly, two with hepatomegaly alone and two with 
splenomegaly alone. Ten (45%) of the LD group had one or more 
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of the cutaneous manifestations associated with chronic liver 
disease (Saraky, 1987): 7 (32%) had palmar erythema, 1 (5%) 
had spider naevi, 1 (5%) had petechiae and 2/11 (18%) of the 
males had gynaecomastia; one of the subjects had both palmar 
erythema, and gynaecomastia. None of these features were 
detected in the NLD subjects. 
None of the patients had any of the clinical features described as 
manifestations of the hyperkinetic circulation associated with 
cirrhosis (Murray et al., 195 8) , although both groups had an 
increased heart rate. 
Analysis of the baseline characteristics of the patients following 
exclusion of the five subjects for whom exercise data was not 
available confirms the similarity of the two groups with respect 
to demographic data. The only differences between the two 
groups were for those factors detailed above which are directly 
related to the presence of hepatic disease. 
Comparison of the haemoglobin concentration of the two groups 
revealed that the LD group had a significantly lower 
haemoglobin concentration (12.7 + 0.3 vs. 14.3 + 0.3 g/dl; 
P<0.001). 
6.2.2. Resting haemodynamic results 
Haemodynamic evaluation revealed that both groups were 
tachycardic and that the resting heart rates were not statistically 
significantly different. The LD group did, however, have a 
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significantly lower mean arterial pressure, elevated cardiac 
output and reduced systemic vascular resistance index (Table 
6.4., Figures 6.3. and 6.4. ). 
The stroke volume and left ventricular stroke work index were 
also significantly higher in the 1D group (Table 6.4. ). 
Resting ventilatory variables, in particular the oxygen 
consumption, but including the oxygen saturation, carbon 
dioxide production, respiratory rate and minute ventilation wete 
not significantly different between the two groups (Table 6.5. ). 
6.2.3. Discriminant function analysis 
Discriminant function analysis was performed to select the 
subset of variables that best describe the differences between 
the NID and ID cohorts. Measured haemodynamic variables 
(excluding derived variables), ventilatory variables and 
haemoglobin were entered into the analysis. The results 
revealed that a combination of the MAP and CI produced the 
best model to allow discrimination between the two groups. 
This model correctly identified 73.9% of the NLD cohort and 
72.7% of the ID cohort. Thus 73.3% of the whole cohort was 
correctly categorised. 
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6.2.4. Exercise results 
Evaluation of the haemodynamic and ventilatory data for the 
forty subjects for whom both resting and exercise data was 
available confirmed statistically significant differences in the 
cardiac output and systemic vascular resistance on exercise. The 
heart rate and mean arterial pressure were not significantly 
different (Table 6.6. ). Graphs showing the resting and exercise 
haemodynamic data are shown in figure 6.5. 
Analysis of the paired data by ANCOVA revealed that the 
changes in haemodynamic variables on exercise were not 
statistically significant. Thus the increment in cardiac output 
caused by exercise was not influenced by the presence or 
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absence of liver disease, suggesting that the peripheral muscular 
adaptation to exercise was similar for the two groups. 
There were no differences in ventilatory parameters between 
the two groups on exercise. The oxygen saturation was similar 
for the two groups and their oxygen consumption and carbon 
dioxide production did not differ significantly (Table 6.7. ). 
Graphs showing resting and exercise ventilatory data are shown 
in figure 6.6. 
6.2.5. Comparison of LD patients based on Child-Pugh 
grade 
Comparison of the haernodynamic variables between Child-Pugh 
grade A and B subjects revealed a significantly higher cardiac 
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index (6.7 + 0.6 vs 5.0 + 0.3 I. min-l. m72; p<0.05) and lower SVRI 
1-5 m72. (916.2 + 93.8 vs 1240.4 + 72.7 dyne. s. cn ., p<0.05) in the 
Child-Pugh group B (those with more severe liver disease) 
subjects at rest. On exercise the Child-Pugh grade B subjects had 
a significantly higher CI (8.7 + 0.7 vs 7.1 + 0.3 I. min-l. m72; 
p<0.05). 
6.2.6. Regression analyses 
Least-squares regression was performed to assess whether 
deteriorating pulmonary function was associated with more 
severe haemodynamic changes. Correlating %PFEV1 with 
haemodynamic variables (heart rate, MAP, CI, SVRI and oxygen 
saturation) revealed the following significant associations: 
At rest %PFEV1 correlated with the heart rate (r =-0.47; 
P<0.05)9 CI (r= - 0.45; p<0.05), SVRI (r = 0.42; p<0.05) (Figures 
6.7. and 6.8. ) and Sa02 (r = 0.45; p<0.05) for the ID group. There 
was no significant correlation with the mean arterial pressure 
(Figure 6.8. ). 
In the NLD group %PFEV1 correlated with heart rate (r =-0.44; 
p<0.05) and with Sa02 (r = 0.48; p<0.05). There were no other 
correlations with haemodynamic variables at rest (Figures 6.9. 
and 6.10. ). 
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6.2.7. Forward stepping multivariate regression 
analysis 
For the purposes of this analysis severity of liver disease was 
categorised into the three gradings derived from the ultrasound 
scoring system: NID (grade 1), ILD (grade 2) and SLD. (grade 3). 
Haemodynamic variables at rest were correlated against this 
liver grade and %PFEV1 to evaluate any possible interaction 
between these two factors. % 
The results revealed a significant increase in correlation for CI 
when regression is performed against both ultrasound grade 
(USS grade) and %PFEV1. While the correlation coefficients for 
both heart rate and SVRI increased on adding the %PFEV1 to the 
statistical model these changes were not statistically significant 
(Table 6.8. ). 
6.2.8. Strain gauge plethysmography 
Mercury-in-Silastic strain gauge plethysmography was 
performed on all 56 subjects entered into the haemodynamic 
study and 12 healthy adult Controls. 
Only subjects with complete plethysmographic records, with 
recordings up to 180 seconds after the hyperaemic response, 
were included in the analysis. Consequently, ten of the cystic 
fibrosis subjects were excluded. 
Four of the NID group were excluded: one as she was unable to 
tolerate the four minutes that the upper cuff was inflated to 
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produce an ischaemic insult prior to assessment of the 
hyperaemic response and another because a leak from the 
rubber tubing resulted in loss of pressure in the cuff isolating 
the wrist from the forearm circulation. The remaining NLD 
subjects and the six 1D subjects had to be excluded due a 
technical problem which resulted in a failure to record the 
hyperaemic response (the baseline of the record had drifted to 
the top of the recording paper and could not be re-centred 
resulting in loss of the immediate recording). 
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There was a small, but significant difference in the temperature 
of the room when the NLD and ID subjects were evaluated (20.3 
+ 0.1 vs 20.7 + 0.1 OC respectively; p<0.05). The room 
temperature for the Control subjects did not differ significantly 
(20.9 + 0.3 OC) from either group. There were no differences in 
the humidity of the room at the time that subjects from the 
three groups were studied (Controls; NLD; ID: 55.3 + 2.3 vs 59.6 + 
1.9 vs 60.9 + 1.8 % respectively). 
The cystic fibrosis subjects (both NID and LD groups) had higher 
forearm skin temperatures than the normal Controls at the start 
(C; NLD; ID: 29.5 + 0.4 vs 31.3 + 0.2 vs 31.1 + 0.3 OC respectively; 
p<0.01 for comparisons between Controls and the other two 
groups) and end (C ; NID ; LD :27.9 + 0.4 vs 2 9.8 + 0.3 vs 2 9.4 + 
0.3 OC respectively; p<0.01 for comparisons between Controls 
and the two other groups) of the study. There was a drop of 
about 1.50C in skin temperature over the time-course of the 
study for aH subjects. 
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Resting forearm blood flow was not statistically significantly 
different between Controls, NLD and LD sub-groups when 
analysed by ANOVA (2.5 + 0.3 vs 3.5 + 0.3 vs 3.5 + 0.2 
ml/100ml/min respectively). 
The FBF response to ischaemia is documented in Table 6.9. and 
Figure 6.11. The log transformed data is shown in Figure 6.12. 
ANCOVA of the log transformed data, with the baseline forearm 
blood flow used as the co-variate, revealed that there was no 
significant difference in the hyperaemic response for the three 
groups (p=0.448). Analysis of the recovery phase, with the 
hyperaemic blood flow entered as the co-variate, showed no 
difference at 30 or 120 seconds (p=0.051 and p=0.189 
respectively). However, at 60 and 180 seconds the differences 
were significant (p=0.048 and p=0.033 respectively). Further 
analysis of the data using Fisher's t based least significant 
difference test revealed a difference in the recovery from 
hyperaemia in the Control group and the NLD cystic fibrosis 
subjects at 60 seconds and between Controls and both NLD and 
LD subjects at 180 seconds. There were no differences in 
recovery between the two cystic fibrosis groups at any stage. 
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W. 
NLD LD p-value 
No. of patients 23 22 
Age (Years) 24.8+1.5 22.2+1.2 NS 
Sex (M: F) 15: 8 NS 
Height (cm) 169.6+1.7 165.4+2.3 NS 
Weight (Kg) 57.4+1.9 53.9+2.2 NS 
Body mass 19.9+0.4 19.5+0.4 NS 
index 
%PFEV1 55.4+4.8 49.6+4.8 NS 
%PFVC 78.8+5.0 70.1+5.4 NS 
Table 6.1. Characteristics of the 45 patients 
included in the final analysis 
(values expressed as mean + SEM) 
%PFEV 1- percentage predicted forced expiratory volume in one second 
%PFVC - percentage predicted forced vital capacity 
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Pharmacological agent NLD 
(n=23) 
LD 
(n=22) 
p-value 
Nebulised Colomycin 8 7 NS 
Nebulised Gentamicin 1 8 <0.005 
Nebulised Carbenicillin 0 1 NS 
Nebulised Tobramycin 0 3 NS 
Nebulised Ceftazidime 0 1 NS 
Oxytetracycline 2 1 NS 
Flucloxacillin 10 11 NS 
Cefador 1 1 NS 
Co-Amoxiclav 0 1 NS 
Ciprofloxacin 2 1 NS 
Ofloxacin 0 1 NS 
Chloramphenicol 0 1 NS 
P2 agonists (neb/inh) 14 15 NS 
Salmeterol inhaler 2 3 NS 
Ipratropium inhaler 2 0 NS 
Steroid inhaler 10 11 NS 
Salbutamol tablets 52 NS 
Aminophylline tablets 32 NS 
Prednisolone tablets 14 NS 
Nebulised rhDNase 31 NS 
Table 6.2. Respiratory related drug therapy for 
the 45 subjects included in the final analysis 
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Pharmacological agent NLD 
(n=23) 
LD 
(n=22) 
p-value 
Pancreatic enzymes 20 21 NS 
Multivitamins 17 18 NS 
Vitamin E 17 18 NS 
Vitamin K 4 12 <0.01 
Ferrous sulphate 0 4 <0.05 
Ranitidine 1 6 <0.05 
Sucralfate 0 2 NS 
Omeprazole 0 1 NS 
Insulin 0 6 <0.01 
Glibenclamide 0 1 NS 
Hyoscine butylbromide 0 NS 
Metoclopranüde 0 NS 
Quinine bisulphate 1 0 NS 
Spironolactone 0 2 NS 
Bendrofluazide 1 1 NS 
m 
Table 6.3. Other pharmacological agents being 
taken by the 45 study subjects on the day of 
haemodynamic testing 
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NLD LD p-value 
Number (n) 23 22 
Heart rate (bpm) 89.7+3.1 97.5+3.1 NS 
Mean arterial 80.1+1.9 74.3+2.1 <0.05 
pressure (mm Hg) 
Systemic vascular 1892.8 + 136.6 1137.3 + 65.5 <O. Owl 
resistance index 
(dyne. s. cm-5. M72) 
Cardiac output 6.1+0.4 8.6+0.5 <0.001 
(I min7l) 
Stroke volume (ml) 67.8+4.4 88.8+6.3 <0.01 
LVSWI (gm. M. M72) 43.0+3.0 55.0+4.0 <0.02 
Table 6.4. Resting systemic haemodynamic 
results 
(mean + SEM) 
LVSWI - left ventricular stroke work index 
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two groups 
223 
U) NID 
LD NLD 
Number (n) 
NLD 
23 
LD 
22 
p-value 
02 saturation (%) 94.4+0.6 93.8+0.7 NS 
02 Consumption 311.7+9.0 326.4 ± 12.0 
IL 
NS 
(ml. min-1) 
C02 Production 280.0+8.0 295.0+11.0 NS 
(ml. min-1) 
End tidal C02 (mmHg) 33.5+0.6 33.8+1.0 NS 
Respiratory rate 19.9+1.2 22.1+1.0 NS 
(breaths. min-1) 
Tidal volume (1) 594.8+25.4 577.0+32.1 NS 
Minute ventilation 11.3+0.5 12.7+0.7 NS 
(l. min-1) 
Respiratory quotient 0.90+0.02 0.89+0.02 NS 
(RQ) 
Ventilatory 36.4+1.5 37.6+1.2 NS 
equivalent for 02 
uptake (VE02) 
Ventilatory 40.5+1.3 41.6+1.0 NS 
equivalent for C02 
_production 
(VEC02) 
Table 6.5. Resting ventilatory results 
(mean + SEM) 
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IL 
NLD LD p-value 
Number (n) 21 19 
Heart rate (bpm) 115.4+3.3 124.7+3.6 NS 
Mean arterial 90.7+2.0 85.4+3.0 NS 
pressure (mm Hg) 
Cardiac output 9.0+0.6 12.0+0.6 <10.01 
(I min- 1) 
Systemic vascular 1431.4 + 99.7 918.5+41.9 <(). Owl 
resistance index 
(dyne. s. cnrs. M-2) 
Table 6.6. Measured haemodynamic variable 
results after 4 minutes of 25W exercise 
(mean + SEM) 
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02 saturation 
02 Consumption 
(ml. min-1) 
C02 PrOdUCtiOn 
(ml. min-1) 
End tidal C02 (mmHg) 
Respiratory rate 
(breaths. min-1) 
Tidal volume (1) 
Minute ventilation 
(l. min-1) 
Respiratory quotient 
(RQ) 
Ventilatory 
equivalent for 02 
uptake (VE02) 
94.4+0.4 
916.7+37.0 
865.7+27.0 
35.3+0.5 
28.1+1.9 
1059.5 + 65.2 
27.4+0.9 
0.95+0.03 
30.5+1.0 
94.4+0.6 
910.0+29.0 
875.3+27.0 
36.3+0.9 
31.4+2.0 
993.7+78.4 
29.0+0.9 
0.95+0.03 
31.7+1.0 
NS 
NS 
NS 
NS, 
1 11 
L. IF NS 
NS 
NS 
NS 
1 
1% k-. # NS 
Ventilatory 32.0+0.6 33.1+0.6 NS 
equivalent for C02 
production (VEC02) 
Table 6.7. Ventilatory variable results for the 
two groups following 4 minutes of 25W exercise 
(mean + SEM) 
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Figure 6.7. Correlations of heart rate and 
cardiac index with %PFEV I for the LD group 
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Figure 6.8. Correlations of mean arterial 
pressure and systemic vascular resistance 
index with %PFEVI for the LD group 
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Figure 6.9. Correlations of heart rate and 
cardiac index with %PFEV 1 for the NLD 
group 
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Figure 6.10. Correlations of mean 
arterial pressure and systemic vascular 
resistance index with %PFEVI for the NLD 
group 
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VARIABLE Step 1r p-value Step 2r p-value 
p-value 
(difference) 
Heart rate %PFEV1 0.40 <0.02 USS Grp 0.46 <0.02 NS 
MAP NS 
ci USS Grp 0.59 0.0001 %PFEV1 0.66 <0.00001 <10.05 
SVRI USS Grp 0.56 0.0002 %PFEV1 0.60 <0.0003 NS 
Table 6.8. Results of the forward stepping multivariate 
analysis for each of the haemodynamic variables. 
r- correlation co-efficient 
MAP - mean arterial pressure Cl - cardiac index SVRI - systemic vascular resistance index USS - ultrasound 
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IL 
Controls NLD LD 
Number (n) 12 24 22 
Time (sec) 
Rest (Pre) 2.5+0.3 3.5+0.3 3.5+0.2 
Hyperaenüa (0) 23.9+1.9 
+30 8.5+1.6 
+60 4.4+0.8 
+120 2.7+0.4 
28.4+2.3 
15.8+2.4 
8.1+1.2 
4.7+0.6 
32.5+2.6 
11.3+1.0 
5.9+0.6 
3.9+0.4 
+180 2.2+0.3 4.0+0.6 3.5+0.3 
0 
Table 6.9. The mean (I SEM) resting forearm 
blood flow (ml. 100ml-I. min-1) for the three study 
groups and their hyperaemic response and 
recovery phase following 4 minutes ischaemia 
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Figure 6.11. Forearm blood flow for 
the three study groups at rest and in 
response to 4 minutes ischaemia 
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Figure 6.12. Log 10 forearm blood 
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IL 
236 
6.3. Discussion 
6.3.1. Haemodynamics 
The results of this haemodynamic study are in keeping with the 
documented hyperdynamic circulation associated with other 
forms of liver disease (Kowalski & Abelmann, 1953; Murray et 
al., 195 8; Martini et al., 1972) in the finding of an elevated 
cardiac output with a reduced systemic vascular resistance indýx 
in subjects with cystic fibrosis associated chronic liver disease. 
In addition, the circulatory changes significantly correlated with 
the severity of liver disease as judged by their Child-Pugh grade. 
This is in keeping with previous reports of a progression of the 
hyperdynan-lic circulatory state as the cirrhosis progresses 
(Braillon et al., 1986a), and with an increase in the degree of 
hepatic dysfunction as measured by Child's classification 
(Braillon et al., 1986a). 
To avoid the risk of complications related to the invasive 
assessment of cardio-pulmonary status in patients with cystic 
fibrosis this study has used a number of non-invasive 
techniques to measure cardio-pulmonary variables. 
The pulsed Doppler system (D) used in the present studies to 
measure cardiac output has been validated in man against 
indicator thermodilution (T), cardiac output measurements and 
also electromagnetic catheter (E) measurements of aortic blood 
velocity; 
237 
DpV = 1.12Epv - 1.97 cm. s-1; r=0.91 (where PV is the peak 
velocity) 
and 
Dsv = 0.86TSV + 5.6 mls; r=0.90; Dco = 0.89TCO + 0.36 I. min-1; 
r=0.92 (Innes et al., 1987; Innes et al, 1988). 
Due to anatomical variability technically acceptable results could 
not be obtained for some subjects, but the failure rate was not, 
unusually high in this patient group (Innes et al., 1988) (the 
technique requires a free path of ultrasound from sternal notch 
to ascending aorta; in some subjects this path is obstructed by 
lung tissue, especially at peak inspiration, resulting in loss of 
signal. In patients with airflow obstruction hyperinflation of the 
lungs may increase this problem). 
The other potential methodological problem in this study is the 
use of a pulse oximeter to estimate arterial oxygen saturation. 
Data supporting the use of a pulse oximeter for these 
measurements was derived from twenty five cystic fibrosis 
subjects, included in the assessment of pulmonary arterio- 
venous shunting reported in this thesis (chapter seven), who had 
simultaneous measurement of the oxygen saturation of arterial 
blood (OSM 2 Hemoximeter, Radiometer A/S, Copenhagen) and 
oxygen saturations measured by pulse oximeter (Ohmeda Biox 
3700). The mean difference between measured and estimated 
oxygen saturations was 2.6% (95% confidence interval: 1-4.2%), 
suggesting that resting measurements Of SaC12 by pulse oximeter 
are reproducible and accurately reflect the true SaC12- 
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These conclusions cannot be extrapolated to the exercise data as 
the accuracy of pulse oximeters is not as good when'the Sa02 
falls below 90% (Orenstein et al., 1993). However, the 
demonstration that paired oximeter measurements accurately 
detect changes in SaO2 from rest to exercise (Ries et al., 1985), 
coupled with the assumption that any methodological inaccuracy 
will apply equally to both cohorts, suggests that any 
methodological limitations %ill not influence the final results in 
this study. 
Concerns that the Sa02 measured by pulse oximetry may have 
been influenced by hyperbilirubinaemia in the LD cohort 
(Chaudhary & Burki, 1978) do not arise as any elevations of 
serum bilirubin were minor. 
The documented haemodynamic changes in the 1D cohort 
IL 
included in this study would not have been suspected on clinical 
examination of the subjects, who in addition to having few of the 
recognised peripheral manifestations of liver disease (a finding 
consistent with the clinical picture of primary biliary cirrhosis 
(Wright, 1987)), had no evidence of the flushed warm 
extremities (7 of the LD subjects did have palmar erythema), 
bounding pulses and systolic ejection murmurs described with 
the hyperkinetic circulation associated with cirrhosis (Murray et 
al., 195 8). 
It is interesting to note, however, that the skin temperatures of 
both cystic fibrosis groups (measured as part of the 
plethysmography protocol) were significantly higher than those 
of the normal Control subjects, suggesting that there may 
have 
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been some cutaneous vasodilatation in both of the cystic fibrosis 
groups. This may be related to the elevated basal metabolic rate 
which is a feature of cystic fibrosis (Vaisman et al., 1987; 
Buchdahl et al., 1988). 
While the LD subjects had evidence of a hyperdynamic 
circulation on exercise the statistical analysis suggests that the 
response of the two groups to exercise is not significantly 
different. While it may have been possible to obtain further 
information by performing a maximal exercise test, the design of 
this study was to compare cardiovascular variables in the two 
groups under matched degrees of metabolic stress; the matched 
oxygen consumptions show that we achieved this aim. Whether 
or not the observed cardiovascular difference would have been 
reflected in different maximal oxygen uptakes is outwith the 
scope of the present study 
The response of all subjects to exercise suggests that the patients 
studied here have a similar capacity to respond to the increased 
metabolic demands of exercise, albeit with increased 
haemodynamic demands consequent upon the resting 
hyperdynamic circulation in the LD group. These results concur 
with previous studies showing a normal response of cirrhotics to 
exercise (Abelmann et al., 1955), although other reports have 
suggested that subjects with alcoholic liver disease, and no 
detectable cardio-pulmonary abnormality, have an impaired 
capacity to respond adequately to physical stress (Kelbaek et al., 
1987). It may be that this latter study identified a group with 
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sub-clinical cardiac disease, which may not be surprising in the 
light of the cardio-toxicity of alcohol. 
The documented haemodynamic changes were not due to 
differences in the severity of pulmonary disease, or to 
differences in lung pathogens. Although there were significantly 
more diabetics in the LD group this is unlikely to have 
influenced the haemodynamic changes and while there were 
some documented differences in the medical therapy of the two 
groups none of the drugs taken by significantly more of the LD 
group are likely to account for the haemodynamic differences. 
The similarities in oxygen consumption between the two groups 
indicate that the increased cardiac output was not due to an 
increased metabolic rate, either at rest or on exercise, in the ID 
group. The elevated oxygen consumption in both cystic fibrosis 
groups relative to normal subjects is consistent with the 
reported increase in resting energy expenditure in cystic fibrosis 
(Vaisman et al., 1987; Buchdahl et al., 1988). 
While there were significant differences in the haemoglobin 
concentrations between the two groups the mild degree of 
anaemia observed in the LD group, which may, in part, be 
explained by plasma volume expansion which occurs in chronic 
liver disease (Murray et al., 1958) (although we have not 
measured plasma volume), is unlikely to be of clinical 
significance. This contention is supported by two lines of 
evidence: firstly the results of the discriminant function analysis 
which included the haemoglobin as a variable and defined the 
MAP and CI as the factors Producing the best discriminant 
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model, and secondly by the comparison of the product of 
haemoglobin and CI which reveals statistically significant 
differences both at rest (NLD vs-LD: 52.5 vs 70.0 g Hb/min 
output; p<0.002) and on exercise (78.6 vs 94.2 g Hb/min output; 
p<0.02) suggesting that the changes in haemodynamic status in 
the LD group are independent of the differences in haernoglobin 
concentration. 
W. 
6.3.2. Plethysmography 
Mercury-in-Strain gauge plethysmography allows non-invasive 
assessment of peripheral blood flow. The results of the baseline 
measurement of forearm blood flow (FBF) in this study show 
that there are no differences between NLD and LD cystic fibrosis 
subjects and healthy Controls. The difference in room 
temperature (0.4 OC) between the two cystic fibrosis groups is 
unlikely to be of any clinical significance. 
FBF measurement using strain gauge plethysmography has been 
validated by comparing it with blood flow measurement using 
an electromagnetic flow cuff around the brachial artery; 
FBFplethysmography ---ý 1.21 x FBFelectromagnetic + 
0.87, r=0.87 
(Longhurst et al., 1974). 
The higher estimate obtained by plethysmography may be due 
to flow through the skin missed by the arterial flow cuff. 
Comparison of values within individuals gave a correlation 
coefficient of 0.96. 
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The mean FBFs of all three groups fell within the normal range 
which has been estimated at between 2 and 4 ml/ 1 00ml/min 
(Elia & Kurpad, 1993). Further examination of the published 
literature shows that the Control subjects' FBF values are lower 
than previously documented in normal subjects by many 
investigators (Whitney, 1953; Lunzer et al., 1975; Jiron et al., 
1988) but higher than those reported by others (Okumura et al., 
1990), while the cystic fibrosis subjects with liver disease have 
FBFs similar to those reported by some investigators (Whitney. " 
195 3; Okumura et al., 1990), but lower than those reported by 
others in studies of cirrhotic patients (Lunzer et al., 1975; Jiron 
et al., 1988). It is likely that a part of these differences between 
studies can be attributed to methodological differences including 
the ambient temperature of the room in which the studies were 
performed (20-2 1 OC in this series), and the fact that, in this 
study, the circulation to the hand was arrested whereas other 
investigators have not measured blood flow in the isolated 
forearm (Lunzer et al., 1975; Jiron et al., 1988). 
The similarities in FBF of the NID and LD groups is in keeping 
with observations made in other studies of well compensated 
cirrhotics (Lunzer et al., 1973; Lunzer et al., 1975; jiron et al., 
1988) where the FBF did not differ from normal controls. It is 
only in patients with more advanced liver disease that increased 
peripheral blood flow has been demonstrated (Abramson & 
I-ichtman, 1937; Martini & Hagemann, 1956). 
While there was no statistically significant difference in the FBF 
in the three groups, the cystic fibrosis subjects had an increased 
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skin temperature and the room was significantly warmer for the 
LD when compared to the N1D cystic fibrosis patients, albeit by a 
mean of only 0.4 OC. This small but significant difference in room 
temperature during the study is unlikely to have affected the 
forearm blood flow as FBF does not change in normal subjects in 
response to heating (Weinberg, 1989). 
The increase in skin temperature has previously been 
documented in cirrhotics with a significantly increased FBF IL 
(Okumura et al., 1990) and has been proposed as a marker of 
increased blood flow (Kontos et al., 1964). The cystic fibrosis 
cohort also had FBFs of approximately lml/100ml/min greater 
than the normal Controls, and while this difference was not 
statistically significant it may reflect the reduced numbers of 
Controls studied. Previous studies have suggested an increase in 
skin blood flow in cirrhotics (Abramson & Lichtman, 1937; 
Martini & Hagemann, 1956), whereas skeletal muscle blood flow, 
which is the major component of forearm blood flow, was not 
increased (Lunzer et al., 1973). It is, therefore, possible that the 
cystic fibrosis subjects were cutaneously vasodilated, although 
this component of peripheral blood flow was not formally 
evaluated in this study. 
Why cystic fibrosis subjects without liver disease should have 
evidence of cutaneous vasodilatation is unclear, but it may be 
hypothesised that this is a consequence of their pulmonary 
disease (see below) or may be related to their elevated basal 
metabolic rate. 
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Further information on cutaneous vasodilatation might have 
been obtained by using experimental techniques that assess 
capillary blood flow. Plethysmography can be used to estimate 
finger blood flow, which is mainly a measure of capillary blood 
flow through the skin, and has been reported to be increased in 
cirrhotics (Martini, 1955). 
Another technique available for assessing cutaneous blood flow 
is laser Doppler flowmetry (Oberg et al., 1984). This allows 
estimation of the total amount of blood moving in the area 
beneath the Doppler probe to a depth of about 1.5mm and 
includes arterio-venous anastamotic flow. However, the 
technique is difficult to reproduce and does not allow absolute 
measurements of blood flow to be made. Consequently it is 
better applied to changes in blood flow within an individual. 
An alternative method is television capillaroscopy which allows 
examination of the skin capillaries and in particular those of the 
nailfold (Intaglietta et al., 1979). By measuring capillary velocity 
and capillary diameter it is possible to calculate capillary volume 
flow, and by estimating capillary density derive the skin 
capillary blood flow. The technique has been used to show 
marked capillary dilatation in the nail beds of patients with 
chronic liver disease (Pirovino et al., 1988). 
Whether this latter technique would have provide more 
information is not known. 
The plethysmography results add further information to the 
results of the systemic haemodynamic study. The lack of 
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correlation between peripheral arterial flow and systemic 
haemodynamic changes in the two cystic fibrosis groups 
suggests that other vascular beds are more important than the 
peripheral vascular bed in deternuinmig overall haemodynamics. 
This is in agreement with studies using the rat model of portal 
hypertension which suggest that it is the splanchnic vasculature 
and in particular the portal-systemic collaterals which are the 
major determinants of cardiac function (Braillon et al., 1986b). 
Further support for this hypothesis in cystic fibrosis liver 
disease comes from studies documenting increased portal blood 
flow in subjects with cystic fibrosis related chronic liver disease 
(Vergesslich et al., 1989). 
This study has also attempted to assess the hyperaemic response 
of all three groups to ischaemia. While there have been no 
previous studies assessing the response of the peripheral 
vasculature of subjects with chronic liver disease to vasodilatory 
stimuli, an impaired vasoconstrictor response to tilting from the 
horizontal to the vertical, to the Valsalva manoeuvre, in 
response to mental exercise (Lunzer et al., 1973; Lunzer et al., 
1975) and to cold stimulation (Okumura et al., 1990) has been 
documented. 
Analysis of the results of this study suggests that there is no 
difference in the hyperaemic response or indeed in the initial 
recovery phase following hyperaemia. These results confirm the 
capacity of the peripheral vasculature to vasodilate in response 
to ischaemia and provide further support for the concept that 
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the peripheral circulation is not significantly dilated in the 
presence of well compensated liver disease. 
6.3.3. Possible underlying mechanisms for the 
documented haemodynamic changes 
The mechanisms for the circulatory changes associated with 
liver disease have not been evaluated in cystic fibrosis related 
chronic liver disease. In addition to factors reported in subjects 
with liver disease of other aetiologies the pathogenesis is likely 
to be complicated by additional factors such as chronic lung 
sepsis. 
6.3.3.1. Mechanisms specific to liver disease 
Hepatic dysfunction is associated with most, but not all (the 
syndrome has been described in patients with portal vein 
thrombosis), described cases of the hyperdynamic circulation 
(Lebrec et al., 1983), there is evidence that the syndrome 
progresses as the cirrhosis progresses (Braillon et al., 1986a), 
and that it correlates with the degree of hepatic dysfunction as 
measured by Child's classification (Braillon et al., 1986a), the 
functioning hepatic cell mass as measured by indocyanine green 
clearance (Ito et al., 1988) and liver histology (Dicarlo et al., 
1979). These data correspond to the observation in this study of 
more severe haemodynamic changes in association with 
increasing Child-Pugh grade and with increasing ultrasound 
247 
score. This suggests a positive correlation between the degree of 
haemodynamic derangement and the severity of liver disease. 
Various mechanisms have been proposed for the development of 
the hyperdynamic circulation which has been reported in up to 
85% of cirrhotic patients (Martinez et al., 1992). These include an 
excess of circulating vasodilatory substances (Benoit et al., 1984) 
and an insensitivity to endogenous vasoconstrictor mechanisms 
(Reichen, 1992). 
The mechanism for increased vasodilator concentrations in 
cirrhosis is contentious, but includes intra- and extra-hepatic 
portal-systemic shunting and the formation of vasodilator 
substances by the diseased liver (Sherlock, 1990). 
IL 
Many substances have been evaluated as potential vasodilators. 
These include: 
Nitric oNide 
Glucagon 
Calcitonin gene-related peptide 
Eicosanoids 
Adenosine 
Bile salts 
Platelet-activating factor 
Gamma-aminobuqrric acid 
The most recent addition to this list of potential vasodilators is 
nitric oxide, originally known as the endothelium-derived 
rela, Ning factor (Palmer et al., 1987). Its role in the pathogenesis 
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of the hyperdynamic circulation associated with liver disease 
has been proposed in response to circulating endotoxins and 
cytokines (Vallance & Moncada,, 1991). These are found in 
increased concentrations in the circulation of cirrhotics, probably 
as a result of portal-caval shunting, even in the absence of 
clinically overt infection (Ohnishi et al., 1987). Alternatively 
release of nitric oxide can be induced by shear stress (Palmer et 
al., 1987) and this may be an important mechanism for 
increased release in patients with chronic liver disease. 
It 
Support for a role for nitric o, ýdde in the pathogenesis of the 
hyperdynamic circulation has been derived from studies 
showing an improvement in circulatory changes in a rat model 
of portal hypertension following the administration of an 
inhibitor of nitric o. Nide synthetase (Pizcueta et al., 1992) and an 
increase in urinary cyclic guanosine monophosphate (cGMIP), 
which dilates blood vessels following activation by nitric o. Nide, 
in the urine of cirrhotics (Miyase et al., 1990). 
Nitric oxide is unlikely to be the sole mediator of the 
haemodynamic vasodilatation as nitric o. -dde inhibitors do not 
completely reverse the circulatory changes (Pizcueta et al., 
1992). Consequently other potential vasodilators must be 
considered. 
Of the other mediators listed glucagon is the most likely to be 
important as it is responsible for about 30% of the increase in 
splanchnic blood flow in the rat model (Benoit et aL, 1986). It 
has been suggested that glucagon may be an important mediator 
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in the early stages of the development of portal hypertension 
(Lee et aL, 1988). 
There is evidence supporting a role for all of the other 
vasodilators listed in the pathogenesis of the hyperdynamic 
circulation. This evidence has either been contradicted or is 
currently insufficient to attribute a major role to them in the 
pathogenesis of the syndrome (Reichen, 1992). 
An alternative explanation for the hyperdynamic circulation is a 
blunted response to endogenous vasoconstrictors. However, this 
is not a uniform observation as the response to some 
vasoconstrictors, such as serotonin, is actually increased in portal 
hypertension (Cummings et aL, 1986). Vasoconstrictors which 
have been implicated in the pathogenesis of the hyperdynamic 
circulation include: 
A. Increased production/blunted response 
p-adrenergic agents 
Angiotensin II 
Vasopressin 
Endothelin? 
B. Increased sensitivity 
Serotonin 
Endothelin? 
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The blunted response to vasoconstrictors may simply reflect the 
presence of increased concentrations of vasodilator substances. 
There is evidence that nitric oxide can impair the response of 
splanchnic arteries to a-adrenergic agents (Sieber & Groszmann, 
1992) and glucagon the response of the rat circulation to 
norepinephrine (Pizcueta et al., 1990). 
6.3.3.2. Mechanisms related to cystic fibrosis 
It 
The theories behind the pathogenesis of the hyperdynamic 
circulation in liver disease are complicated by several other 
potential contributory factors that are related to pulmonary and 
intestinal dysfunction in cystic fibrosis. 
6.3.3.2.1. The lung as a metabolic organ 
The lung functions as an organ of first pass, and is responsible 
for the metabolism of a number of substances in the systemic 
circulation (Junod, 1975). These include glucagon (Geddes, 1979), 
which as discussed above may be an important mediator in the 
pathogenesis of the hyperdynamic circulatory state. 
Prostaglandins El, E2 and F2a are also affected (Ferreira & Vane, 
1967). 
The effect of pulmonary disease on the concentrations of these 
substances is unclear, but it may be speculated that impaired 
metabolism in the diseased lung results in an increase in 
systemic concentrations. Impaired metabolism by the lung may 
be exacerbated by intra-pulmonary arteriovenous shunting. 
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In addition the lung synthesises a number of vasoconstrictor 
substances including angiotensin H (Ng & Vane, 1968). The 
effect of disease on their concentration remains unknown. 
6.3.3.2.2. Chronic sepsis 
Chronic pulmonary sepsis in cystic fibrosis is characterised by 
colonisation of the airways by Pseudomonas aeruginosa, an 
elevation of circulating immunoglobulins (Wheeler et al., 1984) 
and a leukocytosis (Suter et al., 1989). 
Bacterial cell wall lipopolysaccharides may stimulate the 
production of cytokines by monocytes and macrophages (Smith 
et al., 1988). Tumour necrosis factor a (TNFa) is among the 
cytokines produced (Suter et aL, 1989; Norman et al., 199 1) and 
has been shown to circulate in increased concentrations in cystic 
fibrosis patients without overt evidence of lung sepsis (Norman 
et al., 199 1). 
TNFa may be responsible, at least in part, for the changes in 
resting energy expenditure and body composition found in cystic 
fibrosis (Elborn et al., 1993). Some of its effects may be 
mediated through an increase in serum glucagon (Van der Poll & 
Sauerwein, 1993), which may in turn exacerbate the 
hyperdynamic circulatory state in patients with liver disease. 
An increase in cytokines related to chronic lung sepsis may be 
responsible for the proposed cutaneous vasodilatation 
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(suggested by the increased skin temperature in the 
plethysmography study) in the NLD group. 
6.3.3.2-3. Intestinal permeability and orocaecal transit 
time 
The permeability of the small intestine is increased and the 
orocaecal transit time prolonged in cystic fibrosis (Escobar et al., 
1992). It may be speculated that these changes will result in an 
increased prevalence of bacteraemia or endotoxaemia. This may 
contribute to the circulatory changes via mechanisms discussed 
above. 
6.4. Relevance of these circulatory changes to a 
possible covert effect of cystic fibrosis related 
liver disease upon survival 
The circulatory changes in patients with advanced chronic liver 
disease of other aetiologies is associated with reduced oxygen 
consumption despite the increase in oxygen transport (Moreau 
et al., 1988). 
It has been proposed that the discrepancy between oxygen 
delivery and consumption is due to microcirculatory disturbance 
causing a failure to deliver oxygen to the tissue beds where it is 
required (Rappaport, 1979), or in an abnormal limitation of 
oxygen extraction (Moreau et al., 1988). Limitation of tissue 
oxygen extraction is suggested by a low oxygen extraction ratio 
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and elevated mixed venous oxygen concentration (Witte & Witte, 
1983) and may be caused by arterio-venous shunting (Robin, 
1980). Unless the individual can respond by increasing oxygen 
transport (by increasing blood flow) tissue hypoxia. will result 
(Moreau et al., 1988), and may contribute to multi organ failure 
in patients with advanced liver disease (Sherlock, 1990). There 
is good evidence to show that the maintenance of oxygen 
consumption through increases in systemic oxygen delivery 
(mediated by increases in cardiac output) does not continue as 
the hyperdynamic circulatory state worsens (Ito et al., 1988). 
This occurs with deteriorating liver function and worsening of 
Child-Pugh grade (Moreau etaL, 1988). 
In the present study we have documented a hyperdynamic 
circulatory state in the LD cohort with normal levels (for 
patients with cystic fibrosis) of tissue oxygen consumption and 
carbon dioxide production. These findings are typical of the well 
compensated cirrhotic patient (Braillon et al., 1986a). However, 
we have also shown a correlation between deteriorating 
pulmonary function and worsening of the hyperdynamic 
circulation and between deteriorating pulmonary function and a 
falling Sa02- In addition, forward stepping multivariate analysis 
suggests that worsening liver disease and deteriorating 
pulmonary function have an additive effect on the severity of 
haemodynamic changes in the LD cohort. 
It may be hypothesised that as the liver disease and/or lung 
disease progress, so the circulation will become more 
hyperkinetic and result in increased left ventricular work. If this 
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process is associated with a falling Sa02 it is possible that sub- 
clinical myocardial ischaemia may occur and result in 
myocardial damage and sub-endocardial fibrosis. Myocardial 
fibrosis, of unknown aetiology, has been documented at post 
mortem, in patients with cystic fibrosis (McGiven, 1962; 
Oppenheimer & Esterly, 1975b). 
Ultimately the cardiac output may not be able to increase 
sufficiently to maintain oxygen delivery. These factors may 
contribute to the accelerated cardio-pulmonary mortality 
suggested by studies showing increased non-liver related 
mortality in the cohort of cystic fibrosis patients with chronic 
liver disease. 
6.5. Conclusions 
The results presented here suggest that patients with cystic 
fibrosis associated liver disease have a hyperdynamic circulation 
which may be more severe in the presence of both advanced 
pulmonary and liver disease. 
When these factors are combined using forward stepping 
multiple regression analysis there is evidence for an interaction 
between the two factors causing an exacerbation of the 
haemodynamic derangement. 
This interaction, while not clinically apparent, may result in 
increased left ventricular work in the face of deteriorating 
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pulmonary function in the cystic fibrosis patient with liver 
disease. 
It is possible, therefore, to speculate that the hyperdynamic 
circulation may in the presence of progressive pulmonary 
disease, combine to accelerate mortality from cardio-pulmonary 
disease. It is not possible, however, to take the findings of a 
study made on individual patients at a single time point in the 
disease process and extrapolate these findings to conclude that 
these patients always retain a sufficient cardiac reserve to cope 
with increasing haemodynamic derangement as their liver 
disease progresses or a sufficient cardiac reserve to respond to 
the increased venous return and oxygen demands of exercise. To 
evaluate this further would require sequential haemodynamic 
studies as the liver disease progressed, and it might not prove 
ultimately possible to evaluate the patients at the crucial time 
when their capacity to exercise is severely impaired by both 
advancing pulmonary and hepatic disease. 
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CHAPTER 7 
PULMONARY ARTERIO-VENOUS SHUNTING IN 
PATIENTS WITH CYSTIC FIBROSIS 
evidence for the 'hepato-pulmonary' syndrome 
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7.0. Introduction 
A number of changes in the pulmonary circulation have been 
weR documented in patients with cirrhosis. 
The more severe pulmonary vascular changes of chronic liver 
disease may be manifest by cyanosis, finger clubbing and a 
hyperkinetic circulation. They may complain of shortness of 
breath exacerbated by standing up (orthodeoxia). Although most 
have abnormal liver function and peripheral stigmata of liver 
disease the pulmonary abnormalities may antedate severe 
hepatic failure (Bank et al., 1983). These changes are described 
in patients who have no underlying intrinsic respiratory disease 
and have both anatomical and physiological explanations. 
Intrapulmonary arteriovenous anastamoses were first described 
in patients with cirrhosis by Rydell and Hoffbauer in 1956 
(Rydefl & Hoffbauer, 1956). Berthelot et a/. related pulmonary 
vascular changes to documented hypoxaemia in cirrhotic 
patients using post-mortem specimens injected with micro- 
opaque gelatin to highlight the pulmonary vascular tree 
(Berthelot et al., 1966) and demonstrated marked dilatation of 
the fine peripheral branches of the pulmonary artery (at the 
precapillary and capillary level). Spider naevi were apparent on 
the pleura of half of their patients, but true arteriovenous 
communications were found in only one such patient. 
Subsequent post-mortem studies have confirmed these findings 
(Stanley et al., 1977; Davis et al., 1978). 
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The physiological basis for them has been the subject of much 
debate with proposed mechanisms including changes in the 
affinity of oxyhaemoglobin, intrapulmonary and portopulmonary 
shunts, alveolar diffusion limitation for oxygen and ventilation- 
perfusion (V/Q) inequalities (Agusti et al., 1990). The clinical 
consequences of this complex series of interactions have been 
called the hepato-pulmonary syndrome (Sherlock & Dooley, 
1993a). 
it 
We hypothesised that, if patients with cystic fibrosis related 
chronic liver disease had the hepato-pulmonary syndrome, it 
might be a contributory factor to the covert effect of liver 
disease upon survival. 
The purpose of the present study was, therefore, to evaluate 
subjects with cystic fibrosis related chronic liver disease for 
evidence of the hepato-pulmonary syndrome. The results were 
compared with a matched group of cystic fibrosis patients 
without liver disease as the interpretation of the results was 
complicated by the presence of underlying pulmonary disease, 
possible V/Qmismatch (Dantzker, 1987) and the development of 
broncho-pulmonary shunts in the brochiectatic lungs of patients 
with cystic fibrosis (Mack et al., 1965; Moss etaL, 1968) 9 
although this latter manifestation is rarely, if ever, associated 
with systemic arterial desaturation (Liebow et al., 1949). 
Lung function was measured as detailed in chapter six and 
oximetry was used to estimate postural and exercise induced 
changes in the oxygen saturation. The size of pulmonary arterio- 
venous shunts was measured. 
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Intrapulmonary arterio-venous shunting and V/Qmismatch 
were assessed using radionuclide 'shunt-perfusion' scans and the 
1000/6 oxygen rebreathing, technique. The combination of these 
techniques should allow the evaluation of both anatomical and 
functional (physiological) shunting. 
T. 
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7.1. Eatients and Methods 
7.1.1. Patients 
The study cohort included all 56 subjects who were entered into 
the haemodynamic study. 28 subjects were randomly selected 
from this cohort (14 NLD and 14 ID) for the shunt estimation 
studies. 
Patients were categorised into the 1D group on the basis of theijr 
hepatic ultrasound score as detailed in chapter three. 
7.1.2. Methods 
The following methods were used to evaluate the subjects: 
1. Lung function 
Pulmonary function variables were recorded as documented 
previously and expressed as percentage of predicted values for 
age and height (Cotes, 1991). 
7.1.2.2. Arterial oxygen saturation 
To assess whether or not patients with cystic fibrosis liver 
disease were more likely to desaturate on exercise or to have a 
postural faH in oxygen saturation (orthodeo. Nia) arterial oxygen 
saturation was measured in two situations: 
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(a) pre and post exercise following the same protocol as detailed 
in chapter six. 
(b) supine and after standing upright for 60 seconds. 
For the purposes of the exercise induced desaturation only the 
21 NID and 19 1D subjects who had paired data available from 
the exercise study were included. For the postural desaturation 
study all subjects entered into the haemodynamic study were 
, nl; eRgible for inclusion in the analysis. 
IL 
Arterial oxygen saturation was measured using a pulse-oximeter 
with an ear probe attached (Ohmeda Biox 3700, BOC Healthcare 
Ltd. ) following the application of a vasodilator (Finalgon 
ointment, Boehringer Ingelheim) to the left ear lobe. The pulse- 
oximeter was set to 'fast-response' mode to give a continuous 
reading of a3 second moving average of the arterial oxygen 
saturation (Sa02). 
7.1.2.3. Shunt estimation 
Two methods were used to evaluate the presence of pulmonary 
arterio-venous shunting: 
(a) 13 patients underwent radionuclide 'shunt-perfusion' 
scanning with technetium-99m labelled macroaggregated 
albumin (99mTc-MAA) and lung, brain and kidney imaging with 
a gamma-scintillation camera (Krowka & Cortese, 1989). 
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The technique is dependent upon the size of the 99mTc-MAA 
particles (20 to 60 [tm) which should not pass through the 
normal pulmonary capillaries which are less than 15 Rm in 
diameter. The presence of true arterio-venous anastamoses or a 
dilated capillary bed will, in theory, allow passage of 99mTc- 
MAA particles. The shunt can be estimated on the basis that the 
combined renal and cerebral circulations account for 32% of the 
cardiac output in the resting state (Wade & Bishop, 1962). 
I 
100 MBq of 99mTc-MAA (Amersham Laboratories, Amersham, 
UK) were injected into an antecubital vein with the patient 
sitting upright. Ten minutes after the injection the subject was 
placed in the supine position, and the amount of radioactivity 
was measured within posterior lung images using a wide field of 
view gamma camera (Scintronix, Aura Ltd., UK) fitted with a 
general purpose, low energy collimator. Immediately afterwards, 
the radioactivity was measured within the brain (anterior view 
of the skull) and kidneys (posterior view of the abdomen). 
Measurements were made by drawing regions of interest over 
the lungs, brain and kidneys and estimating the amount of 
radio-activity in each of these areas using a dedicated micro 
computer (Micas V, Bartec). In some subjects radioactivity had 
already reached the bladder at the time of abdominal scanning, 
so a further region of interest was drawn over the bladder. 
A further region of interest was drawn between the kidneys for 
the estimation of background counts to allow measurements to 
be corrected for scatter from the lungs. The kidney and bladder 
counts were corrected by subtraction of background activity. 
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The number of counts in a region of interest was corrected for 
area by dividing by the measured area of the organ and for the 
acquisition time by dividing by the number of seconds over 
which the images were obtained. The corrected counts were 
expressed as counts/pixel/second. 
The amount of shunted radio-labelled albumin was estimated 
from: 
(Corrected kidney & bladder + corrected brain counts) x 100/32 
I (Corrected kidney & bladder + brain) x 100/321 + Corrected lung counts 
This ratio was expressed as a percentage 
(b) 27 patients underwent shunt estimation using the 100% 
oxygen rebreathing method. 
Subjects underwent baseline arterial blood gas analysis (ABL 
300, Radiometer A/S, Copenhagen), sampled from the radial 
artery using a heparinised 5 ml. glass syringe and 23 gauge 
needle, to ensure that there was no carbon dioxide retention. 
The seated subject then breathed 100% oxygen, from a Douglas 
bag, via a mouthpiece and two way valve with a nose clip 
applied to ensure that no nasal ventilation occurred. The subject 
was encouraged to keep their lips tightly sealed around the 
mouthpiece. 
Arterial oxygen saturation was measured using a pulse-oximeter 
(Ohmeda Biox 3700), with ear probe attached, following the 
application of Finalgon ointment to the ear lobe. 
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To ensure that an adequate end-point was reached for all 
subjects the end expiratory nitrogen concentration was 
measured using a mass spectrometer (MGA 200, Centronic, UK) 
that had already been calibrated using room air and a standard 
gas mixture (5% C029 12% 02, balance N2). 
The oxygen saturation, end expiratory nitrogen and end-tidal 
carbon dioxide concentration were recorded on a multi-channel 
recorder (TA400, Gould Electronics, USA). The end-point, v 
(complete nitrogen washout), was defined as less than 1% 
nitrogen detectable in the expired gas. 
Once the end-point had been reached a further arterial sample 
was obtained from the other radial artery whilst ensuring that 
the subject continued to breathe 100% oxygen and maintain an 
airtight seal around the mouthpiece. The sample was 
immediately placed on ice and analysed in the blood gas 
analyser. 
Correction of the result obtained was made to allow for the non- 
linear relationship between the actual Pa02 and the measured 
value obtained from the blood gas analyser for partial pressures 
greater than 100mm Hg. The correction factor was obtained by 
tonometering 10 m1s. of heparinised venous blood, from a 
healthy non-smoking adult, with 100% oxygen for 20 minutes 
(Tonometer 237, Instrumentation Lab, Italy), and measuring the 
Pa02 of the tonometered blood using the blood gas analyser. The 
expected value is given by the formula: 
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Expected Pa02 : --- 
PBAR - 47 x 100 where PBAR is the barometric 
pressure. 
The corrected Pa02 
(Expected Pa02/Tonometered NOD x Measured Pa02 
Right to left shunting was calculated from the Pa02 value 
obtained and the haemoglobin (Hb; g/dl) concentration and 
SaO2- (%) measured on the same sample (OSM 2 Hemoximeter, 
Radiometer A/S, Copenhagen) by using the classical equation to 
give the volume of the shunt as a percentage of cardiac output 
(Bergrren, 1942; Chilvers et al., 1990). 
Qs/QX ---: KC02 - CA02)/(CC02 - CV02)) X 100 
where 
Qs is the volume of the shunt 
Qr is the cardiac output 
Ca02 is the oxygen content of arterial blood (ml/100ml) 
Cv02 is the oxygen content of mixed venous blood (ml/100ml) 
Cc02 is the end pulmonary capillary blood oxygen content 
(MI/ 100ml) 
These values are calculated from the following formulae: 
Ca02 (Hb x 1.34) + (Pa02 x 0.003) 
Cc02 (Hb x 1.34) + (Pc02 x 0.003) where Pc02 is the partial 
pressure of oxygen in pulmonary end capillary blood and is 
given by the formula Pc02 ---: PBAR - 47 - PaC02(the arterial 
partial pressure of carbon dioxide). 
266 
These calculations assume a physical solubility of oxygen in 
blood of 0.003 ml/100ml/mm Hg and a blood oxygen content 
equal to dissolved 02 and HbO2. 
CV02 was not measured but was assumed to be 5ml/100ml 
MOW the Ca02 (Cv02 = CaO2 - 5). 
7.1.2.4. Statistical analysis 
I& 
Results were expressed as mean + SEM and where the sample 
size was small as median (range). 
Results for the two groups were compared using X2 for 
categorical data and Mann-Whitney U (for the 99mTc-MAA 
shunt-perfusion scans) and unpaired t tests (for the remaining 
comparisons) for continuous data. A probability value <0.05 was 
considered a significant result for a two-tailed test. 
7.2. Results 
7.2.1. Pulmonary function tests 
There were no significant differences in the following lung 
function variables: FEV1, FVC, forced expiratory flow between 
25 and 75% volume (FEF25-75%), total lung capacity (TLC), 
residual volume (RV), transfer factor (TLCO) or its value 
corrected for lung volume (KCO) (Table 7.1. ). 
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7.2.2. Oximetry 
7.2.2.1. Exercise 
Paired readings for pre and post exercise oxygen saturations 
were available for 40 subjects (21 NLD; 19 LD). There were no 
age or sex differences between the two groups (see chapter 6). 
There were no significant differences in Sa02 when these were 
compared, and the mean change in oxygen saturation with IL 
exercise was not different for the two groups (-0.3 + 0.2 vs. -0.5 
±Q. 2 %; p=NS). The maximum fall in oxygen saturation re-corded 
with exercise was 3% for both groups (Table 7.2. ). 
7.2.2.2. Posture 
Data on postural changes in oxygen saturation was available for 
fifty subjects (26 NLD; 24 LD). It was not recorded in the other 
six subjects who underwent haemodynamic evaluation. The 
groups were well matched for age (NLD vs. LD: 24.8 + 1.3 vs. 
2 2.6 + 1.3 years) and sex (9 female; 17 male vs 11 female; 13 
male). 
There were no significant differences in lying or standing oxygen 
saturations between the two groups and there was no difference 
in the mean change in saturation on moving from lying to 
standing (0.8 + 0.3 vs. 0.0 + 0.4 %: p=NS). The maximum 
desaturation recorded on standing was 4% in the NLD group and 
5% in the LD group (Table 7.2. ). 
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7.2.3. Shunt estimations 
The oximetry data for the twenty eight subjects included in the 
shunt analysis is documented in tables 7.3. (NLD group) and 7.4. 
(ID group). 
7.2.3.1.99mTc MAA 'Shunt-perfusion' scans 
13 randomly selected subjects (5 NID; 8 LD) underwent 99mTc 
MAA 'shunt-perfusion' scans. The groups were well matched for 
age (20.2 + 1.5 vs 20.3 + 1.8 years) and sex (2 female: 3 male vs 4 
female: 4 male). All the scans demonstrated lung perfusion 
abnormalities consistent with parenchymal lung disease. 
Four (44%) of the LD group had significant shunts. In three 
subjects these were greater than 10% and in one larger than 6% 
(Tables 7.5. and 7.6.; Figure 7.1. ). However, the median shunt 
fraction was not statistically significantly different for the NLD 
and LD groups (4% (range 0.6-5%) and 6.9% (range 3.1-13.3%)) 
respectively. 
7.2.3.2.100% oxygen re-breathing shunt estimation 
27 subjects were included in the oxygen re-breadiing study (13 
NLD and 14 LD). The groups were well matched for age (25.1 + 
1.9 vs 21.9 + 1.4 years) and sex (4 female: 9 male vs 6 female: 8 
male). Twelve of the subjects who underwent 99mTc MAA shunt- 
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perfusion scans were included. The thirteenth subject declined 
to participate in the study due to a needle phobia. 
Arterial blood gas analysis revealed mild hypoxaemia in both 
groups, but the partial pressures of oxygen did not differ 
significantly between the two groups (Tables 7.5. and 7.6. ). The 
other baseline characteristics of the two groups were normal and 
were well matched. 
Shunt estimations documented no statistical difference in the '* 
size of shunt in both groups (4.8 + 0.6 vs. 5.3 + 1.1 %). However, 
two subjects in the ID group had shunts >10% (Tables 7.5. and 
7.6.; Figure 7.2. ). One of these had had a similar level of shunting 
demonstrated by 99mTc MAA shunt-perfusion scan. The other 
two subjects who had had a shunt >10% documented by 99mTc 
MAA shunt-perfusion scan did not have an elevated shunt 
fraction on measurement by the oxygen re-breathing technique. 
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NLD LD 
%PFVC 73.8+4.7 
%PFEV1 50.5+4.4 
%PFEF25%-75% 22.8+4.2 
WOPTLC 101.3+3.3 
%PRV 184.0+15.1 
'YOPIrLco 76.3+3.6 
70.4+4.7 
50.0+4.2 
23.3+3.2 , 
98.1+2.6 
182.4+9.8 
71.3+4.4 
OMIKCO 106.6+2.7 103.3+4.3 
Table 7.1. Pulmonary function test details for 
the whole of the cohort included in the 
haemodynamic study 
(mean + SEM) 
%PFVC - percentage predicted forced vital capacity 
%PFEV1 - percentage predicted forced expiratory volume in one second 
%PFEF25%-75% - percentage predicted forced expiratory flow between 25 
and 75% of vital capacity 
%PTLC - percentage predicted total lung capacity 
%PRV - percentage predicted residual volume 
%PTLCO - Percentage predicted transfer factor for carbon monoxide 
%PKCO - percentage predicted transfer factor corrected for lung volume 
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NLD LD 
Number (n) 21 
SaO2rest N 95.1+0.3 
Sa02 exercise M 94.4+0.4 
Number (n) 26 
Sa02 lying (%) 95.4+0.3 
19 
94.4+0.6 
94.4+0.6 
24 
94.6+0.6 
SaO2 standing (%) 95.7+0.3 95.1+0.6 
Table 7.2. Oxygen saturation data from rest to 
exercise and from lying to standing for the whole 
evaluable cohort 
(mean + SEM) 
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Subject 02 sat. 02 sat. Difference 02 sat. 02 sat. Difference 
rest exercise lying standing 
(IYO) (%) 
1 95 96 1 94 95 
2 93 92 -1 93 94 
3 95 92 -3 95 95 0 
4 96 92 -4 96 94 +2 
5 96 93 -3 97 95 +2 
6 95 93 -2 99 99 0 
7 93 93 0 97 99 -2 
8 93 - - 96 96 0 
9 93 89 -4 94 94 0 
10 94 96 +2 94 95 -1 
11 94 94 0 96 95 -1 
12 97 96 -1 96 96 0 
13 93 95 +2 96 97 -1 
14 93 93 0 93 94 1 
Table 7.3. Oxygen saturations pre and post 
exercise and from lying to standing for the NLD 
cohort who underwent shunt estimation 
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Subject 02 sat. 02 sat. Difference 02 sat. 
rest exercise lying 
(11/0) (11/0) (11/0) (0/0) (IMI) 
1 95 95 0 95 97 -2 
2 97 97 0 97 96 +1 
3 95 97 +2 96 94 +2 
4 98 98 0 97 97 0 
5 91 92 +1 - - - 
6 97 92 -5 97 97 0 
7 96 98 +2 97 98 -1 
8 94 90 -4 92 91 1 
9 92 92 0 93 94 1 
10 96 94 -2 95 96 1 
11 92 90 -2 91 94 -3 
12 90 91 +1 92 93 -1 
13 94 94 0 96 96 0 
14 
ýMmmý 
94 95 +1 96 96 0 
Table 7.4. Oxygen saturations pre and post 
exercise and from lying to standing for the LD 
cohort who underwent shunt estimation. 
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02 sat. Difference 
standing 
Subject pH PaC02 
(mmHg) 
PaO2 
(mmHg) 
Sa02 
(940) 
PaO2 
post 
1000/0 02 
(mm. Hg) 
looo/o 
02 
Shunt 
0/6) 
99niTC 
MAA 
Shunt 
N 
1 7.465 35.7 73.8 95.3 541.6 6.89 - 
2 7.405 41.4 69.1 93.3 552.4 5.77 4.8 
3 7.427 42.9 55.6 90.6 567.2 4.96 3.8 
4 7.451 36.8 69.1 94.3 594.9 1.8 4.0 
5 7.454 37.6 74.9 93.8 633.6 3.01 - 
6 7.416 43.1 85.2 94.4 626.8 3.57 - 
7 7.451 41.7 70.8 92.6 607.0 4.4 - 
8 7.445 41.3 64.7 92.8 612.4 3.83 - 
9 7.434 44.7 68.95 93.7 514.3 8.46 - 
10 7.426 43.95 73.2 95.2 611.3 3.21 - 
11 7.444 44.0 64.8 - 523.5 8.07 0.6 
12 7.429 37.8 85.0 96.5 633.5 2.76 - 
13 7.406 31.8 103.7 98.1 596.3 5.49 
14 5.0 
Table 7.5. Arterial blood gas and shunt data for 
the NLD cohort 
(subject number corresponds to number in table 7.3. ) 
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Subject pH PaC02 
(mm. Hg) 
PaO2 
(mm. Hg) 
mm 
Sa02 
(9/6) 
mmmmm 
Pa02 
post 
1009'/0 02 
(mm. Hg) 
1000/0 
02 
Shunt 
(%) 
99MTC 
MAA 
Shunt 
1 7.448 40.2 85.4 
ý 
96.9 611.3 2.72 
2 7.431 35.4 80.4 96.8 530.6 8.36 3.4 
3 7.467 33.2 55.3 90.5 446.9 11.35 11.0 
4 7.469 31.5 71.2 95.6 555.1 4.21 7.6 
5 7.446 34.3 76.7 96 591-95 3.29 12.8 
6 7.426 37.9 72.3 93.4 568.1 2.52 - 
7 7.397 35.2 94.1 96.3 635.7 0.79 3.1 
8 7.408 51.6 65.0 93.5 620.9 3.12 6.2 
9 7.467 40.5 70.1 93.6 582.7 4.68 13.3 
10 7.41 44.2 70.7 - 576.9 4.75 4.8 
11 7.452 38.8 63.0 93.3 607.5 4.24 - 
12 7.469 44.7 68.95 93.7 354.8 15.68 - 
13 7.427 42.55 62.7 90.7 620.4 3.1 - 
14 7.438 39.8 82.1 - 579.6 5.65 - 
Table 7.6. Arterial blood gas and shunt data for 
the LD cohort. 
(subject number corresponds to number in table 7.4. ) 
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Figure 7.1. Scattergram of 99mTc MAA 
shunt-perfusion shunt estimations 
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Figure 7.2. Scattergram, of 100% oxygen 
rebreathing shunt estimations 
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LID NIJD 
7.3. Discussion 
7.3.1. General 
The hepato-pulmonary syndrome is characterised by a number 
of abnormalities which combine to cause hypoxaemia, cyanosis 
and clubbing. The first is a reduced affinity of haemoglobin for 
oxygen due to an elevated concentration of 2,3- 
diphosphoglycerate (Agusti, 1985), although this is not thought 
to be a major contributory factor. The second is arterio-venous 
shunting through anatomical arterio-venous communications 
(Rodriguez-Roisin et al., 1992) and pre-capillary dilatation of the 
pulmonary vessels (Berthelot et al., 1966). These dilated 
pulmonary vessels are preferentially located at the lung bases 
and may explain the fall in arterial PaC12 sometimes seen J 
patients with cirrhosis when rising from the supine to upright 
position (orthodeoxia) (Agusti, 1985). The third is the so called 
'diffusion-perfusion' defect in which the combination of a dilated 
vascular bed in association with a high cardiac output results in 
impaired access of oxygen to the midstream of the capillary 
blood (Agusti et al., 1989). The reduced TLCO frequently seen in 
these patients (Agusti, 1985) and the tendency for the arterial 
PaC12 to fall during exercise when the increased cardiac output 
will result in even less time for the haemoglobin to be 
oxygenated (Krowka & Cortese, 1989) might be related to this 
mechanism. The fourth is the presence of ventilation-perfusion 
(V/Q) inequality which may result from a disproportionate 
increase in capillary perfusion (due to abnormal vessel 
dilatation) to some lung units and a relative failure of hypoxic 
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pulmonary vasoconstriction to redress the balance (Agusti et al., 
1990). Exercise might also result in a significant fall in Pa02 if 
this were the mechanism. 
V/Qmismatch is also the predominant mechanism by which 
patients with parenchymal lung disease become hypoNic 
(Dantzker, 1987). 
While all of these mechanisms may be contributory, it is 
generally believed that the hepato-pulmonary syndrome is molre 
functional than anatomical with a combination of a dilated 
pulmonary vascular bed, impaired hypoxic pulmonary 
vasoconstriction and oxygen diffusion limitation being the 
predominant features (Rodriguez-Roisin et al., 1992). This 
hypothesis is supported by the reversibility of the syndrome 
following orthotopic liver transplantation (Eriksson et al., 1988; 
Stoller et al., 1990). 
Not all cases with a dilated intrapulmonary vascular bed are 
hypoxaemic, suggesting that subclinical pulmonary 
vasodilatation can occur before the development of a Pa02 <70 
mmHg (Krowka & Cortese, 1990). Anatomical shunting may be 
important in the more severe cases, but is relatively uncommon 
(Rodriguez-Roisin et al., 1992). 
The results of the present study suggest that there is no 
limitation of pulmonary diffusion in cystic fibrosis patients as 
both groups had normal carbon monoNide transfer when this 
was corrected for their increased lung volumes (KCO). However, 
a normal diffusing capacity for carbon mono, -dde does not imply 
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a normal diffusing capacity for oxygen as they have different 
diffusive capacities. 
None of the subjects demonstrated a significant fall in oxygen 
saturation upon exercising or upon standing suggesting that 
neither of these manifestations of the hepato-pulmonary 
syndrome were problems for the cohort evaluated in this study. 
The results of the shunt estimations would also suggest that 
large anatomical and physiological pulmonary shunts are not a" 
significant problem in this cohort. However, 5/14 (36%) patients 
in the ID group did have larger shunts than would have been 
expected on the basis of their underlying pulmonary disease. 
A small amount of blood is normally shunted through the 
bronchial and thebesian system and amounts to less than 3% of 
the cardiac output (Dantzker, 1989). However, in a study of 
patients with underlying pulmonary disease, (lobar collapse, 
pleural effusion or pneumothorax), using the 100% oxygen 
rebreathing technique it has been shown that as much as 6.9% of 
the cardiac output may reach unventilated lung segments 
(Bergrren, 1942). The shunt fraction in normal subjects in this 
study was less than 0.6% (Bergrren, 1942). 
These results concur with the shunt fractions obtained in the 
majority of subjects within this study, with shunts of less than 
8.5% in all the NID subjects and in 10/14 (71%) of the LD group. 
However, four of the LD subjects had shunt fractions that might 
be clinically important (>100/6), with a fifth subject in the LD 
group having a 99mTc MAA shunt of 7.6%. The largest 
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documented shunt (15.7%) was in the only IJD subject with 
spider naevi. Patients with spider naevi and liver disease tend to 
have the most severe pulmonary vascular changes (Rodriguez- 
Roisin et al., 1987) and it has been suggested that spider naevi 
are one of the most useful markers of altered pulmonary blood 
vessels in these patients. 
Interestingly spider naevi were an uncommon finding in the 
cohort of cystic fibrosis patients included in the ultrasound 
study presented in chapter three, suggesting that true 
anatomical shunts may not have a high prevalence in patients 
with cystic fibrosis related chronic liver disease. 
Various methods have been proposed for quantifying the shunt 
fraction including the 99mTc MAA shunt-perfusion (Krowka & 
Cortese, 1989) and 100% oxygen rebreathing (Bergrren, 1942) 
methods used in the present study. These techniques primarily 
detect anatomical shunts although both will give abnormal 
results in the presence of a dilated pulmonary vascular bed 
(physiological shunt). The former will be abnormal if the 
vascular bed is sufficiently dilated to allow the passage of the 
99mTc-NlAA particles which are 20-60gm in diameter and 
should normally be trapped in the pulmonary vascular bed 
(diameter up to 15 tLm) and the latter if the vascular bed is 
sufficiently dilated and the cardiac output high enough to ensure 
rapid transit of red blood cells past the alveoli causing reduced 
haemoglobin oxygenation as a result of the so called 'diffusion- 
perfusion' defect (Krowka & Cortese, 1990). 
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1000/6 oxygen rebreathing will also be abnormal in the presence 
of significant V/Qmismatch- Neither technique will allow the 
differentiation of the various mechanisms thought to be 
involved in arterial hypoxaemia in cirrhotic patients, although it 
has been suggested that the 100% oxygen rebreathing method or 
a combination of tests may help. 
If (following oxygen rebreathing in subjects without underlying 
lung disease) the Pa02 remains essentially unchanged, then an, 
anatomical problem is likely to be the predominant mechanism, 
if there is a moderate increase in Pa02 (>300 mmHg) a true 
arterio-venous shunt cannot be excluded, and if there is a 
substantial increase (>500mmHg) then V/Qmismatch is likely to 
be the predominant problem (Davis et al., 1978; Krowka & 
Cortese, 1989). 
In this study the two ID subjects with shunts >10% increased 
their Pa02 to above 300 mmHg making a true anatomical shunt 
unlikely and suggesting that V/Qmismatch is the likely 
mechanism for shunting. A similar mechanism is suggested for 
all the other NLD and LD subjects who underwent oxygen 
rebreathing shunt estimation as they had a substantial increase 
in their Pa02 to greater than 500 mmHg (Tables 7.5. and 7.6. ). 
However, comparison of the shunt fractions obtained for the 
twelve subjects who were studied using both techniques may 
provide additional information. It has been suggested that up to 
6% of the injected 99mTc-MAA particles may pass into the 
systemic circulation in a normal person (Wolfe et al., 1977) 
suggesting that four of the LD subjects had elevated shunt 
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fractions by this technique (3 were >10%). However, only one of 
the subjects had a shunt of similar size measured by the oxygen 
re-breathing technique suggesting that this subject may have 
had a true anatomical shunt that did not correct at all with 1OW6 
oxygen rebread-iing. 
The reduction of shunt, on oxygen rebreathing, documented in 
the other three subjects, coupled with the increase in Pa02 to 
above 500 mmHg suggest that these three subjects had a 
functional problem similar to the 'diffusion-perfusion' defect or 
had V/Q mismatch which was largely corrected by the 
administration of 100% oxygen. The other LD subject with a 
large oxygen rebreathing shunt did not have a 99mTc NIAA scan, 
but it may be hypothesised that some or all of the shunt had an 
anatomical basis due to the presence of cutaneous spider naevi. 
These results are in agreement with previous studies which 
have suggested a good correlation between the two methods of 
shunt estimation when they are used to measure anatomical 
shunts (Whyte et al., 1992), and others which have shown a 
large discrepancy when they are used to evaluate some patients 
with chronic liver disease (Wolfe et al., 1977). The study in 
patients with chronic liver disease suggested that the oxygen 
rebreathing technique underestimated shunting in patients with 
a dilated intrapulmonary vascular tree because the increased 
driving pressure of oxygen resulted in improved oxygenation of 
haemoglobin carried by red blood cells in the middle of the 
blood stream with a consequent attenuation of any 'diffusion- 
perfusion' problems and reduction in the measured shunt. In 
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contrast the radionuclide passed through the dilated pulmonary 
vessels and gave a true reflection of shunt size. This would 
appear to be the case in the subjects studied here. 
On this basis, therefore, the patients with LD in this study 
appear to exhibit many of the features of the hepato-pulmonary 
syndrome. Particularly elevated shunt fractions are probably 
due to a combination of the 'diffusion-perfusion' defect, V/Q 
mismatch and true anatomical shunts. It is likely that in the 
other patients inappropriate perfusion of diseased or 
unventilated lung segments resulted in V/Q mismatch and 
oxygen rebreathing shunts of larger size than would be expected 
in the normal population. 
The techniques used in this study are well recognised for the 
evaluation of arterio-venous shunting. There are, however, other 
techniques for investigating pulmonary abnormalities which 
may have provided additional information. These include 
pulmonary angiography which may reveal a 'spongy' distal 
arterial tree in the lung bases corresponding to the basilar 
infiltrates sometimes seen on chest radiographs (Oh et al., 1983) 
and contrast-enhanced two-dimensional echocardiography 
(Krowka & Cortese, 1989). The latter technique identifies echoes 
(microbubbles of air or indocyanine green) in the left atrium 
within three to six beats of their visualisation in the right heart 
when a shunt is present (Krowka & Cortese, 1989). The 
microbubbles (up to 9(ý, tm) are usually trapped in the 
pulmonary vascular tree. The technique does not, however, 
allow the differentiation of functional and anatomical shunts 
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(Rodriguez-Roisin et al., 1992), and will not allow the detection 
of V/Q mismatch. Its only advantage over the methods used in 
this study is its ability to differentiate intrapulmonary and 
intracardiac shunting (when the bubbles will appear 
immediately) (Krowka & Cortese, 1990). 
An alternative approach is the use of the multiple-inert gas 
elimination technique (MIGET) (Evans & Wagner, 1977). This 
technique allows the estimation of the functional distribution of 
V/Qratios within the lung on the basis of the pattern of 
elimination of dissolved infused inert gases of different 
solubility. On the basis of studies using this technique it has 
been proposed that V/Q mismatching (perfusion of 
underventilated lung segments by dilated pulmonary vessels) 
and intrapulmonary shunting are the principal causes of a 
reduced Pa02 in cirrhosis (Rodriguez-Roisin et al., 1987; Melot et 
al., 1989; Edell et al., 1989; Castaing & Manier, 1989; 
Hedenstierna et al., 199 1). Whether or not the use of this 
technique would have been more sensitive or yielded different 
results in this study involving patients with significant 
parenchymal lung disease is not known. 
7.3.2. Potential mechanisms and therapeutic 
implications 
This study has detected shunting in 36% of the subjects in the ID 
group, while there was no evidence of significant shunts in the 
NlD cohort. Four of the ID group had a shunt fraction > 10% and 
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one a shunt fraction of 7.6% using the shunt-perfusion 
technique. In at least three of these patients this is likely to be 
the result of intrapulmonary shunting and V/Qmismatch due to 
a dilated puhnonary vascular tree. 
The mechanisms for the vascular abnormalities in the lung in 
cirrhotic patients are likely to be similar to those proposed for 
the hyperdynamic systemic circulatory disturbance. A putative 
pulmonary vasodilator originating from the mesenteric 
circulation which fails to be metabolised or cleared by the 
diseased liver has been suggested (Krowka & Cortese, 1989). 
Potential pulmonary vasodilators including prostacyclin (Zipser 
et a], 1979), atrial natriuretic factor (Gines etaL, 1988) and 
platelet activating factor (Caramelo et al., 1987) have been 
detected and may be responsible for attenuating hypo. -dc 
pulmonary vasoconstriction. Alternatively an absent or impaired 
vasoconstrictor may be responsible (Krowka & Cortese, 1989). In 
addition, there is likely to be a contribution from the 
hyperkinetic systemic circulation documented in these patients. 
In cystic fibrosis perfusion of underventilated or diseased lung 
segments in association with anomalous vascular formations 
associated with bronchiectatic lung segments may have an 
additional effect (Mack et al., 1965; Moss et al., 1968). 
The implications for treatment in the context of cystic fibrosis 
are unclear. While drug therapy has not been shown to 
consistently benefit patients with the 'hepato-pulmonary' 
syndrome (Krowka & Cortese, 1987; Cadranel et al., 1992), liver 
transplantation has been shown to reverse it (Eriksson et al., 
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1988; Stoller et al., 1990). It is possible, therefore, that patients 
with cystic fibrosis related liver disease and severe hypoxemia 
thought to be due to pulmonary- shunting could be considered 
for isolated hepatic transplantation or triple organ 
transplantation to attempt to reverse the functional changes. 
7.4. Conclusions 
IL 
This study has identified features of the hepato-pulmonary 
syndrome in 36% of patients with cystic fibrosis associated 
chronic liver disease . Documentation of larger shunts in 4/14 
(29%) of LD subjects is similar to the prevalence of the hepato- 
pulmonary syndrome reported in other series (Rodman et al., 
1960) 
When present the hepato-pulmonary syndrome may result in an 
inappropriately low Sa02- It may be speculated that the 
combination of an increased cardiac output and arterio-venous 
pulmonary shunting in a patient with liver disease might 
accelerate the deaths of patients (perhaps by causing sub- 
clinical myocardial ischaemia) with progressive lung and liver 
disease. Sequential monitoring of shunting and systemic 
circulatory changes would be required to test this hypothesis 
further. 
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Chapter 8 
CONCLUSIONS 
and suggestions for further work 
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8.0. Summarv 
As the median age of survival continues to increase with 
improvements in the respiratory care of Patients with cystic 
fibrosis it is likely that there will be an increase in the 
prevalence of cystic fibrosis related chronic liver disease. 
The work presented within this thesis suggests that liver disease 
is an important factor influencing survival. However, very few 
patients died as a direct consequence of chronic liver disease 
(<3%), thus implicating indirect effects of the liver disease upon 
survival. 
The prognostic value of chronic liver disease highlights the need 
for the early diagnosis of the chronic biliary liver disease of 
cystic fibrosis and also of identifying effective therapeutic 
agents. 
Considerable sampling error has seriously restricted the reliance 
of accurate diagnosis upon histology. Ultrasonography seems, in 
experienced hands, to be an ideal method for evaluating hepato- 
biliary involvement. Having confirmed the characteristic 
ultrasonographic features of cystic fibrosis liver disease as 
coarseness of the hepatic parenchyma, periportal fibrosis and 
marked irregularity of the margin of the liver, we have been 
able to construct an ultrasound based scoring system which 
allows earlier identification of patients with hepatic 
involvement. The simplicity of the scoring system should allow 
experienced ultrasonographers in other centres to confidently 
assess the severity of liver disease in cystic fibrosis. 
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As an alternative to histology the scoring system was validated 
against a number of biochemical tests measuring functioning 
hepatic cell mass and hepatic fibrosis. In general, these tests 
correlated well with the ultrasound scoring system. 
Quantitative hepato-biliary scintigraphy also appeared to 
provide objective data regarding the presence or absence of 
liver disease. In particular a normal ultrasound scan and a 
normal EHIDA scan correlate closely. 
It 
The biochemical tests evaluated for the detection of liver disease 
proved disappointing with no greater sensitivity or specificity 
than some of the conventional tests of liver function in the 
identification of patients with an ultrasound diagnosis of liver 
disease. 
Of the tests evaluated the measurement of the primary 
metabolite of lignocaine, MEG-X, appeared to be the most 
promising both with the regard to the diagnosis of hepatic 
disease and assessment of disease severity in that it allowed 
discrimination between the NLD, ILD and SLD groups defined by 
the ultrasound scoring system as well as correlating well with 
the ultrasound score. While the other biochemical parameters 
measured proved disappointing in the assessment of disease 
severity, they may all, together with quantitative hepato-biliary 
scintigraphy, have a role in monitoring the response of patients 
to therapeutic intervention for hepatic disease. 
This thesis has also assessed one of the potential mechanisms by 
which liver disease might influence survival. It was 
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hypothesised that this adverse influence might be attributable, 
in part, to the systemic and pulmonary circulatory changes 
documented in chronic liver disease of other aetiologies. 
Two potentially important inter-relating factors have been 
observed. Firstly patients with cystic fibrosis related chronic 
liver disease have a hyperdynan'lic circulation similar to that 
observed in other forms of chronic liver disease. Secondly some 
patients with liver disease have significant pulmonary arterio- 
venous shunts. These changes were documented in patients who 
were stable and not in an advanced disease state at the time of 
the study and who may not, therefore, fully express the extent 
of the abnormalities in question. 
It may be speculated that these changes interact to accelerate 
mortality in the cohort of cystic fibrosis patients with liver 
disease. The exact mechanism for this effect on survival may 
relate to the increased left ventricular work, associated with the 
increased cardiac output and tachycardia, causing increased 
myocardial oxygen demands and reduced diastolic myocardial 
perfusion time. This may result, particularly in the context of a 
falling oxygen saturation consequent upon progressive 
pulmonary disease and pulmonary arterio-venous shunting, in 
myocardial ischaemia, myocardial dysfunction and myocardial 
damage. Such sub-endocardial. fibrosis has been documented at 
post mortem in cystic fibrosis. 
In addition, a falling oxygen saturation in patients with 
pulmonary arterio-venous shunting may accelerate the 
development of pulmonary hypertension and cor pulmonale. It 
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is possible, therefore, that it is the patients who do develop 
pulmonary arterio-venous shunting who are most vulnerable to 
the premature decline. 
These hypotheses remain a matter for speculation. To test them 
further would require sequential studies of individual patients 
over time and it may not ultimately prove possible to study the 
patients at the crucial time when they begin to decline. 
It 
1. Conclusions 
This thesis highlights the importance of chronic liver disease in 
the long-term management of cystic fibrosis despite the 
perceived slow progression of the hepatic lesion. 
The need for simple and reliable, non-invasive tests to confirm 
the presence of liver disease has been addressed with the 
conclusion that a hepato-biliary ultrasound in conjunction with 
the measurement of MEGA may represent the best approach. 
It is suggested that part of the mechanism for the increase in 
mortality associated with hepatic involvement is related to the 
systemic and pulmonary circulatory changes documented in 
patients with chronic liver disease. 
8.2. Suggestions for further work 
A number of questions are posed by the work presented in this 
thesis: 
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1. The prognostic index presented in this thesis must now be 
prospectively evaluated to confirm its applicability, not only in 
the Brompton Hospital patients, but also in other cohorts of 
patients with cystic fibrosis. 
Such an assessment in patients undergoing transplantation 
would also give further guidance as to the appropriate time to 
nutiate transplant assessment in other patients. 
2. There are currently no criteria by which to judge the severiry 
of liver disease in patients undergoing transplantation. Current 
criteria allowing estimation of disease severity are confined to 
the documentation of episodes of decompensation (jaundice, 
ascites, encephalopathy) in the absence of a precipitating insult 
such as a respiratory exacerbation. 
Use of quantitative hepato-biliary scintigraphy, in particular the 
hepatic extraction fraction, the MEGA test and possibly total 
fasting serum bile acids, may give an estimate of how well 
preserved hepatic function is. Prospective evaluation of these 
tests in patients undergoing transplantation will provide data on 
whether or not they are useful in predicting patients who will 
decompensate following surgery or alternatively those who will 
benefit from triple-organ transplantation. 
3. Further work elucidating the covert effect of liver disease 
upon survival may present further therapeutic options. 
(a) Sequential evaluation of systemic and pulmonary 
haemodynamics may give further insight into whether this 
mechanism is important. 
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(b) Measurement of potential mediators such as glucagon, and 
the inflammatory cytokines IL-1, IL-6 and TNF a may provide 
further insight and produce new avenues for therapy. 
(c) Evaluation of other proposed mechanisms, such as the 
immune function of cystic fibrosis patients with and without 
chronic liver disease may be instructive. 
4. If liver disease has an important negative influence on 
longevity in cystic fibrosis, and if as many experts anticipate thb 
prevalence of liver disease increases as a consequence of 
improved survival, so the identification of an effective 
therapeutic agent for treating liver disease becomes even more 
important. 
Ursodeoxycholic acid has already been identified as a potential 
therapeutic agent, but while improvements in conventional 
biochemical tests and the half-time of hepatic excretion of IDA 
agents have been documented there is no data to show an 
improvement in other parameters of hepatic function. A double 
blind placebo controlled trial addressing this issue is urgently 
needed. 
In addition, in the light of the fact that ursodeoxycholic acid is 
an extremely well tolerated medication, its use for prophylaxis 
against the development of liver disease in a high risk 
population, such as those patients who present in infancy with 
meconium fleus, must be considered. 
Furthermore, the role of other therapeutic agents, such as the 
prolyl-4-hydroxylase inhibitors, should be addressed. 
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